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Summary  
With approximately 160 million people being persistently infected with hepatitis C virus 
(HCV), which bears a high risk of serious liver damage (fibrosis, cirrhosis, hepatocellular 
carcinoma), infections with HCV represent a major global health burden. Recent advances in 
the development of HCV-specific direct acting antiviral drugs have substantially improved the 
success rates of antiviral therapy. Nevertheless major challenges such as high costs, high 
number of undiagnosed infections and the possibility of reinfection even after therapy-
induced virus elimination remain. There is increasing evidence that infections with this 
hepatotropic virus are tightly linked to lipid metabolism. For instance, lipid droplets (LDs) play 
an important role in the replication cycle of HCV, but also of the related Dengue virus 
(DENV). Moreover, HCV induces profound upregulation of lipogenic genes and its replication 
is attenuated by certain statins, which are known inhibitors of the cholesterol synthesis 
pathway. 
With the overall goal to decipher the role of cellular lipid homeostasis for the HCV replication 
cycle I have studied two interrelated aspects. The first one aimed at gaining a better insight 
into the link between HCV and LDs, the cellular lipid storage organelles. By performing a 
RNAi screen targeting host factors implicated in LD homeostasis the aim was to identify 
novel candidates involved in the replication cycle of HCV, and for comparative purposes, 
DENV, as well as genes involved in the regulation of LD-linked pathways. Obtained results 
highlighted a central role of LDs in the replication cycle of both viruses and revealed the 
cellular DEAD box RNA helicase 3 (DDX3) as a key factor in the replication cycle of HCV 
and DENV. By using reverse genetics and biochemical assays I found that DDX3 is recruited 
to LDs via the HCV core protein, but loss of recruitment had no discernable effect on the viral 
life cycle. Nevertheless, our results identified a yet unexplored role of DDX3 in the production 
of infectious HCV. 
The second part of this PhD thesis focused on another aspect related to the link between 
HCV and lipid homeostasis. Similar to other positive-strand RNA viruses, HCV remodels 
endomembranes to generate viral replication factories. There is increasing evidence that 
HCV co-opts cellular pathways in order to generate a specific lipid microenvironment that 
harbors the viral replication machinery. Using a set of microscopy-based approaches I found 
that HCV reorganizes the distribution of free cholesterol and possibly recruits it from the 
plasma membrane to the sites of viral replication. To understand the molecular mechanisms 
responsible for the reshaping of the cholesterol distribution, I performed a small scale RNAi 
screen targeting a selection of lipid transfer proteins (LTPs) implicated in direct, non-
vesicular lipid transport. In this way I identified several LTPs (i.e. Niemann-Pick disease type 
C1 (NPC1), Oxysterol-binding protein-related protein 1A, StAr-related lipid transfer domain 
protein 3, membrane associated phosphatidylinositol transfer protein 1) required for HCV 
replication, highlighting the critical role of endosomal cholesterol transport for efficient virus 
propagation. Pharmacological inhibition of endosomal cholesterol export induced lipid 
accumulation in lysosomal vesicles and impaired the transfer of free cholesterol to potential 
sites of viral replication. Concomitantly, viral RNA replication was impaired, implying that 
HCV RNA replication depends on the redistribution of plasma membrane unesterified 
cholesterol through the endosomal pathway. Thus, HCV might usurp LTPs such as NPC1 to 
allow recruitment of free cholesterol to the viral replication factories. 
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Zusammenfassung 
 
Man schätzt dass weltweit ca. 160 Millionen Menschen chronisch mit dem Hepatitis C Virus 
(HCV) infiziert sind. Da diese Infektion die Wahrscheinlichkeit für schwere Leberschäden  
(Leberfibrose, Leberzirrhose, hepatozelluläres Karzinom) massiv steigert, stellen Infektionen 
mit dem HCV ein globales Gesundheitsproblem dar. Die Fortschritte in der Entwicklung 
effektiver und selektiver Wirkstoffe haben in den letzten Jahren maßgeblich zur 
Verbesserung der antiviralen Therapie beigetragen. Dennoch stellen die damit verbundenen 
hohen Kosten, die hohe Anzahl an nicht diagnostizierten Infektionen sowie die Möglichkeit 
der erneuten Infektion nach erfolgreicher antiviraler Therapie weiterhin eine große 
Herausforderung in der Bekämpfung der HCV Infektion dar. Es deutet immer mehr darauf 
hin, dass Infektionen mit diesem hepatotropen Virus stark an den Lipid Metabolismus der 
Wirtszelle gekoppelt sind. So spielen beispielsweise Fett Tröpfchen (LTs) eine wichtige Rolle 
im Replikationszyklus des HCV, aber auch in dem des verwandten Dengue Virus (DENV). 
Des Weiteren induziert HCV die Expression von Genen, die im zellulären Lipid-Metabolismus 
involviert sind. Darüber hinaus beeinträchtigt die Behandlung mit Statinen, welche Inhibitoren 
des zellulären Cholesterol-Synthese Wegs sind, die Virusvermehrung.  
Mit dem Ziel die Rolle der zellulären Lipid Homöostase im Vermehrungszyklus des HCV 
besser zu verstehen habe ich zwei komplementäre Aspekte adressiert. Im ersten Teil meiner 
Arbeit habe ich versucht einen besseren Einblick in die Funktion der LTs, den zellulären 
Lipidspeicherorten, im HCV Vermehrungszyklus zu erlangen. Ausgangspunkt war ein RNAi-
basierter Suchtest, der zum Ziel hatte zelluläre Faktoren zu identifizieren welche sowohl für 
die zelluläre LT Homöostase also auch für den HCV und DENV Replikationszyklus relevant 
sind. Die hierbei erzielten Resultate zeigen, dass LTs von zentraler Bedeutung im 
Vermehrungszyklus beider Viren sind und deuten auf eine für beide Viren wichtige Funktion 
der zellulären DEAD box RNA Helikase 3 (DDX3) hin. Aufgrund der Ergebnisse 
biochemischer Versuche und reverser Genetik konnte ich feststellen, dass DDX3 durch das 
HCV Kapsidprotein an LTs rekrutiert wird, jedoch der Verlust dieser Rekrutierung keinen 
erkennbaren Einfluss auf die virale Vermehrung hat. Damit bleibt noch unklar, welche 
Funktion DDX3 für die Produktion von infektiösen Hepatitis C Viruspartikeln hat.  
Im zweiten Teil meiner Doktorarbeit fokussierte ich mich auf einen weiteren Aspekt der 
Wechselwirkung zwischen HCV und der zellulären Lipid Homöostase. Wie auch schon für 
andere Plusstrang RNA Viren beobachtet, induzieren die HCV Proteine eine massive 
Umorganisation intrazellulärer Membranen, die ein wesentliches Element der viralen 
Vermehrungsfabriken darstellen. Diese Vermehrungsfabriken besitzen eine spezifische 
Lipidzusammensetzung. Mit Hilfe verschiedener Mikroskopie-basierter Experimente konnte 
ich feststellen, dass das HCV die Verteilung von unesterifiziertem Cholesterol in der Zelle 
beeinflusst und dieses Lipid möglicherweise von der Plasmamembran zu den 
Replikationsorganellen rekrutiert wird. Im nächsten Schritt versuchte ich die molekularen 
Mechanismen aufzudecken, die es dem Virus erlauben diese Umverteilung von Cholesterol 
zu induzieren. Zu diesem Zweck habe ich einen RNAi Suchtest durchgeführt mit dem Ziel die 
für das HCV wichtigen Proteine des direkten Lipid Transports zu identifizieren. Auf diese 
Weise konnte ich verschiedene Lipid Transport Proteine (LTPs) wie etwa das Niemann-Pick 
Disease Type C1 Protein, Oxysterol-binding protein-related Protein 1A, StAr-related lipid 
transfer domain Protein 3 oder das membrane associated phosphatidylinositol transfer 
protein 1 identifizieren, welche wichtig für die Vermehrung des HCV sind. Diese Ergebnisse 
deuten auf eine wichtige Rolle des endosomalen Cholesterol Transports im viralen 
Vermehrungszyklus. So führte die pharmakologische Inhibierung des endosomalen 
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Cholesterol Transports zu einer Anreicherung von Lipiden in lysosomalen Vesikeln und 
reduzierte darüber hinaus den Transport von unesterifiziertem Cholesterol zu den viralen 
Replikationsorganellen. Gleichzeitig konnte ich beobachten, dass die virale RNA 
Vermehrung reduziert war. Es ist deshalb zu vermuten, dass die Vermehrung der viralen 
RNA von der Umverteilung und Rekrutierung von Cholesterol von der Plasmamembran 
durch den endosomalen Weg abhängt. Demzufolge scheint das HCV die Funktion von LTPs 
wie beispielsweise NPC1 zu nutzen, um unesterifiziertes Cholesterol zu den viralen 
Vermehrungsfabriken zu rekrutieren.  
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1 Introduction
2 I Introduction 
 
1.1 General aspects of hepatitis C virus (HCV) 
 
1.1.1 Hepatitis 
 
The term „hepatitis“ originates from the Greek hēpar = liver + itis = inflammation, which 
describes the inflammation of the liver. Hepatitis may result from several causes, such as 
prolonged abuse of alcohol or certain drugs, autoimmune or metabolic diseases, but also 
infectious agents such as bacteria or viruses [1]. The most common cause of hepatitis is the 
infection with either one of the five hepatitis viruses: hepatitis A virus (HAV), HBV, HCV, HDV 
and HEV. Due to their divergent molecular biology these viruses belong to different virus 
families, however all of them are strongly liver-tropic, causing liver inflammation. Acute 
infections with either virus might be asymptomatic or cause flu-like symptoms, jaundice 
(yellowing of the eyes and skin) abdominal pain, extreme fatigue, vomiting or nausea. While 
infections with HAV and HEV are mainly self-limiting, infections with type B, C and D often 
lead to chronic liver diseases, which increases the risk of infected patients to develop 
hepatocellular carcinoma (HCC) [2]. Acute infections with HCV remain most often 
unrecognized due to the lack of specific symptoms. Persistency is established in the majority 
(50-80%) of infected patients, which progressively develop hepatosteatosis and liver fibrosis, 
which is followed by liver cirrhosis and can then ultimately lead (in 3-5% of all chronically 
infected patients) to HCC [3]. Disease progression is suggested to be influenced by factors, 
such as age at time point of infection, gender, heavy alcohol consumption as well as co- 
infections such as with the Human Immunodeficiency virus (HIV) [4]. 
 
1.1.2 Discovery and classification of HCV 
 
The discovery made in the 1970ies, that the disease of many patients suffering of 
transfusion associated hepatitis, was neither linked to an infection with HBV nor with HAV led 
to the search for the identification of the non-A non-B infectious agent [5]. It was only in 1989 
that the HCV RNA genome was identified and isolated from non-A non-B positive patient 
serum [6].   
HCV has been grouped to the genus of Hepaciviruses within the family of Flaviviridae, 
which comprises members of two more genera such as the pestiviruses (i.e. Border-Disease 
virus (BDV)) and the flaviviruses (i.e. Dengue virus). All members of this family are 
enveloped viruses of 40-60 nm in diameter that exhibit a positive-sense single-stranded RNA 
genome [7]. The high mutation rate of the RNA-dependent RNA polymerase of HCV and the 
lack of proof-reading both account for the high heterogeneity of the viral genome. 
Accordingly, HCV circulates as a highly heterogenic population, named quasispecies, in the 
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blood of infected patients [8]. Conversely, the diversity is constrained by the intimate 
dependency of the virus on the cellular machinery [9].  On the basis of sequence analysis, 
HCV variants are classified into 7 groups, designated as genotype 1-7, that differ by 31-33% 
in their nucleotide sequence. Each group comprises further variants, designated as subtypes 
(labeled by letter a, b, etc.) that vary from each other by 20-25 % in their nucleotide 
sequence [8-10]. Despite the substantial genetic divergence between the genotypes, all 
variants share phenotypic features, such as a common virion structure, similarities in the viral 
life cycle, and the ability to cause persistence. In contrast some viral counteractions that aim 
to protect the virus from clearance through the immune system, appear to be genotype-
specific [9]. This becomes most clear when comparing the genotype specific susceptibility 
towards the standard-of-care (SOF) therapy, which allows the clearance of about 85% of all 
genotype 2 and 3 but only 45% of all genotype 1 infections. The mechanisms underlying 
these differences are still elusive [11]. 
 
1.1.3 Epidemiology and treatment 
 
Since its discovery almost 30 years ago and having been recognized as major cause of liver 
cancer, HCV has been focus of intense research [12]. Currently 3% of the world’s population 
is thought to be infected, 160 million people of which are chronically infected [13]. About 
350000-500000 deaths per year are attributed to HCV infections, deaths mainly caused by 
liver cirrhosis or HCC [12, 14]. Globally, approximately 27% of all liver cirrhosis and 25% of 
HCCs are attributed to HCV, indicating the massive health burden caused by the viral 
infection [15]. HCV infections are found worldwide, however the prevalence differs between 
countries. In some cases a high prevalence in a given country could be traced back to the 
use of contaminated medical equipment. Indeed Egypt is suggested to have the highest 
prevalence in the world (estimated at >10%) likely caused by the reuse of contaminated 
syringes and needles during a large schistosomiasis eradication program in the 1980s [16]. 
Furthermore, countries located in Africa, Latin America, Eastern Europe and Asia have been 
reported to have prevalence rates of about 3%, while the infection rates in countries of North 
America and Western Europe are lower (< 2%) [14]. In developing countries, new infections 
are mainly caused by the use of unscreened blood or blood products or unsterile medical 
equipment, while in developed countries the major transmission route is through unsafe 
injection drug use. Sexual transmission or the direct spread from mother to her baby have 
been reported but occur rather seldom [12, 13]. Interestingly genotypes are differently 
distributed throughout the world, with genotype 1 being the most common type accounting 
for 46.2% of all HCV infections. While genotype 1 is widely spread and accounts for the 
majority of infections in Europe, the Americas, Australia, and Asia, the second most common 
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genotype, genotype 3, is mainly restricted to South Asia and some Scandinavian countries. 
Genotypes 2, 4, and 6 are responsible for the majority of the remaining cases. Genotype 4 is 
mainly found in Africa and the Middle East, including Egypt. Genotype 6 is most common in 
South East Asia and genotype 2 is mainly in west and central Africa. Genotype 5 is only 
present in South Africa while the recently discovered genotype 7 was isolated in Canada 
from a patient from Central Africa (Figure 1.1) [17, 18]. As indicated above, the strong 
heterogeneity of HCV poses a great challenge in the development of pan-genotypic 
treatments or vaccines [12, 18].  
	  
Figure 1.1  Countries according to their most prevalent HCV genotypes. Data includes 1217 studies of 117 
countries, which represents 90% of the world’s population. Genotype 1 (indicated in red) is the most prevalent 
worldwide and accounts for 46.2% of all infections.  This is followed by genotype 3, giving rise to 30.1% of all 
infections, especially found in South Asia and parts of Scandinavia. The rest of all infections is caused by 
genotype 2, 4, and 6. Infections with genotype 5 are rather rare (1%). Adapted from [18].   	  
The ultimate goal of antiviral therapy is the cure from viral infection, which is indicated by a 
sustained virological response (SVR), defined as the absence of detectable HCV RNA in the 
patient’s serum 24 weeks after the end of treatment [19]. The standard-of-care (SOC) 
therapy comprises the combination of PEGylated interferon-alpha and the nucleoside 
analogue Ribavirin [20]. As indicated earlier, the success of SOC largely depends on the viral 
genotype. The fact that infections with genotype 1, the worldwide most prevalent genotype, 
are cleared with a success rate lower than 50% highlights the need of more efficient anti-viral 
therapeutics [21]. 2011 two direct-acting antiviral agents (DAA) targeting the NS3/4A 
protease, namely boceprevir and telaprevir, were approved and implemented in triple 
combination with the SOC for genotype 1 infections, thereby drastically increasing the SVR 
rate to around 75% [20]. However, the low barrier to resistance for these drugs, in addition to 
the severe side effects of triple therapy raises the need for improvement. Novel DAAs are 
currently being developed that aim at pan-genotypic activity with limited side effects [22]. 
Vaccine development has been challenging due to the large genomic heterogeneity of the 
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virus and the lack of immuno-competent small animal models that would allow the evaluation 
of the efficacy of vaccine candidates [23].  
 
1.2 Molecular biology of HCV  
 
1.2.1 HCV genome organization and viral proteins 
 
The HCV RNA genome consists of a single-stranded RNA molecule of positive polarity.  A 
single open reading frame (ORF) comprises approximately 3000 amino acids that encode for 
10 viral proteins [11]. At its 5’ and 3’ end the ORF is flanked by non-translated regions 
(NTRs) which form particular secondary RNA structures. Those structures are essential for 
viral genome replication and cannot be complemented in trans, thus called cis-acting RNA 
elements. Importantly the 5’ NTR encodes an internal ribosomal entry site (IRES) that directs 
cap-independent translation of the viral genome. Given the genome´s positive polarity, the 
viral RNA is directly translated by cellular ribosomes, giving rise to a viral polyprotein 
precursor [24, 25]. The N-terminus of the polyprotein comprises the structural proteins core 
and envelope glycoproteins, E1 and E2 that are constituents of the HCV particle. Together 
with the viroporin p7 and NS2, they are mediating particle assembly and release and thus 
are designated as the assembly module. The remaining non-structural (NS) proteins are 
involved in steps of RNA replication, thus summarized as the replication module (Figure 1.2) 
[11]. 
 
	  
Figure 1.2 Hepatitis C virus genome organization. The viral genome encodes for a single open reading frame 
(ORF) flanked at its 5’ and 3’ end by non-translated regions (NTR) important for RNA replication. Simplified RNA 
secondary structure of both NTRs as well as the start (AUG) and stop codon are indicated. An internal ribosomal 
entry site (IRES) is present in the 5’ NTR which induces ribosome-mediated translation of viral RNA giving rise to 
a single polyprotein precursor which is cleaved by viral proteases NS2-3 and NS3-4A (light and dark purple 
arrows) and cellular signal peptidases (scissors). The viral genome can be divided into the structural proteins 
comprising core and the two envelope glycoproteins E1 and E2 and the non-structural (NS) proteins 2, 3, 4A, 4B, 
5A, 5B. The viral core protein, E1, E2, p7 and NS2 are required for virus assembly, thus designated as the 
assembly module, while the remaining proteins are involved in genome replication and thus called the replication 
module. The asterisk indicates the cleavage of the core protein at its carboxy-terminal region, necessary for its 
translocation to lipid droplets. Adapted from [11]. 
  
6 I Introduction 
  
Interestingly all of the NS proteins have further been implicated in HCV assembly, although 
the precise mechanism is far from being understood [26]. Co- and post-translational 
processing of the viral polyprotein by cellular and viral proteases yields in mature structural 
and non-structural (NS) proteins. Endoplasmic reticulum (ER) signal peptidases catalyze the 
cleavage at the envelope glycoprotein E1/E2, E2/p7, p7/NS2 and core/E1 junction [11] . The 
latter cleavage yields in a core protein that remains bound to the ER through its association 
with the E1 signal peptide. Subsequent processing through a signal peptide peptidase then 
allows the liberation of the core protein from the ER and its association with lipid droplets 
[27].  Processing of the non-structural proteins is mediated by the viral proteases NS2-3, and 
NS3-4A [11, 21]. A general feature shared by all viral proteins is their association with host 
cell membranes. E1, E2, NS2, p7 as well as NS4B exhibit transmembrane domains, while 
hydrophobic domains such as amphipathic helices allow the tethering of the viral core 
protein, NS3, NS5A, NS5B and NS4A to membranes. The latter also acts as adaptor for NS3 
[11, 28]. The membrane topology of the viral proteins is schematically depicted in Figure 1.3.  
	  
Figure 1.3 Schematic representation of the membrane topology of cleaved HCV proteins. The viral proteins 
are tethered either through transmembrane domains (E1, E2, p7, NS4B) or hydrophobic segments such as 
amphipathic helices (core, NS3, NS4A, NS5A, NS5B) to host cell membranes. NS3 is associated with 
membranes through its cofactor NS4A but also through a small alpha- helix. Note that most of the viral proteins 
form higher oligomeric complexes or homo-/ heterodimers, but only a NS5A dimer is depicted. For instance the 
transmembrane domains of E1 and E2 are involved in their heterodimerization. Predicted functions of the proteins 
are indicated. Adapted from [11, 28]. 
Unraveling HCV protein function has been the focus of intense research and a brief 
overview of the current general concepts is presented in the next section.  
 
The HCV core protein (21-23 kDa) is the first protein being synthesized from the incoming 
viral RNA and thought to constitute the viral nucleocapsid [29]. The premature core protein is 
composed of three domains, of which large parts of the C-terminal domain 3 are involved in 
regulating the premature protein’s recruitment to the ER [30]. As indicated earlier, proteolytic 
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cleavage of the C-terminal 20 amino acids allows the release of the mature core protein and 
its subsequent association with lipid droplets [27]. The mature protein is divided by its amino 
acid composition into two domains. The N-terminal domain 1 (approximately 117 amino 
acids) is largely hydrophilic being enriched in positively charged amino acids, that most likely 
contribute to the RNA binding capacity of the protein [31, 32]. Domain 1 further catalyzes the 
homo-oligomerization of the core protein but also its interaction with the glycoprotein E1 
which might substantially contribute to nucleocapsid formation [33, 34]. The hydrophobic 
domain 2 at the C-terminus mediates membrane association, for example to lipid droplets, 
which is suggested to be important for core protein folding and stability [35]. An alternative 
reading frame resulting from a ribosomal frameshift near codon 11 in the HCV core 
sequence gives rise to a protein of up to 160 amino acids, designated alternative reading 
frame protein (ARFP). Although this protein was found to be expressed in HCV infected 
patients, its function in viral infection remains elusive [28, 36]. Interestingly the HCV core 
protein, in addition to NS4B (of genotype 3a), was reported to contribute to HCV-associated 
steatosis, most likely through the induction of the expression of lipogenic genes, thereby 
enhancing de novo lipid synthesis and uptake [37, 38] 
 
The envelope glycoproteins E1 (35 kDa) and E2 (70 kDa) are heavily glycosylated type 1 
transmembrane proteins with a large N-terminal ectodomain facing the ER lumen, and a 
small C-terminal transmembrane domain that contains an ER retention signal [39]. E1 and 
E2 are suggested to heterodimerize through their transmembrane domain [40]. Being 
constituents of the virion, they are suggested to be involved in early stages of viral entry such 
as receptor binding and membrane fusion [41, 42]. 
 
P7 (7 kDA) is a small hydrophobic ER resident protein, with two transmembrane passages 
linked through a short hydrophilic segment [43]. Given its ability to form pores in artificial 
membranes and its ion channel activity the protein is suggested to belong to the family of 
viroporins [28, 44-46]. P7 was shown to be dispensable for HCV RNA replication and this is 
most likely the case for virus entry too. However, it appears to be of significant importance for 
infectious particle production, which might require its ion channel activity but also direct 
interactions with other viral proteins, such as the non-structural protein 2 [44, 47, 48].  
 
Similar to p7, NS2 (23 kDa) is not directly required for RNA replication but essential for 
infectious virion assembly [28, 49]. NS2 is a cysteine protease localized to the ER membrane 
through three N-terminal transmembrane domains [50]. Together with the N-terminal one 
third of NS3 it catalyzes its autoproteolytic cleavage from the N-terminus of NS3, which is 
important to allow the formation of an active replicase [51]. NS2 is believed to act as scaffold 
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for virion assembly by bringing together constituents of the replicase machinery (NS3, NS5A) 
and the envelope glycoproteins. Indeed NS2 was shown to interact with NS3, NS5A, p7 and 
the envelope glycoprotein E2. Mutations that abrogate this interaction were also reported to 
impair HCV particle production, while pseudoreversions that restored these interactions also 
restored particle production to various extents [52, 53]. 
 
Besides being a cofactor for the NS2 protease, NS3 (72 kDa) exhibits multiple enzymatic 
activities. The N-terminal part of NS3 forms together with its cofactor NS4A (16 kDA) a 
protease that mediates the downstream processing of the polyprotein [54]. Two-thirds of the 
NS3 C-terminus harbors a RNA helicase/NTPase function, which mediates the ATP 
hydrolysis coupled unwinding of RNA duplexes or single-stranded RNA regions with 
extensive secondary structures [55, 56]. While the precise function of NS3 RNA helicase 
activity in the viral replication cycle remains elusive the protein has been shown to be 
involved in HCV RNA replication and particle assembly [57, 58]. NS3-4A is localized to the 
ER and can be found in ER–mitochondrial membrane contact sites, which likely promotes its 
ability to interfere with the cellular innate immune induction. In fact NS3-4A is able to cleave 
the RIG-I (retinoic acid inducible gene) adaptor MAVS (mitochondrial antiviral signaling 
protein) and the Toll-like receptor 3 adaptor protein TRIF [59] that mediate the type I 
interferon induction in response to upstream viral RNA recognition [60].  
 
While the N-terminus of NS4A (16 kDa) is involved in tethering NS3 to cellular membranes, 
and the proteins central core serves as cofactor to form the functional NS3-4A protease, little 
is known about the function of the C-terminal part of NS4A [61]. Alanine scanning 
mutagenesis studies on the protein’s C-terminus suggested an involvement of NS4A in RNA 
replication as well as particle production, possibly by interacting with other viral NS proteins 
[62, 63]. 
 
NS4B (27 kDa) is an integral membrane protein that contains a central core of four predicted 
transmembrane domains, while its C- and N-terminus are suggested to face the cytoplasm 
[64]. Only little is known about the function of NS4B binding to viral RNA and its NTPase 
activity [65]. In contrast the best described characteristic of NS4B is its ability to deform 
membranes. Upon overexpression, NS4B was found to localize to cytoplasmic spots [64]. 
Immunoelectron microscopy studies further suggested that these spots might correspond to 
a collection of highly curved membranes that were designated as the membranous web 
(MW) [64-66]. The latter was shown to harbor components of the replicase as well as 
subgenomic RNA and thought to represent the viral replication factories [67]. How NS4B can 
deform intracellular membranes remains elusive, however, its oligomerization appears to be 
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of importance. NS4B is thought to be a key driver of the virally induced membranous web, 
and therefore plays a crucial role in HCV RNA replication [68]. The recent observation that a 
particular mutation within the NS4B gene enhanced virion biogenesis, while not affecting 
RNA replication, points to a novel function in HCV particle production [69]. 
 
The present literature on NS5A (56-58 kDa) is enormous indicating the strongest interest in 
this still enigmatic protein. Although no enzymatic activity has been described for NS5A it is 
involved in HCV RNA replication, particle production and the modulation of the cellular 
environment [70].  Two differentially phosphorylated forms of NS5A, designated according to 
their molecular mass namely the basal p56 and hyperphosphorylated p58, have been 
described. The relevance of the NS5A phosphorylation status is unknown, however it was 
reported that changes in the p56/p58 ratio alter RNA replication efficiency [71]. NS5A is 
tethered through its N-terminal alpha helix to the cytosolic leaflet of the ER membrane, which 
is crucial for RNA replication [72]. Furthermore, the protein is divided into one highly 
structured domain (DI) and two unstructured domains (DII and DIII), which are separated by 
so-called low-complexity sequences (LCS). While large parts of DII and DIII can be deleted 
without affecting RNA replication, DI seems to be essential. Although it is widely accepted 
that domain I mediates NS5A dimerization, the mode of dimerization and the thus resulting 
structure of the dimer remains under debate [11]. Extensive mutagenesis studies on DII and 
DIII revealed that only the very C-terminal part of DII is necessary for RNA replication, while 
the remainder appears to be dispensable. Similarly complete or large deletions within DIII do 
not alter RNA replication efficiency, which allowed the generation of fluorescent fusion 
proteins of NS5A in the context of a RNA replication competent replicon [73]. Nevertheless 
these mutants are substantially impaired in particle production, most likely due to the loss of 
NS5A interaction with the viral core protein [74, 75]. The highly unstructured character of DII 
and DIII is thought to promote the numerous interactions of NS5A with viral and cellular 
proteins. Indeed the list of NS5A interaction partners is extensive and believed to allow the 
virus to interfere with various cellular pathways [76]. One of the most prominent interaction 
partners is the Phosphatidylinositol-4-Kinase III alpha (PI4KIIIA), an enzyme with lipid and 
protein kinase activity. The PI4KIIIA kinase activity is thought to be stimulated through its 
interaction with NS5A, catalyzing the phosphorylation of the viral protein as well as of 
phosphatidylinositol (PtdInsP) leading to the massive accumulation of Phosphatidylinositol-4-
phosphate (PtdIns4P) [77, 78]. Furthermore, NS5A was found to interact, depending on its 
phosphorylation status, with the vesicle-associated membrane protein A (VAP-A), which 
could possibly be important for the recruitment of downstream effectors such as the 
oxysterol-binding protein (OSBP) capable of binding VAP proteins [77, 79, 80]. A very recent 
study of two NS5A DIII mutants revealed distinct functions of the respective mutants in the 
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coordination of RNA encapsidation. In fact the mutation of a basic cluster disrupts NS5A-
RNA binding, while the protein correctly localizes to core covered LDs. The presence of a 
functional serine cluster is important to recruit NS5A to LD-associated core, while the 
protein’s RNA binding capacity remains unaltered [81]. It is proposed that NS5A, possibly in 
conjunction with NS2 [52], mediates the delivery of the viral genome from sites of RNA 
replication to the viral core protein (at LDs) for genome encapsidation [81]. 
 
Last but not least, NS5B (65 kDa) is the RNA-dependent RNA polymerase (RdRp) that 
catalyzes the propagation of the viral genome. The protein comprises a C-terminal catalytic 
domain that is linked to a hydrophobic transmembrane domain [57, 82, 83]. The viral RdRp 
uses the genomic RNA as template for the generation of a negative-strand RNA, from which 
then progeny RNA of positive polarity is generated [28]. 
 
1.2.2 Tools to study the HCV replication cycle 
 
Despite the discovery of HCV in 1989, it took another ten years until the development of a 
first cell culture system that allowed to study viral RNA replication [84].  
 
The establishment of the subgenomic replicon system was a major breakthrough that 
allowed to study the intracellular steps related to viral RNA replication and thus opened new 
doors for the search of antiviral drugs [84]. The subgenomic replicon is defined as the 
minimal viral genome capable of autonomous replication in cell culture. The first bicistronic 
replicon was established based on the full-length genome of gt1b, in which core to NS2 were 
replaced by a selection marker (neomycin phosphotransferase) under the control of the HCV 
IRES followed by the EMCV IRES regulating the expression of the non-structural proteins. 
Importantly the construct was flanked by the 3’ and 5’ NTR of HCV [85]. Further advances 
were made with the discovery of cell culture adaptive mutations present in the viral genome 
that were found to strongly enhance RNA replication [86, 87]. Additionally it appeared that 
throughout the selection process of replicon cells, only those that were most permissive were 
recovered, thus representing a small proportion of the whole cell population. This led to the 
observation that cell clones (Huh7.5 and Huh7/Lunet) that were “cured” from RNA replication 
through IFN-alpha treatment were more permissive to HCV RNA replication as compared to 
their parental cell line [88, 89]. These discoveries set the ground for the establishment of 
subgenomic replicons of different genotypes such as of 1a, 2a, 3a 4a, and 5a of which only 
genotype 2a does not require adaptive mutations for efficient RNA replication [87, 90-93]. 
The development of reporter (i.e. Firefly luciferase) replicons substantially facilitated 
measurement of subgenomic RNA replication [84]. However attempts to broaden this system 
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to the replication of full-length virus failed, most likely due to the fact that adaptive mutations 
that enhance replication are detrimental for infectious particle production [94, 95].  
 
The development of HCV pseudoparticles (HCVpp) allowed studying basic steps in virus 
entry.  These particles consist of a retroviral core governing a retroviral genome that encodes 
a reporter or fluorescent protein to ease detection of viral entry. Importantly the lipid envelope 
comprises the authentic HCV envelope glycoproteins E1 and E2. Thus by the use of the 
pseudoparticles the role of both glycoproteins in early events of viral entry can be studied. 
Given that the HCVpp does not reflect an authentic HCV particle, that in fact is heavily 
lipidated through its association with lipoproteins and neutral lipids, it may not recapitulate 
the authentic virus entry [96, 97]. 
 
The establishment of HCV trans-complemented particles (HCVTCP) is based on the ability 
of efficient trans-encapsidation of HCV subgenomic RNA into infectious particles. These 
particles are obtained by the in trans expression of the core-NS2 cassette in cells that 
replicate the subgenomic replicon. The thereby formed particles contain the subgenomic 
replicon RNA and thus are only able of a single round of infection and do not spread.  This 
contributes to the beauty of the TCP system that allows to study the entire viral replication 
cycle under improved biosafety levels (BSL2) [98].  
 
A major breakthrough that finally allowed the recapitulation of the complete HCV replication 
cycle in cell culture (the HCVcc system) was the isolation of a full-length HCV genome 
(genotype 2a) from a patient suffering from fulminant hepatitis, thus designated as JFH1 
(Japanese fulminant hepatitis 1). This unique isolate was found to efficiently replicate and 
produce infectious particles without the need of adaptive mutations in cell culture [99]. 
Subsequent generation of an intragenotypic chimera led to the establishment of the 
frequently used Jc1 chimera, that exhibits the core-NS2 moiety of the 2a isolate J6CF fused 
to NS3-5B and flanked by the 3’ and 5’ NTR of JFH1 [100]. This chimera showed exceptional 
high virion assembly efficiency and was basis for the establishment of several full-length 
reporter viruses such as the Renilla luciferase reporter virus JcR2A [77, 100].  
 
1.2.3 The viral replication cycle  
 
When studying the viral replication cycle it becomes apparent that HCV propagation is 
tightly linked to hepatocyte function. Some details showing the link between cellular lipid 
metabolism and the viral replication cycle are discussed under 1.2.4.  In the following section 
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a brief overview of the distinct steps of the viral replication cycle are presented, which is 
illustrated in Figure 1.4. 
	  
Figure 1.4 Schematic representation of the HCV replication cycle. Step 1: The engagement of the virion with 
several cell surface receptors triggers its uptake through clathrin-mediated endocytosis. Step 2: Upon release of 
the viral RNA into the cytosol it becomes translated through ribosomes at the rough ER giving rise to the viral 
polyprotein. The latter is processed through cellular and viral proteases giving rise to the mature proteins that 
build up the replicase. Step 3: Genome replication is suggested to occur at remodeled intracellular membranes, 
induced by a concerted action of viral and host proteins. The so-called membranous web (MW) harbors single, 
double and multi-membrane vesicles. Step 4: The viral RNA-dependent RNA polymerase NS5B catalyzes the 
generation of a negative-sense RNA, which is then used as template for the synthesis of multiple progeny RNA 
copies of positive polarity. Step 5: Lipid droplets (LD) can be found in close proximity of the MW and are most 
likely involved in the assembly process of infectious virions. The viral nucleocapsid it suggested to bud into the 
ER, thereby acquiring the glycoprotein E1 and E2 containing lipid envelope. Step 6: Secretion of the virion might 
follow the conventional secretory pathway. Adapted from [11]. 
A series of events mediate the entry of HCV into target cells. Viral particles circulate in blood 
in association with very-/ low-density lipoproteins (VLDL/ LDL) and this feature might 
substantially dictate receptor binding and membrane fusion during viral entry [101]. Initial 
attachment of the viral particle to the cell surface is mediated most likely by the interaction of 
envelope glycoproteins or virion associated lipoproteins with cell surface glycosaminoglycans 
or the LDL receptor (LDLR) [39, 102, 103]. This is followed by specific interactions of the 
envelope protein E2 with the tetraspanin Cluster of Differentiation 81 (CD81) [104] and the 
scavenger receptor class B type I (SR-BI) [105], followed by subsequent binding to the tight 
junction protein claudin-1 (CLDN1) [106] and occluding (OCLN) [107], the latter of which is 
involved in post attachment steps (Figure 1.4, step1). The involvement of two more 
  Introduction I 13    
 
receptors, namely the LDLR and NPC1L1 will be presented in more detail in 1.2.4. The virus 
enters through clathrin-mediated endocytosis [108] and fusion requires low ph in endosomes 
[109] possibly involving the action of the envelope proteins E1 and E2 [110, 111]. Low pH in 
endosomes but also other triggers might contribute to the fusion of the viral envelope with 
endosomal membranes [109]. Upon uncoating the viral single-strand RNA genome is 
released into the cytosol, where it can directly be translated by ribosomes of the rough ER 
driven by the IRES at the 5’NTR of the genome [28]. One prominent host factor known to 
modulate viral RNA translation is the microRNA 122 (mir122) that binds the HCV RNA at 
three different positions. Mir122 is highly expressed in (and specific to) liver cells and is 
thought to stimulate RNA translation through enhancing the interaction with ribosomes, but 
also to increase RNA stability and RNA replication (Figure 1.4, step2) [11, 112]. Upon viral 
RNA translation the polyprotein precursor is processed by the action of host and viral 
proteases giving rise to the mature viral proteins (Fig 1.4, step2) [28].  
 
Viral genome replication is suggested to occur in association with ER-derived membranes. 
Indeed, similar to other positive-strand RNA viruses, HCV has been shown to remodel 
intracellular membranes in conjunction with several host factors, such as the PI4KIIIA. The 
thereby generated membranous web harbors the presumed sites of RNA replication (Figure 
1.4, step3) [66, 77, 113, 114]. Details on the structure and biogenesis of these replication 
factories will be summarized in 1.2.4. The fact that in HCV replicating cells there is about a 5-
to 10-fold excess of positive-sense RNA as compared to the negative-strand template, 
indicates that the latter can be used by the NS5B RdRp to generate multiple progeny RNAs 
[85]. 
 
The LDL/ VLDL-like nature of HCV virions found in patient serum suggests an involvement of 
the VLDL pathway in HCV particle assembly [115],  which is presented in more detail in 
1.2.4. In a first step viral RNA needs to be transported from the replication sites to sites of 
particle assembly. The latter are presumably at close proximity to LDs covered by the HCV 
core protein (Figure 1.4, step4) [116]. How this transfer is orchestrated is still elusive. It may 
involve NS2 that could bring assembly and replication compartments together through 
multiple interactions with other viral proteins such as NS3, NS5A and the envelope protein 
E2 [52, 53]. Additionally NS5A was suggested to deliver viral RNA from potential sites of 
replication to core to promote nucleocapsid formation [81]. Through subsequent budding of 
the nucleocapsid into the ER the virion most likely acquires its lipid shell containing the viral 
glycoproteins E1 and E2. The motors that could drive the budding event are not deciphered 
yet. HCV particles are finally secreted through their export along the conventional secretory 
pathway (Figure 1.4, step5, 6) [11, 117].  
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1.2.4 HCV and cellular lipid metabolism 
 
Many steps of the HCV replication cycle are linked to the cellular lipid metabolism. In 
the following section only a few highlights are presented, demonstrating the intimate 
connection of the virus and lipid metabolic pathways. 
 
A key characteristic of infectious HCV particles is their heterogeneous but low buoyant 
density with particles of lowest density being most infectious [115, 118]. Numerous studies 
on the biochemical composition of HCVcc and serum-derived HCV revealed common 
features with serum LDL and VLDL, thus called lipoviroparticle (LVP), implicating a tight link 
of host lipid metabolism with virus entry and particle production. In fact, several classes of 
Apo-lipopoteins were found to be associated with serum-derived as well as HCVcc particles 
[115, 119-121]. Furthermore mass-spectrometry analysis of purified HCVcc particles 
revealed striking similarities in the lipid composition with LDL and VLDL with the virion being 
especially enriched in cholesterol esters [115, 120]. The viral mimicry of LDL/ VLDL might 
confer several advantages for instance by providing ligands for receptor-mediated 
endocytosis into hepatocytes [122].  
 
As indicated before HCV entry is a multi-step process that involves the interaction of the 
virion with various cellular receptors (Figure 1.4, step 1). It is interesting to note that the 
physiological role of three of them, namely SR-B1, LDLR and NPC1-L1 lies in the uptake of 
low density particles and cholesterol. SR-B1 and LDLR are present at the basolateral site of 
hepatocytes, the site of virus entry [122, 123]. The assumption of LDLR being a pivotal entry 
factor has recently been challenged, favoring, given the physiological function of the receptor 
in cholesterol metabolism, its involvement in post entry steps such as replication [122, 124]. 
SR-B1 is a crucial factor for HCV entry into hepatocytes and an authentic receptor for the 
uptake of HDL [105, 122]. Gene silencing or chemical inhibition of NPC1-L1 was reported to 
impair HCVcc infection [125]. With the receptor present at the apical site of hepatocytes, 
NPC1L1 is most likely indirectly involved in HCV entry through regulation of the cellular 
cholesterol uptake [122]. While the mimicry of LDL or VLDL might facilitate the attachment to 
entry receptors, the lipid composition of the virion as well as of the target membrane is 
crucial for membrane fusion events [111, 126]. Cholesterol depleted or sphingomyelin-
hydrolyzed viral particles exhibited markedly reduced infectivity [126]. Interestingly the 
fusogenicity of HCVcc with liposomes was enhanced by the presence of cholesterol or 
cholesterol and sphingomyelin in target membranes [111]. Thus, the lipid and protein 
composition of both host and viral membranes is crucial for receptor recognition and cell 
entry.  
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A hallmark of HCV replication is the tremendous rearrangement of intracellular membranes, 
characterized by the accumulation of vesicles and designated as membranous web (MW). 
Extensive studies have aimed at elucidating the function as well as lipid and protein 
composition of the MW. Early studies showed that the HCV induced MW contained replicase 
components such as non-structural proteins and viral RNA of positive polarity [67].  
Subsequent electron microscopy studies on the course of MW morphology throughout HCV 
infection revealed that while single and double membrane vesicles (DMVs) were the main 
constituents of the MW, the appearance of DMVs correlated well with the viral RNA 
replication kinetics. Furthermore, they represented the predominant type of vesicles. Later in 
the course of viral infection multi-membrane vesicles were observed, which could possibly 
result from ER stress [113]. Biochemical analysis of purified DMVs from HCV stable replicon 
cells showed their enrichment in replicase components, as well as active replicase capable 
of de novo HCV RNA synthesis, indicating that DMVs might represent sites of viral RNA 
replication [114]. Although NS4B and NS5A alone can efficiently perturbate membranes, 
authentic MW formation requires the expression of the NS proteins 3 to 5B, while HCV RNA 
replication is dispensable [113]. The origin and lipid components of the membranous 
web and DMVs are far from being deciphered. DMVs were shown to remain associated with 
their outer membrane to the ER and form primarily closed structures (90%), which raises the 
question of how important components of RNA replication can be exchanged [113]. Several 
findings point to a specific lipid environment of the viral replication sites: i) The membrane-
protected nature of viral RNA against RNAse digestion is overcome under treatment 
conditions that disrupt detergent resistant membranes (DRMs) [127]. ii) The association of 
non-structural proteins with detergent resistant membranes is sensitive to cholesterol 
removal [127, 128]. iii) Depletion of cholesterol from purified DMVs alters their size, 
suggesting the lipid being of importance for vesicle structure [114]. iv) The most prominent 
evidence is the massive generation of PtdIns4P at HCV replication sites through NS5A-
mediated PI4KIIIA induction, reported to be critical to retain the structure of DMVs [77]. It has 
been reported that the locally elevated PtdIns4P levels could serve to facilitate host 
membrane reorganization through the recruitment of PtdIns4P binding effectors, such as the 
lipid transfer proteins OSBP and FAPP2/PLEKHA8 (Oxysterol-binding protein and four-
phosphate adaptor protein 2/plekstrin homology domain containing A8 protein) to HCV 
replication sites. The virus might then exploit the proteins physiological function for the 
recruitment of specific lipid species [79, 129].  
HCV benefits from multiple functions of DMVs. The formation of membrane enclosed 
compartments allows to increase the local concentration of factors needed for RNA 
replication and could serve as physical tether for the RNA replication complex. Being 
surrounded by membranes, recognition or degradation of the viral RNA through innate RNA 
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sensors or cellular RNAse respectively, might become limited. Additionally 
compartmentalization could promote the effective coordination of different steps of the viral 
replication cycle such as RNA translation, replication and encapsidation by spatially 
separating the involved factors (i.e. ribosomes, core proteins). Thus it is not surprising that 
the formation of specialized membranous compartments is shared by diverse positive-strand 
RNA viruses (reviewed in [130]). 
 
Additional to the tremendous membrane rearrangement observed in HCV infected cells, the 
virus causes less ‘obvious’ alterations in the cellular lipid metabolism. Indeed, transcriptomic 
and proteomic analysis of infected cells revealed changes of factors involved in lipid 
biosynthesis [131, 132]. In fact, HCV infection was reported to induce the activation and 
expression of SREBPs in hepatic cells, which are transcription factors stimulating cellular 
lipogenesis [37]. In agreement with this, the levels of lipogenic transcripts such as of the fatty 
acid synthase (FASN) and of the HMGCoA (3-hydrox-3-methylglutaryl coenzyme-A) 
reductase (HMGCoAR), the rate limiting enzyme of the mevalonate cholesterol synthesis 
pathway, are elevated in infected cells [57, 132]. Over the past years, the contribution of 
cholesterol to genomic RNA replication has gained increasing attention. First insights were 
obtained by the use of statins, being potent inhibitors of the cholesterol mevalonate pathway 
targeting the HMGCoA reductase and impairing viral replication [133]. However it has to be 
taken into consideration that statins do not only interfere with cholesterol but also non-sterol 
isoprenoid synthesis [134]. Indeed, it was reported that the addition of isoprenoid 
geranylgeraniol restored viral replication upon statin treatment, arguing for an involvement of 
geranylgeranylation in HCV replication [135]. Nevertheless, in line with the notion of 
cholesterol being an important structural component of the viral replication sites, depletion of 
cholesterol has been reported to impair viral replication [79]. 
 
HCV particle production is suggested to involve lipid droplets, although their precise 
contribution is not well understood [116]. The notion of LDs to occupy a central role in 
infectious particle production, is supported by an increasing amount of experimental 
evidence: i) Throughout HCV infection, the viral structural core protein coats cytosolic lipid 
droplets (cLDs) which is followed by the recruitment of the viral replicase machinery [136, 
137]. ii) HCV particle production is hampered when the recruitment of core or NS5A to cLDs 
is stalled [136, 138]. iii) DGAT1 and DGAT2 are catalyzing the last step in triacylglycerol 
synthesis, thus being crucial for LD biogenesis. Inhibition of DGAT1 mediated recruitment of 
the HCV core protein to LDs was reported to impair assembly of infectious particles [139]. iv) 
Electron-microscopy studies revealed a close proximity of LDs to DMVs and to virus-like 
particles [113, 136].  
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The fact that HCV circulates in the blood as particles of low buoyant density similar to LDL 
and VLDL suggests a tight connection of lipid droplet homeostasis and the VLDL pathway 
with the assembly and release of infectious particles [115]. The microsomal triglyceride 
transfer protein (MTP) catalyzes early steps in VLDL assembly comprising the lipidation of 
ApoB [140]. While some studies reported a dependency of HCV particle production on MTP 
function, others found that the expression of core results in the host protein’s inactivation 
[141, 142]. Details on how different lipid and protein components are brought together for 
VLDL formation, and how and when it converges with HCV particles assembly, are not fully 
elucidated yet. One possibility is that the nascent virions acquire neutral lipids and 
lipoproteins such as ApoE during the budding process, forming a hybrid particle. On the 
other hand the virion might encounter VLDL at a later stage during particle egress [57, 143]. 
 
1.3 Dengue virus – lipid droplets and the membranous web 
 
While the herein presented study focuses mainly on investigating the connection of HCV and 
the cellular lipid homeostasis, Dengue virus was included as a phylogenetically related but in 
its molecular biology partially distinct virus. Being another member of the family of 
Flaviviridae (genus Flavivirus) DENV shares similarities but also substantial differences with 
HCV in its genome organization and replication cycle, which are not focus of this work. The 
dedicated reader is referred to [144, 145]. However the next section aims to illustrate a 
selection of differences and similarities between DENV and HCV and their intimate link to 
cellular lipid metabolism. To this point the current knowledge on the role of lipid droplets in 
the DENV replication cycle will be presented. Moreover general features of the DENV 
induced membranous web will be highlighted.  
The role of lipid droplets (LDs) in the DENV replication cycle is far from being understood. 
The present knowledge on the function of LDs in DENV replication is scarce and partially 
contradicting. In fact some studies report an increase in LD number upon DENV infection 
[146] others describe a DENV-induced autophagy dependent consumption of LDs, potentially 
for the generation of ATP through fatty acid beta-oxidation [147]. In contrast to HCV the 
DENV capsid protein is the only viral protein found at LDs [136, 146]. A DENV capsid 
mutant, carrying a mutation that abrogates membrane, thus LD association, was shown to be 
impaired in particle production. However it cannot be excluded that the impaired virion 
production was caused by a general defect of the cytosolic capsid mutant per se. Intriguingly 
the in trans expression of the aforementioned mutant was shown to impair RNA replication 
[146]. This could suggest that capsid localization to LDs is important for the coordination of 
distinct steps of the viral replication cycle and might serve to prevent untimely encapsidation 
of viral RNA at early stages of replication [148]. While in case of HCV the recruitment of the 
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viral replicase to LDs [136] as well as the presence of LDs at close proximity to the viral 
replication sites and to virus like particles points to a role of LDs in particle assembly [113], 
no such evidence is present for DENV. In fact, in case of DENV, virions were frequently 
observed at sites directly opposing the viral replication organelles, indicating that virion 
assembly might occur in their direct proximity and not involve LDs [149].  
Similar to other RNA viruses, DENV has been reported to substantially remodel intracellular 
membranes inducing various membrane morphologies, including convoluted membranes 
and vesicular invaginations of the rough ER [130, 149]. This stands in contrast to HCV that 
primarily induces the formation of DMVs [113]. Immuno-electron microscopy analysis 
indicated the presence of viral dsRNA, a marker for replicating RNA, as well as of NS 
proteins in the DENV induced ER invaginations. These vesicles were further shown to exhibit 
pores that connect the interior of the vesicle with the cytosol that could allow the exchange of 
constituents needed for RNA replication and RNA per se [149]. As mentioned earlier, the 
HCV mediated induction of the MW and RNA replication was reported to substantially 
depend on the lipid kinase activity of PI4KIIIA. In contrast DENV RNA replication does not 
require PI4KIIIalpha/beta [77, 130]. Interestingly DENV NS3 was shown to recruit the FASN 
and to stimulate FASN activity [147]. 
 
1.4 The DEAD box RNA helicase 3, X-linked, (DDX3X, DDX3) 
 
DDX3 belongs to the family of DEAD box RNA helicases, characterized by nine conserved 
motifs, one of which is eponymous. These conserved motifs are required for helicase activity 
and shared by all members of the family, while flanking sequences possibly confer helicase 
specificity mediating the interaction with other factors [150]. The family members, including 
DDX3, have been implicated in several cellular RNA related processes, such as RNA 
splicing, RNA export, transcriptional and translational control. DDX3 has further been 
implicated in tumorigenesis, acting either as oncogene or tumorsupressor [151]. The 
discovery that Vaccinia V7 protein can interfere with virus induced IFNβ induction possibly 
through its interaction with DDX3, shed light on a novel role of DDX3 in antiviral signaling 
[152]. By now several reports suggest an involvement of DDX3 in the type I IFN induction 
pathway, either at the level of RNA sensing, at the level of intermediate signaling or at the 
level of transcriptional control of IFNβ promotor activation [151]. Besides the described 
antiviral function in case of Vaccinia virus infection, DDX3 was reported to be an important 
host dependency factor for HIV, DENV or HCV replication [76, 151, 153, 154]. A yeast two-
hybrid screen that aimed to identify host proteins of human liver cells interacting with the 
HCV core protein identified DDX3 as a putative interaction partner. This interaction was 
further mapped to a N-terminal region of the HCV core and a C-terminal arginine and serine 
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rich sequence of the DEAD box RNA helicase [155, 156]. It still remains to be elucidated 
whether this interaction is of any benefit to the virus. Until now several reports indicated a 
proviral role of DDX3 in early events of the HCV replication cycle. However given the wide 
spectra of possible functions exerted by the protein its precise role has not been unraveled 
[76, 154, 157]. Very recently DDX3 was suggested to act as sensor of HCV RNA, inducing a 
signaling cascade that leads to the induction of lipogenesis and increases the cellular neutral 
lipid content, thereby possibly promoting viral assembly [158]. Several other members of the 
DEAD box RNA helicase family have further been implicated to support HCV genomic RNA 
replication, such as DDX1 and DDX6 [159]. 
 
1.5 Cellular membrane homeostasis 
 
1.5.1 Cellular membrane compartmentalization  
 
The ability to form spatially and functionally different compartments is essential for the 
cell to create appropriate microenvironments for the simultaneous execution of distinct 
cellular processes. These compartments are substantially dependent on the lipid composition 
of their limiting membrane, which not only gives rise to a physical border but defines the 
identity of the cellular organelle [160]. The intrinsic biophysical properties of each lipid have a 
major influence on membrane curvature, thickness, fluidity and charge, which affects the 
partitioning of proteins. Indeed the phospholipids phosphatidylserine (PtdSer) and 
phosphatidylinositol (PtdIns) are key determinants giving rise to a negative surface charge 
that favors the interaction with positively charged domains of peripheral and membrane 
proteins [161]. The unique distribution of different phosphoinositides (PtdInsP) species, the 
phosphorylated forms of phosphatidylinositol, substantially contributes to the function of the 
corresponding organelle by regulating the recruitment of specific effector proteins. Just to 
mention a few, the Phosphatidylinositol-4,5-bisphosphate is mainly found at the PM and 
serves as an adaptor for the endocytic machinery thus initializing clathrin-mediated 
endocytosis. Phosphatidylinositol-3-phosphate (PtdIns3P) is present in the limiting 
membrane of endosomes and participates in essentially most of endosomal functions by 
recruiting of PtdIns(3)P binding proteins. Golgi function is dependent on the presence of 
Phosphatidylinositol-4-phosphate and its effectors, regulating the transport of Golgi vesicle 
formation [162, 163]. A hallmark of the plasma membrane (PM) is its enrichment in lipid rafts 
composed of sphingolipids and 65% of the cellular free cholesterol. This substantially 
contributes to the PM membrane properties, being more rigid and thicker as compared to the 
rather loosely organized ER membrane that is, despite being the site of cholesterol 
synthesis, low of cholesterol and mainly composed of neutral unsaturated phospholipids 
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[161, 162, 164]. The lipid composition of the endosome system varies from early endosome 
(EE) to late endosome (LE). According to this the content of cholesterol gradually decreases 
with the maturation of EE to LE [162]. Given that the lipid composition substantially 
contributes to the membrane’s signature and thus organelle function [163], it is of major 
importance for the cell to maintain distinct lipid territories while providing dynamic exchange 
between organelles for biosynthetic and endocytic traffic [161]. 
 
1.6 Intracellular lipid traffic 
 
In order to maintain a non-random lipid distribution, the cell employs different strategies. 
The PtdInsP signature of intracellular membranes is under control of a cohort of 
phosphoinositide kinases and phosphatases that catalyze the lipids inter-conversion directly 
at the target membrane [163, 165]. While such local synthesis accounts for the regulation of 
PtdInsP pools, this does not hold true for sterols and sphingolipids [166]. In fact, the ER 
represents the cell’s main lipid factory generating phospholipids and sterols destined for 
various intracellular membranes. On the contrary sphingolipid synthesis is restricted to the 
Golgi compartment [161, 166]. According to this, lipids need to be efficiently transported 
along the biosynthetic but also the endocytic pathway [167]. In principle different motilities 
contribute to the lipids’ unique cellular distribution. Although to a different extent, they may 
move laterally, which enables lipid transfer between connected membranes. Furthermore 
energy dependent or independent exchange of lipids between the membrane leaflets allows 
the generation of an asymmetric lipid distribution. However, transport of large amounts of 
lipids to distant organelles mainly depends on vesicular traffic [166, 168]. How lipid sorting 
occurs and how vesicles choose their specific lipid cargo for a particular compartment is not 
fully elucidated yet. Nevertheless it has been demonstrated that depending on the intrinsic 
properties of the lipid they preferentially sort into high ordered or disordered phases [169]. 
This feature contributes to lipid sorting, especially since the distinct lipid domains were 
reported to differ in their flexibility and ability to be modulated and shaped into tubular or 
vesicular structures [169-171]. Indeed COPI vesicles mediating the retrograde transport of 
cargo from the Golgi to the ER were found to exhibit a lower sphingomyelin content as 
compared to the parental Golgi membrane [171]. Thus exclusion of sphingomyelin from the 
retrograde transport might favor its anterograde traffic along the secretory pathway [166]. 
The concept of specific lipid species becoming excluded from the retrograde transport might 
at least, in part, account for the traffic of cholesterol, which preferentially associates with 
sphingolipids forming lipid rafts [172]. Although bulk transport of lipids is to a large extent 
mediated by an energy-dependent vesicular transport, increasing evidence points to 
alternative non-vesicular transport mechanisms for specific lipid species, particularly 
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essential for organelles not connected to the vesicular transport machinery such as 
mitochondria and lipid droplets [166, 168]. The generation of membrane contact sites, where 
two membranes are brought to close proximity of about 10 nm, might favor spontaneous 
monomeric lipid transport [166]. In fact, the ER generates MCS with several 
endomembranes, such as lysosomes, lipid droplets, mitochondria, the Golgi apparatus and 
the plasma membrane and for each of them lipid transfer activity has been reported [166, 
173-175]. Given the slow and inefficient spontaneous diffusion of lipids from donor to target 
membranes, monomeric lipid transport is often assisted by lipid transfer proteins (LTPs) 
[168].  
 
1.6.1 Lipid transfer protein (LTP)-assisted lipid transport  
 
1.6.1.1 The concept of Lipid transfer protein (LTP)-assisted lipid transport  
 
LTPs are suggested to facilitate lipid transfer at MCS by increasing the rate of lipid 
desorption from the donor membrane [168].  
 
	  
Figure 1.5 Scheme of Lipid transfer protein (LTP)-assisted lipid traffic at membrane contact sites (MCS). 
(A)Through a specific targeting motif, a LTP can associate with the donor membrane which leads to the opening 
of the hydrophobic lipid binding pocket. Upon desorption of the target lipid from the donor membrane and its 
binding through the LTP, the LTP engages a closed conformation (shown in graph) which then allows the 
transport of the lipid through the aqueous phase (indicated by dashed line). At the target membrane the lipid is 
released into the membrane leaflet. As indicated recognition of both cellular compartments is mediated by specific 
membrane targeting domains of the LTPs, that recognize particular lipid species or proteins, designated as 
'membrane receptors' in the graph. (B) LTPs can interact with both membrane receptors simultaneously thus 
stabilizing the MCS and increasing the efficiency of lipid transfer. Adapted from [166]. 
In principle LTPs may engage two major conformations: an ‘open’ conformation, that reflects 
the membrane bound form of the protein ready for the uptake of the target lipid and a ‘closed’ 
conformation representing the transport-competent form, with a lid covering the lipid 
containing binding pocket [166, 176]. The association of LTPs to the donor membrane 
possibly induces a conformational change, which leads to the opening of the hydrophobic 
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lipid-binding cavity. Upon absorption of the target lipid, the LTP dissociates from the donor 
membrane and shuttles to its destination, where the lipid is introduced into the target 
membrane (Figure 1.5) [166, 168]. Although the directionality of LTP-mediated transport is 
defined by the lipid’s concentration gradient, specific sequence motifs drive their membrane 
association, thus restricting LTP activity to certain cellular locations [168, 177-180]. For this 
reason, monomeric lipid transport through LTPs might represent a transfer mechanism that 
allows the extraction or delivery of specific lipid species at a certain membrane domain [168].  
	  
Figure 1.6 Model of lipid transfer at the Golgi/ER interface mediated by the membrane associated 
phosphatidylinositol transfer protein 1 (PITPNM1), the oxysterol-binding protein (OSBP) and the ceramide 
transfer protein (CERT). PITPNM1 can bind to VAP proteins present at the ER and mediates the bidirectional 
transfer of phosphatidylinositol (PtdIns, from ER to Golgi) and phosphatidylcholine (PC, from Golgi to ER). PtdIns 
at the golgi is substrate of the Phosphatidylinositol-4-kinase III beta (PI4KIIIbeta) for the generation of 
phosphatidylinositol-4-phosphate (PtdIns4P).  OSBP and CERT can become recruited to the ER through their 
interaction with VAP proteins. Additionally they bind PtdIns4P present at the Golgi. CERT drives the transfer of 
ceramide from the ER to Golgi membranes, while OSBP might catalyse the bidirectional traffic of cholesterol and 
PtdIns4P. The ER resident phosphatidylinositol phosphatase Sac1 hydrolyzes PtdIns4P to PtdIns. Importantly, a 
concerted action of PITPNM1, PI4KIIIbeta and Sac1 allows the maintenance of a PtdIns4P gradient, which 
determines the directionality of lipid transport mediated through OSBP or CERT. Note, only lipids directly involved 
in the lipid transfer are depicted [181, 182]. Adapted from [181]. 
According to their lipid binding specificity, LTPs are grouped into three major classes: 
Phospholipid transfer proteins, sterol transfer proteins and sphingolipid transfer proteins 
[168]. Prominent members of these classes are the membrane associated 
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phosphatidylinositol transfer protein 1 (PITPNM1/ Nir2), the oxysterol-binding protein OSBP 
and the ceramide transfer protein (CERT) suggested to drive in a concerted fashion 
monomeric lipid transport between ER and Golgi. For details see Figure 1.6 [180, 181, 183]. 
 
1.6.2 Lipid transfer proteins involved in sterol transport 
 
Sterol transfer proteins of several protein families are implicated in non-vesicular sterol 
transfer [184]. The LTPs studied in this work are presented in more detail in the following 
section. 
 
The oxysterol binding protein (OSBP)-related/ like protein (ORP/OSBPL) family 
consists of at least 12 members, which share a highly conserved sterol binding domain at the 
C-terminus and in most cases a pleckstrin homology domain (PH) and/ or a VAP (vesicle 
associated membrane protein (VAMP)- associated protein) binding motif, denoted FFAT (two 
phenylalanine (FF) in acidic stretch) important for their cellular targeting [185, 186]. The most 
prominent and also founding member of this family is OSBP that has so far obtained most 
attention. OSBP is a multifunctional protein involved in lipid transport, cell signaling and 
regulation of cholesterol homeostasis [79, 186]. Recent in vitro studies propose a four step 
model of OSBP-mediated cholesterol (dehydrogesterol (DHE)) transfer between PtdIns4P 
rich and VAP-A containing membranes, supposedly the Golgi and ER compartments [182]. 
By interacting with VAP-A (ER) and PtdIns4P (Golgi), through its FFAT or PH domain 
respectively, OSBP allows the tethering of two opposing membranes. Subsequently the 
protein acts as a sterol/ PtdIns4P exchanger, catalyzing the bidirectional transport of 
cholesterol and PtdIns4P. PtdIns4P is then hydrolyzed by the ER resident Sac1 
phosphatase, which might provide the metabolic energy driving the lipid transport (Figure 
1.7) [182].  
As indicated in Fig 1.6, OSBP function at ER Golgi MCS is tightly linked to the action of other 
LTPs. Interestingly several viruses have been reported to exploit the sterol transfer activity of 
OSBP. Indeed, some enteroviruses and HCV were recently shown to recruit OSBP to 
PtdIns4P rich replication organelles, likely for the delivery of cholesterol that may support the 
formation of the tremendous membrane rearrangements induced by both viruses [79, 187]. 
  
24 I Introduction 
	  
Figure 1.7 Scheme of Oxysterol-binding protein (OSBP) mediated cholesterol and phosphatidylinositol-4-
phosphate (PtdIns4P) exchange at ER/ Golgi membrane contact sites. Step 1: Membrane tethering: OSBP 
can promote the formation of ER/ Golgi membrane contact sites through binding VAP-A at the ER and PtdIns4P 
at the Golgi through its FFAT motif or the plekstrin homology (PH) domain, respectively. Step 2: Cholesterol is 
then bound by the sterol binding (SB) domain and transported from the ER to the Golgi. Step 3: In exchange, 
PtdIns4P is trafficked from the Golgi membrane to the ER. Step 4: The ER resident phosphatidylinositol-4-
phophate phosphatase Sac1 hydrolyses PtdIns4P, which leads to the formation of phosphatidylinositol (PtdIns). 
The concentration gradient of PtdIns4P from Golgi to ER determines the directionality of the lipid transport. Note, 
the lipid composition of the ER and Golgi membranes is not adequately depicted. Only lipids directly involved in 
the OSBP cycle are shown. Adpated from [182]. 
Another member of the OSBPL family, OSBPL1A was shown to regulate the association of 
LE with the microtubule transport machinery depending on the organelles cholesterol 
content. Thus OSBPL1A acts as sterol sensor that links the LE sterol levels to their cellular 
positioning [188, 189]. Interestingly RNAi-mediated gene silencing of another OSBPL, 
namely OSBPL5 has been reported to induce the accumulation of cholesterol in late 
endosomes, indicating its potential role as cytosolic lipid acceptor [190]. The functions of the 
other ORP/OSBPL family members and their true involvement in cholesterol transport, is far 
less understood [191].   
 
The second main family involved in sterol transfer comprises members of the steroidogenic 
acute regulatory protein (StAR)-related lipid transfer (START) domain protein family, 
characterized by a conserved 210 AS sequence that folds into a hydrophobic lipid binding 
pocket. The 15 members of this family are further grouped into six subfamilies depending on 
their sequence similarity and ligand binding affinity, which varies from binding to cholesterol, 
oxysterol, phospholipids or sphingolipids to possibly fatty acids [184, 192, 193]. 5 of them 
have been reported to bind cholesterol: StAR (STARD1) and STARD3 are both tethered to 
the mitochondria or LE membrane respectively, with the former protein being essential for 
the cholesterol transport from the outer mitochondrial membrane (MM) to the inner MM, thus 
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catalyzing the rate limiting step in steroid synthesis [184]. Mutagenesis studies on STARD3 
revealed its importance in the mobilization of cholesterol from LE and transfer to either 
mitochondrial membranes or possibly other acceptors [184, 194]. STARD4, 5 and 6 are 
cytosolic proteins that share an affinity for cholesterol or hydroxycholesterol. STARD4 has 
been reported to regulate the transport of cholesterol to the endocytic recycling compartment 
(ERC) and the ER and therefor altering cholesterol esterification and cholesterol mediated 
regulation of cellular lipid homeostasis [192, 195]. The involvement of STARD5 and STARD6 
in cellular cholesterol traffic has not been elucidated yet [192].  
 
The Niemann-Pick Type C (NPC) disease is a lipid storage disorder caused by mutations in 
the NPC1 or NPC2 gene that cause an accumulation of LDL derived unesterified cholesterol 
in lysosomal compartments [196, 197]. The role of NPC1 and NPC2 in cholesterol mobility 
from lysosomes is described in more detail in the following section.  
 
1.6.3 Lipid transfer proteins – Niemann-Pick Disease Type C (NPC) 1 (NPC1) protein  
 
Pioneer work of Albert Niemann and Ludwig Pick in the 1920s led to the identification of a 
neurodegenerative lysosomal lipid storage disorder, autosomal recessively inherited, and 
designated as “Niemann-Pick disease” [196, 198]. To date two different groups are defined: 
Niemann-Pick Disease Type A and B are caused by defects in sphingomyelinase, resulting 
in intracellular accumulation of sphingolipids, thus designated as sphingolipidosis. Niemann-
Pick disease type C is caused in 95% of the cases by roughly 300 distinct single point 
mutations in the NPC1 gene and in rare cases by mutations in the NPC2 gene [198, 199]. 
With the discovery of defective esterification of exogenous LDL and abnormal intracellular 
cholesterol traffic in NPC, the disorder was considered to be primarily a cholesterol lipidosis 
[198, 200]. NPC disease phenotype is very heterogeneous regarding the onset and severity 
of disease progression but ultimately lethal. Symptoms are neurologic, manifesting besides 
others in progressive ataxia (failure of muscular coordination), dystonia (abnormal muscle 
contraction) and dementia (loss of cognitive abilities) [201-203]. Treatment is currently mainly 
restricted to treatment of symptoms [202]. 
 
NPC1 is a transmembrane protein, localized to the limiting membrane of late endosomal 
and lysosomal compartments [204, 205]. As mutations in NPC1 were reported to be linked to 
a cholesterol trafficking defect characterized by the lipid’s accumulation in lysosomal 
structures, NPC1 was suggested to function in the mobilization of free cholesterol from LE/ 
LY [206]. Recent reports propose a handoff mechanism that involves both NPC1 and NPC2 
in endosomal cholesterol transport, the latter protein being a small glycoprotein resident in 
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the lysosomal lumen. According to this NPC2 might catalyze the transfer of free cholesterol 
resident in the internal membranes to the limiting membrane of LEs, where it could be 
subsequently accessed by NPC1 [207]. How cholesterol is next transported to the PM, the 
ER or the Golgi network remains unclear. Nevertheless it is likely that post-lysosomal 
cholesterol traffic involves the vesicular transport machinery, possibly under the control of 
NPC1 function [206, 208, 209]. In fact, it has been reported that the motility of NPC1 positive 
vesicles is almost abolished in presence of an inactive form of the protein [210]. It remains to 
be elucidated whether the trafficking defect of endosomal structures in NPC1 deficient cells 
is a consequence of cholesterol accumulation that in turn has been reported to alter the 
association of endosomes with the cellular transport machinery [211]. Although cholesterol 
accumulation has been described as the hallmark of NPC1 disease pathogenesis it is not 
surprising that other lipids passing through the LE/LY system such as sphingolipids and 
gangliosides are also affected [196, 212].  
 
1.6.4 Sterol transport and sterol homeostasis 
 
The cell depends on the maintenance of specific local cholesterol concentrations, 
characterized by a gradual increase of the membranes’ cholesterol content from the ER to 
the Golgi and to the PM. Similarly, vesicles of the early endocytic pathway, such as the 
recycling endosomes contain high cholesterol levels, which decrease along compartments of 
the later endocytic route, such as LE and LY [162, 167]. On the one hand the uneven 
distribution of cholesterol is modulated by a concerted action of vesicular and non-vesicular 
mechanisms, on the other hand, overall cellular cholesterol content is tightly regulated in 
order to prevent detrimental effects of excess free cholesterol [213, 214]. Three major 
pathways allow the cell to adapt to changing cholesterol needs. Through the regulation of de 
novo synthesis of cholesterol, its uptake from the plasma membrane or lipoproteins or 
through altering cholesterol efflux and lipid conversion, fine-tuning of cellular cholesterol 
levels is achieved. The abundance of proteins involved in these pathways is regulated either 
at the transcriptional level, or in need of acute modulations by ubiquitin dependent 
degradation [215]. Two major transcription factors, the liver X receptors (LXRs) and the sterol 
regulatory element binding proteins (SREBPs) control the expression of proteins involved in 
cholesterol homeostasis depending on the cellular sterol levels [215].  
 
Proteins involved in de novo synthesis of cholesterol are expressed as a function of the 
cellular sterol content [216]. The ER appears to be the major organelle when it comes to 
cellular cholesterol turnover, as it is place of cholesterol synthesis and esterification. 
Additionally sensing of the cellular free cholesterol content involves SREBPs and the 
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accessory proteins SCAP (SREBP cleavage activating protein) and Insig present in a protein 
complex at the ER [217, 218]. In detail, low cholesterol levels induce a conformational 
change in SCAP which allows the dissociation of SREBP-SCAP from the ER retention 
protein Insig. Once SREBP-SCAP reaches the Golgi, proteolytic cleavage allows the release 
of SREBP and its transport to the nucleus in order to induce transcription of the respective 
target genes [217, 219, 220]. At present, three different isoforms of SREBPs are known, with 
SREBP1c and SREBP2 regulating the expression of genes of fatty acid synthesis or of 
cholesterol metabolism, respectively, while SREBP1a is suggested to target both pathways. 
Important target genes of SREBP2 encode for the HMGCoAR and the LDL receptor [215, 
221].  
 
The uptake of LDL is catalyzed by clathrin dependent LDL receptor (LDLR)-mediated 
endocytosis [215]. Cholesterol is then liberated from cholesteryl esters of LDL through the 
activity of acid lipase present in early compartments So far it is unresolved at which stage 
cholesterol leaves the endocytic pathway to be further trafficked to the PM and the ER [217, 
222]. Hepatocytes can further obtain cholesterol through the SR-B1 mediated uptake and 
processing of HDL [223]. 
 
The efflux or conversion of cholesterol to cholesterol derivatives allows the cell to prevent 
the accumulation of excessive free cholesterol. Members of the ATP-binding cassette 
transporter (ABC) protein family, in particular ABCA1, have been reported to catalyze the 
transfer of cholesterol to apolipoproteins for the secretion of HDL particles [215, 224, 225]. 
Interestingly the expression of ABCA1 and others is under the control of the LXR 
transcription factor, which itself is activated by oxidized cholesterol derivatives (oxysterols) 
[226, 227]. Cholesterol can further be converted into precursors of bile acids, which are 
subsequently secreted. Most importantly excessive cholesterol at the ER is readily esterified 
and transferred for the reversible storage in lipid droplets [217]. 
 
1.6.5 Lipid droplets  
 
Lipid droplets are spherical structures, which consist of a neutral lipid core, mainly 
composed of triacylglycerides and cholesterol esters, surrounded by a phospholipid 
monolayer associated with proteins [228, 229]. Different models are suggested for the 
biogenesis of LDs, each of them involving the ER membrane, which is the site of neutral lipid 
synthesis [230]. Most likely, the accumulation of neutral lipids between ER leaflets leads to 
the formation of a lipid lens, which subsequently grows and buds from the ER giving rise to a 
nascent cytosolic LD. The nascent droplet may also remain connected to the ER. Alternative 
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models describe instead of a budding process an excision of LDs from both ER leaflets, 
leaving a pore behind. According to the vesicular budding model the accumulation of neutral 
lipids at the luminal site of the ER drives the formation of a vesicle giving rise to LDs [229, 
231]. LDs have for a long time been underappreciated as simple storage vessels of neutral 
lipids. Indeed excess fatty acids and cholesterol are converted into neutral lipids and 
deposited in LDs, thus protecting the cells from toxic effects of exceeding lipid accumulation 
[232]. This storage is transient and can be reversed when cells are in need of lipids for 
membrane synthesis or the generation of energy [233]. Increasing evidence suggest a 
dynamic involvement of LDs in lipid homeostasis, but also in signal transduction by providing 
precursors for the synthesis of messengers compounds [230].  
The particular function of a LD is mainly determined by its protein coat composition [230]. 
Members of the PAT (perilipin, adipose differentiation related protein (ADRP), tail anchoring 
protein 47 (Tip47)) protein family are so far the best characterized LD associated proteins 
that substantially alter neutral lipid storage. Perilipin is of particular interest, as upon 
phosphorylation, the protein switches from its role in neutral lipid storage to lipid mobilization 
by the recruitment of the hormone sensitive lipase (HSL). ADRP is suggested to function 
similarly and regulates the accessibility of the LD core through the Adipose triglyceride lipase 
(ATGL). Importantly both PAT (perilipin and ARDP) proteins are constitutively associated 
with LD [234]. Tip47 potentially function in the biogenesis of LDs [235]. With the aim two 
identify novel proteins regulating LD homeostasis, two different siRNA screens were 
performed in drosophila cells, monitoring the effect of gene knockdown on different LD 
features such as LD size and distribution. This led to the identification of the COPI system, 
that appears to substantially regulate lipolysis. Pharmacological inhibition or gene 
knockdown of COPI subunits induced neutral lipid storage, manifested in larger LDs [236, 
237]. Interestingly, interference with COPI function led to an accumulation of the two PAT 
proteins ADRP and Tip47 at LDs, while the levels of ATGL were reduced [237].  
Hepatocytes have the ability to store neutral lipids not only in cytosolic LDs but also in ER 
luminal LDs, possibly providing essential lipids for the synthesis of very low density 
lipoproteins [140]. As indicated in section 1.2.4 and 1.3, LDs play a central role in the 
replication cycle of HCV and DENV respectively.  The observation that a pathogen exploits 
LDs function is not only restricted to HCV or DENV, but a common feature of multiple 
pathogens.  There is a substantial list of bacteria which usurp LDs most often for nutritional 
purpose [230]. 
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1.7 Aim of study 
 
In the herein presented work I aimed at obtaining a better insight into the link between HCV 
and host cell lipid homeostasis. Being an obligate intracellular virus, HCV depends on and 
hijacks cellular pathways in order to reshape cellular functions for its own benefit. Indeed, 
similar to other plus-strand RNA viruses HCV remodels endomembranes for the generation 
of its replication factories and usurps cellular organelles, such as LDs, the latter being 
involved in cellular lipid metabolism.  
 
In the first part of my PhD thesis I focused on investigating the role of LDs in the replication 
cycle of the two LD-dependent viruses HCV and DENV. To this end, I used as starting point 
a RNAi screen that was performed by Dr. G. Alvisi in our laboratory. This screen targeted 
host genes implicated in LD homeostasis and aimed at identifying novel candidates 
regulating the HCV/ DENV replication cycle as well as LD-dependent pathways. Top hits 
were several components of the COPI machinery as well as DDX3. By using additional 
knock-down approaches as well as biochemical methods and reverse genetics I wanted to 
decipher the role of these host cell factors and their contribution to efficient replication of 
HCV and DENV.  
 
The second part of my PhD thesis aimed at unraveling the molecular details of whether and 
how HCV impacts the cellular cholesterol homeostasis, as earlier studies had shown that 
cholesterol is a critical component of the membranous HCV replication factory. By the use of 
several cholesterol-specific dyes I first sought to visualize the dynamic distribution of 
endogenous or exogenously added unesterified cholesterol in HCV replicating cells. To 
unravel the molecular details how HCV might remodel cholesterol homeostasis I performed a 
small scale RNAi screen targeting a selection of LTPs implicated in direct lipid transfer. The 
results of this screen should set the basis for subsequent studies that aimed at 
understanding the role of LTP-mediated endosomal cholesterol traffic in the viral replication 
cycle. Using several HCV model systems and shRNA-mediated gene knockdown, I sought to 
define the viral steps dependent on LTP function. These studies should be complemented by 
pharmacological perturbation of the LTP-mediated endosomal lipid transport and by 
evaluation of these perturbations on the different steps of the HCV replication cycle as well 
as lipid distribution. Finally, I planned to use electron microscopy in order to determine 
whether endosomal cholesterol traffic contributes to the integrity of the HCV replication 
factory.   
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2.1 Materials 	  
2.1.1 Antibodies and dyes 
 
Table 2.1 Primary antibodies and dyes used in this study 
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Table 2.2 Secondary antibodies used in this study 
	  
2.1.2 Buffers and solutions 
 
Table 2.3 Buffers and solutions used for protein work 
	  
 
Table 2.4 Buffers and solutions used for nucleic acid work 
	  	  	  
34 I Materials and Methods 
 
Table 2.5 General buffers and solutions  
	  	  
Table 2.6 Buffers and solutions for luciferase activity assays  
	  	  
2.1.3 Plasmid constructs 	  
Table 2.7 pTM-based expression constructs 
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Table 2.8 pFK based viral vectors used in this study
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Table 2.9 NPC1 expression constructs 
	  	  
Table 2.10 Retroviral vectors 
	  
 
2.1.4 Chemicals and compounds 
Table 2.11 Chemicals and reagents 
 
Table 2.12 Compounds used in this study 
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2.1.5 Media and antibiotics 	  
Table 2.13 Media  
 
Table 2.14 Antibiotics  
	  	  
2.1.6 Enzymes and kits 
 
Table 2.15 Enzymes  
	  	  
 
Table 2.16 Kits 
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2.1.7 DNA and RNA oligonucleotides 
 
Table 2.17 DNA oligonucleotides (oligos) used for cloning 
	  	  
Table 2.18 DNA oligonucleotides (oligos) used for qPCR 
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Table 2.19 shRNA oliognucleotides used in this study 
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Table 2.20 siRNA oligonucleotides used in this study 
	  	  
2.1.8 Instruments 
 
Table 2.21 Instruments relevant for this study 
	  	  
2.1.9 Transfection reagents 
 
Table 2.22 Transfection reagents 
	  	  
2.1.10 Cell culture 
 
Eukaryotic cell lines 
HEK-293T: highly transfectable derivative of the human embryonic kidney 293 cells that 
contains the SV40 T antigen [238].  
Huh7.5: highly permissive cell line for genomic and subgenomic HCV RNA replication 
derived from a human hepatoma cell line that was cured from subgenomic HCV RNA 
replication by IFN-alpha treatment [88]. 
Huh7.5FLuc: Huh7.5 cells that constitutively express the Firefly luciferase that can be used 
as an estimate for cell number [77]. 
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Huh7/Lunet: highly permissive for HCV genomic and subgenomic HCV RNA replication, but 
not for infection due to low CD81 expression levels. Cell line derived from Huh7 human 
hepatoma cells that were cured from subgenomic HCV RNA replication by treatment with an 
inhibitor for NS5B [239]. Compared to naive Huh7 cells, Huh7/Lunet exhibit a higher potency 
of HCV RNA replication.  
Huh7/LunetCD81H: derived from the parental cell line Huh7/Lunet by stable transfection of a 
CD81 expression construct [240]. 
Huh7/Lunet_Lucubineo_JFH1 (here designated as LucUbiNeo_JFH1): Huh7/Lunet cells 
stably replicating the subgenomic HCV RNA of genotype 2a and the Firefly Reporter under 
the selection of G418 (1mg/ ml) [241].  
Huh7/Lunet_Lucubineo_Con1ET (here designated as LucUbiNeo_Con1ET): Huh7/Lunet 
cells stably replicating the subgenomic HCV RNA of genotype 1b and the Firefly reporter 
under the selection of G418 (0.5 mg/ ml). Replication enhancing mutations are: E1202G, 
T1280I and K1845T [86].  
Huh7/Lunet-T7 (Zeocin/ Blasticidin): Huh7/Lunet cells constitutively expressing the T7 RNA 
polymerase of the T7 bacteriophage that allows the cytosolic expression of T7 driven 
expression constructs under Zeocin or Blasticidin selection [242].  
Huh7/LunetCD81H-RFP: Huh7/LunetCD81H cells stably expressing the Tag-RFP-T that 
allows the visualization of the cell boundary, generated by Dr. G. Alvisi [243]. 
Huh7/LunetCD81H_core-NS2: Huh7/LunetCD81H cells stably expressing the core-NS2 
proteins of JFH1 (gt2a), kindly provided by Dr. JY. Lee.  
VeroE6 cells: African green monkey kidney cells [244].  
 
Bacteria 
For classical cloning the chemically competent E-ColiDH5α (F-, ϕ80dlacZΔM15, Δ(lacZYA-
argF)U169, deoR, recA1, endA1, hsdR17(rK-, mK+), phoA, suE44, λ-, thi-1, gyrA96, relA1) 
were used (homemade). 
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2.2 Methods 	  
2.2.1 Cell culture 
 
Long-term storage and thawing of cells 
Cells were kept at -80°C or in liquid nitrogen for long-term storage. Therefor cells of a 
confluent 15 cm dish were detached by trypsinization and resuspended in DMEMcplt. Cells 
were spun for 5 min at 700 g and the pellet was resuspended in 11 ml of ice-cold cryo 
solution. The cell suspension was immediately aliquoted in re-chilled cryotubes. Cells were 
first frozen at -80°C before transfer to liquid nitrogen. 
For thawing of the cells, the cryotubes were heated in a 37°C water bath before 
resuspending in 10 ml preheated DMEMcplt. Cells were spun for 5 min at 700 g, the pellet 
was resuspended in fresh DMEMcplt and cells were seeded in the respective cell culture 
dish. If necessary, 24 h post seeding the media was replaced by antibiotic containing media 
for selection. 
 
2.2.2 Nucleic acid standard methods 
 
DNA restriction digest 
Restriction digest of plasmid DNA or PCR products was performed using NEB enzymes. The 
amount of enzyme added to the reaction was adjusted depending on the amount of DNA, on 
the number of restriction sites, as well as on the unit definition given by the manufacturer. 
Digest was either performed in a total volume of 100 µl (for preparative digestions) or 20 µl 
(for analytic digestions).  
 
Dephosphorylation of DNA 
In order to prevent ligation of linearized dsDNA without the integration of the desired insert 
during ligation, the 5’ phosphates were dephosphorylated using calf intestine alkaline 
phosphatase (CIP). Subsequently the DNA was purified by agarose gel electrophoresis. 
 
Ligation of DNA 
Ligation of the insert DNA fragment and the respective DNA backbone was carried out using 
the T4 DNA Ligase. The reaction mixture contained 1x Ligase Buffer, 1U T4 DNA Ligase and 
the respective amounts of DNA in a 1:3 ratio of backbone to insert. Ligation was performed 
at RT for 2 h. An empty control lacking the insert was included in order to estimate true 
integrations of the insert into the backbone. 
 
Agarose gel electrophoresis and gel extraction 
DNA fragments can be separated according to their size in an agarose gel matrix by applying 
an electric field. Depending on the size of the respective DNA fragments 0.8-2%  agarose 
gels in ionic 1x TAE buffer were prepared. For visualization of the DNA under ultraviolet light 
ethidium bromide (0.1% final concentration) was added to the agarose gel. The DNA was 
mixed with 1/6 volume of 6x protein loading buffer before loading onto the gel. The addition 
of a DNA molecular weight marker (Lambda-DNA/Eco130I/Styl) allowed the determination of 
the length in base pairs of the respective DNA fragment. After electrophoresis the desired 
DNA fragment was cut out of the gel and purified using the Nucleospin Extract II kit 
according to the manufacturer’s protocol.  
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Transformation of competent E.Coli DH5α 
50 µl of competent E.Coli DH5α  were incubated with the desired DNA or ligation reaction for 
10 min on ice. Heat shock was performed for 45 sec at 42°C allowing the uptake of DNA, 
followed by a 5 min incubation of the bacterial suspension on ice. Next, 250 µl of plane LB-
medium were added and the bacteria were incubated for 1 h at 37°C while shaking. Finally 
they were plated on the respective antibiotic-containing LB agar plate and incubated over 
night at 37°C to allow colonies to form. 
 
Plasmid DNA isolation and purification from bacteria 
Depending on the desired amount of DNA, small scale (6 ml), medium scale (100 ml) or 
large scale (200 ml) bacterial E.Coli culture were grown over night. Extraction and 
purification of the desired DNA from the bacterial culture was performed according to the 
manufacturer’s protocol. 
 
Quantification of nucleic acid concentration 
Determination of nucleic acid concentration was performed using the NanodropLite 
Spectrophotometer (Thermo Fisher Scientific, Waltham USA) measuring the absorbance at 
260 nm. The ratio of absorbance at 260 and 280 nm A260/280 was used as an indicator of 
nucleic acid purity, with proteins exhibiting an absorbance peak at 280 nm. Therefor 
A260/280 between 1.8 and 2 was considered to represent pure DNA, and when larger than 2 
pure RNA. 
 
DNA transfection by lipofection 
Target cells were seeded 1 day prior to transfection. Transfection of plasmid DNA was 
performed according to the manufacturer’s protocol (Mirus Biol, Madison, USA).  
 
RNAi transfection by lipofection 
Target cells were seeded either one day prior to transfection or transfected while being 
seeded according to the manufacturer’s protocol using the Lipofectamine® RNAimax 
transfection reagent (Thermo Fisher Scientific, Waltham, USA). 
 
RNAi transfection by electroporation 
Cells were detached from the cell culture dishes, thoroughly resuspended and counted. The 
required amount of cells was spun down, resuspended and washed in PBS and again spun 
down. The pellet was finally resuspended in cytomix to a final concentration of 1.5x10^7 
cells/ ml in case of Huh7.5 or 1x10^7 cells/ ml in case of bigger cells such as Huh7/Lunet 
cells. For big electroporations 400 µl of the cell suspension were added to either 5 µg of 
subgenomic viral RNA or 10 µg of full-length viral RNA and electroporated at the following 
settings: High Capacity 975 µF, voltage 270 V, expected time constant approx. 18/20 ms. In 
case of small epos 100 µl of the cell suspension were mixed with either 2.5 µg of viral RNA 
or 2.5 µl of 100 µM siRNA at the following settings: High Capacity 0.5 µF, voltage  166 V, 
expected time constant approximate 12/14 ms. In case of co-electroporation equal volumes 
of siRNA and vRNA were used in a total volume of 2.5 µl. Electroporated cells were 
immediately resuspended in fresh DMEMcplt. The electroporations were performed using the 
gene pulser II (Bio-Rad Laboratories Inc., Hercules, USA) and GenePulser®/MicroPulserTM 
Electroporation cuvettes with 0.2 or 0.4 cm gap respectively (Bio-Rad). 
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In vitro transcription and RNA transfection  
For the generation of in vitro transcripts 10 µg of the respective plasmid DNA were linearized 
by enzymatic digest (i.e. MluI in case of JFH1 based constructs) and subsequently purified 
using the Nucleospin® RNAII kit (Machery-Nagel, Düren, Germany). Next the in vitro 
transcription reaction mixture consisting of 80 mM HEPES (ph 7.5), 12 mM MgCL2, 2 mM 
spermidine, 40 mM dithiothreitol (DTT), 3.125 mM of each nucleoside triphosphate, 1u/µl of 
RNasin (Promega), 0.6 U/µl of T7 RNA polymerase (homemade), 1U/µl RNasin (Promega) 
and the purified DNA in a total volume of 100 µl was incubated for 2 h at 37°C. Subsequently 
0.3 U/µl of T7 polymerase was added for another 4 h of incubation. Transcription was 
terminated by the incubation with 2U of RNAse free DNAse (Promega) per µg DNA for 1 h at 
37°C. RNA was purified by acidic phenol/chloroform extraction at 4°C followed by 
precipitation with isopropanol at room temperature. RNA pellets were dissolved in RNAse 
free water. The quality of the obtained in vitro transcript was checked by agarose gel 
electrophoresis.  
 
Total cellular RNA isolation  
Isolation of total cellular RNA was carried out using the Nucleospin® RNAII kit (Machery-
Nagel, Düren, Germany). Typically 350 µl of buffer A1 supplemented with 1% beta-
Mercaptoethanol were added to a confluent 24 well and RNA isolation was performed as 
described in the manufacturer’s protocol.  
 
Quantification of cellular RNA by reverse transcription (RT) and quantitative PCR 
(qPCR) 
In order to generate cDNA from isolated RNA the High Capacity cDNA Reverse Transcription 
Kit (Thermo Scientific, Waltham, USA) was used. First a 2x reaction master mix (5ul/sample) 
was prepared containing 2x RT Buffer, 4 mM dNTP Mix, 2x RT Random Primer, 25 U 
Reverse transcriptase and RNase inhibitor. This was then added to 5 µl of the isolated RNA, 
mixed well and centrifuged to eliminate air bubbles. The reaction mixture was placed into a 
Thermocycler (Eppendorf, Hamburg, Germany) using the following program: 10 min at 25°C, 
120 min at 37°C, 5 min at 85°C, storage at 4°C.  The cDNA was diluted 1:10 in RNase free 
water and directly used for qPCR using the iTaq Universal SYBR Green Kit (Bio-Rad, 
München, Germany). A master mix (12 µl/ sample) consisting of 2x iTaq Universal Bio Rad 
and 0.5 µM of the corresponding sense and antisense primer was prepared, to which 3 µl of 
pre-diluted cDNA was added. Each reaction was conducted in triplicates. Additionally the 
RNA levels of the housekeeping gene GAPDH were determined in parallel for each 
condition. 
 
2.2.3 Standard cloning methods 
 
Polymerase chain reaction (PCR) 
The PCR allows the specific amplification of a desired DNA fragment from a given DNA 
template. The PCR reaction mixture contained 0.2 mM of each dNTP, 2 µM of sense and 
antisense primer, 0.5 µg template DNA, 1x PCR Buffer in addition to 0.02 U/µl FideliTaq for 
amplicon sizes smaller than 1.5 kb. Amplification was carried out using a thermocycler 
following the program: i) 2 min at 95°C, ii) 30 sec at 95°C for denaturation, iii) 30 sec at 55°C 
for annealing of the primers, iv) 1 min per 1kb for elongation, v) 4 min at 68°C followed by 
termination at 4°C. Steps ii)-iv) were repeated 15-20 times. For amplification of DNA 
fragments bigger than 1.5 kb the AccuPrime (Thermo Scientific, Waltham, USA) was used 
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according to the manufacturer’s protocol. In short the reaction mixture of a total volume of 25 
µl contained 1x PCR reaction buffer, 0.5 µg of template DNA, 2 µM of sense and antisense 
primer and 0.25 µl AccuPrime. The above-described PCR cycling program was used with an 
extended elongation time allowing the amplification of long DNA fragments. 
 
Site-directed mutagenesis using overlap PCR 
By performing overlap PCR, point mutations were introduced into the respective target DNA. 
In principle PCR in combination with the use of partially complementary 
oligodesoxyribonucleotide primers containing nucleotide alterations allow the introduction of 
mutations into the target sequence. In addition to the mutagenesis primers two primers 
flanking the target sequence upstream and downstream are needed. In a first PCR either the 
upstream primer (sense) and the mutagenesis primer (antisense) or the downstream primer 
(antisense) and the mutagenesis primer (sense) were combined leading to the generation of 
DNA fragments that contained the desired nucleotide alteration either at the 3’ or 5’ end.  
These fragments were separated by agarose gel electrophoresis and subsequently purified 
using the Nucleospin Extract II Kit (Machery Nagel). In a last PCR 1 µl of each purified PCR 
product was used as template in combination with the upstream primer (sense) and the 
downstream primer (antisense). This overlap PCR allowed the generation of amplified DNA 
fragments that carried the desired mutations.  
 
Cloning of Y35A or F24A mutants 
These mutations were separately introduced by site directed mutagenesis into the respective 
backbones (Table 2.8).  
 
Table 2.23 Constructs generated in this study with the respective restriction enzymes used for cloning 
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A summary of the primer pairs used for site directed mutagenesis as well as the enzymes 
used for the digest of the backbone and insert are listed in Table 2.23.	  
 
Cloning of NPC1 expression and shRNA rescue construct 
A plasmid encoding the human NPC1 cDNA was ordered from Amsbio and used as template 
for cloning a shRNA resistant construct into the retroviral pWPI vector. To this end 5 single 
silent point mutations were introduced into the target sequence of the shRNA of interest. The 
respective primer and enzymes used for cloning are depicted in the table below.  
 
Table 2.24 NPC1 expression plasmids used in this study  
	  
 
Sequence analysis 
DNA was sequenced using the sequencing services by GATC Biotech (Konstanz, Germany). 
 
2.2.4 Protein analysis standard methods 
 
Protein concentration determination by Bradford assay 
Protein concentration determination by Bradford is based on the absorbance of the dye 
Coomassie Brilliant Blue G-250, which binds under acidic, conditions to cationic and apolar 
side chains of proteins. The unbound form exhibits an absorbance maximum at 470 nm, 
which shifts to 595 nm upon protein binding. The increase of absorbance at 595 nm is 
proportional to the bound form and a good measure of the amount of present protein. First 
Bradford assay solution was allowed to reach room temperature. A protein standard curve 
was prepared by making serial dilutions of BSA in HPLC water starting from 20 µg/ ml to 0 
µg/ ml in a final volume of 20 µl. To each dilution 5 µl of the respective lysis buffer were 
added. For the determination of the protein concentration in the sample of interest 5 µl of the 
cell lysate were added to 20 µl of HPLC water. 1 ml of Bradford solution was added to each 
cuvette mixed well and incubated for 10 min at room temperature. Absorbance was 
measured at 595 nm.  With the help of a standard curve, based on different BSA 
concentrations, the protein concentrations were determined in the samples of interest. 
 
Preparation of samples for protein standard analysis methods 
Cells were typically lysed in an appropriate amount of RIPA Buffer supplemented with 1x 
Protease Inhibitor cocktail. Lysates were incubated for 45 min on ice and cleared by 
centrifugation at maximum speed for 45-60 min at 4°C. The perinuclear supernatant was 
then transferred into a fresh tube and used for subsequent analysis.  In case that lysis was 
not carried out with RIPA buffer, cells were directly lysed in 2x Protein Loading buffer and 
sonicated (2x15 pulses).  
 
Sodium Dodecyl Sulfate polyacrylamide gel electrophoresis (SDS PAGE) 
Similar to the agarose gel electrophoresis the SDS page allows the separation of 
macromolecules according to their mobility in an electric field. For proteins, a sodium dodecyl 
sulfate containing buffer is added to the sample followed by cooking at 95°C that leads to 
complete denaturation and linearization of the protein of interest. The binding of the anionic 
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SDS imparts a negative charge to the denatured protein and the amount of bound SDS 
depends on the mass of the protein. This allows the separation of the denatured protein 
dependent on its length and mass to charge ratio in an acrylamide matrix. Depending on the 
molecular weight of the protein of interest samples were loaded onto 6-12% acrylamide gels 
and run for 1.5 h at 100V. To estimate their molecular weights a prestained protein marker  
was added as a reference. Proteins separated through SDS page were further processed by 
Western Blot analysis for their visualization.  
 
Western Blot analysis 
After SDS page, proteins were electro-transferred onto a PVDF membrane (PerkinElmer Life 
Sciences) for 1-4 h either using the semidry or wet-transfer apparatus. Membranes were 
blocked by incubation with 5% Skim milk dissolved in PBS-Tween (0.5%) for 1 h at room 
temperature, followed by their incubation with primary antibody for 1 h at RT or overnight at 
4°C. Primary antibody was removed by washing three times for 5 min with PBS-Tween. Next 
the membranes were incubated with the respective secondary antibody conjugated with 
horseradish-peroxidase for 1 h at RT. Membranes were washed again as before and 
developed by using the Western Lightning Plus-ECL reagent (Perkin Elmer) and visualized 
on Amersham Hyperfilm ECL (GE Healthcare) or by using the Intas science imager.  
 
2.2.5 Virological methods 
 
Preparation of Hepatitis C virus stocks and PEG precipitation 
Huh7.5 cells were resuspended in cytomix to a final concentration of 1.5x10 x10^7 cells/ ml. 
400 µl of the cell suspension were mixed with 10 µg of full-length viral RNA and 
electroporated as described earlier. Two electroporations were resuspended in 20 ml of fresh 
medium and seeded onto one 15 cm cell culture dish. The next day the supernatants were 
removed and fresh media (15-20 ml) was added. 48, 72 and 96 h post electroporation the 
supernatant was collected and spun down for 10 min at 1500 rpm or sterile filtered through 
0.45 µm sterile filters, (Merck Millipore, Darmstadt, Germany). The supernatant was either 
directly frozen at -70°C or further concentrated. For virus precipitation sterile polyethylene 
glycol (PEG)-8000 was added to the virus supernatants to a final concentration of 8% PEG-
8000. The mixture was incubated over night at 4°C and then spun at 8000g for 90 min at 
4°C. Pellets were resuspended carefully in fresh media. Aliquots of 100 µl were stored at -
70°C. 
 
Preparation of Dengue Virus stocks 
Dengue virus stocks (serotype 2a, DENVR2A and DENV-2 166681) were kindly provided by 
Dr. E. Acosta. 
 
Lentivirus production 
One day prior to transfection 4.7x10^6 293T cells were seeded per 10 cm cell culture dish. 
For each transfection reaction 400 µl optimem and 30 µl jetPEI (Polyplus transfection, 
Illkirch, France) were mixed as well as 400 µl optimem with 4.3 µg of packaging plasmid 
pCMV-dR8.91, 1.4 µg of the envelope plasmid pMD.G and 4.3 µg of the transfer plasmid 
encoding the desired shRNA or cDNA. Both mixtures were brought together, vortexed for 10 
sec and incubated for 10 min at room temperature. Finally 800 µl were transferred drop-wise 
while shaking the 10 cm dish to allow an even distribution of the transfection reagent. 6 h 
post transfection the supernatant was removed and fresh media (8 ml) was added. 48 and 72 
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h post transfection the supernatants were harvested and filtered through 0.45 µm filters in 
order to remove dead cells. Aliquots of 1.5 ml were stored at -70°C. 
 
Determination of virus titers by limiting dilution assay (TCID50/ ml, 50% tissue culture 
infective dose per ml) 
1x10^4 Huh7.5 cells/ 96 well were seeded in 160 µl of DMEMcplt. The following day 200 µl of 
the pure supernatant from a previous virus production or a respective dilution was added per 
well into the first 6 wells of the 96 well. For serial 1:5 dilutions 40 µl were then transferred to 
the next row, resuspended well by pipetting up and down and subsequently transferred to the 
following row. 72 h after titration cells were fixed with cold methanol for at least 20 min at -
20°C. For visualization of infected cells, cells were washed 3 times with PBS followed by 
incubation for 1 h at room temperature with an antibody against NS3 or NS5A diluted 1:1000 
or 1:10000 respectively. Next, cells were washed 3 times with PBS and subsequently 
incubated with the respective secondary antibody conjugated with horseradish-peroxidase 
for 1 h at room temperature. Prior to addition of the substrate (5 ml Acetate, 1.5 ml Carbazol, 
20 µl Peroxide, filtered) cells were washed 3 times with PBS. The reaction was stopped by 
addition of water when a strong positive signal was detectable. The plates were counted 
considering a cell as infected when a strong cytosolic red staining was apparent. Virus titers 
were determined according to Spearman [245]. 
 
Determination of Lentivirus titers by colony forming assay 
A frozen aliquot of the lentivirus of interest was thawed on ice. As lentiviral transduction of 
the cells was carried out while seeding the cells two dilutions (1:400 and 1:10000) were 
prepared beforehand. Therefor 94.5 µl of DMEMcplt and 2 µl of polybren were mixed. For an 
initial 1:40 dilution 92.3 µl of the premix were added to 2.5 µl of the virus stock and vortexed 
well. 4 µl of this dilution were then added to 95.8 µl of the premix resulting in a 1:100 
predilution. 8 µl of each dilution were next added to 75 µl of cell suspension (8000 cells/ 75 
µl) in a 96 well plate giving rise to a final 1:400 and 1:10000 dilution. Each dilution was 
carried out in duplicates. One day after transduction, cells were selected with the appropriate 
antibiotic (Puromycin 1 µg/ ml). Additionally cells that had not been transduced were either 
treated with media with or without any antibiotic as controls for the selection process. 
Selection was stopped when all the control cells had died and colonies of around 5-7 
adjacent cells were apparent for the transduced conditions. Therefor cells were washed twice 
with PBS and incubated with 50 µl of 1% crystal violet solution for 15 min at RT. The 
remaining crystal violet was recycled followed by two more washings with water. Before 
counting the colonies the water was removed and the wells were allowed to dry. The mean of 
the counted duplicates was used for determination of the viral titers as follows: 1:400 dilution: 
4800x number of colonies, 1:10000 dilution: 120500 number of colonies.  
 
2.2.6 Experimental procedures 
 
Full-length wild-type (wt) and Renilla luciferase reporter virus infection/ reinfection 
assays 
Infection assays with wt or Renilla luciferase reporter virus (both HCV or DENV) were either 
carried out in 24 or 96 well plates. Typically Huh7.5, Huh7.5Fluc or LunetCD81H cells were 
used. Cells were infected with Renilla luciferase reporter virus at a MOI of 0.2 or wt virus at a 
MOI of approximately 5.  Infection with wt virus was mostly used for immunofluorescence 
analysis. 6 h post infection the supernatant was changed into 500 µl/ 24 well or 100 µl/ 96 
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well respectively. If not otherwise stated the infection was allowed for 48 h. Cells were then 
harvested for luciferase reporter activity assay by addition of 100 µl/ 24 well or 30 µl/ 96 well 
of luciferase lysis Buffer.  Cells were further harvested for i) extraction of total cellular RNA 
by the addition of 350 µl of A1 + 1% beta-mercaptoethanol per 24 well ii) 
immunofluorescence analysis by fixation with 4% PFA in PBS at room temperature for 15 
min or iii) Western Blot analysis by the addition of 50 µl of either 2x SDS sample buffer or 
RIPA buffer. In case of reinfection of naive Huh7.5 cells, the supernatants were harvested 
and spun at full speed for 10 min to remove cell debris. Reinfection was performed in 24 
wells and allowed for 48 h.  
 
Determination of intracellular and extracellular viral titers 
In short 400 µl of cell-cytomix suspension of 1x10^7 Huh7/Lunet cells/ ml were 
electroporated with 10 µg of full-length viral RNA. Electroporated cells were resuspended in 
20 ml DMEMcplt. 3 ml were transferred into a 6 well. 24 h post electroporation the 
supernatant was replaced by 2 ml of fresh media. 48 and 72 h post electroporation the 
supernatants and cells were harvested for determination of intra- and extracellular viral titers. 
The supernatant was collected in 2 ml safe lock Eppendorf tubes and spun 10 min at 
maximum speed at 4°C in order to pellet present cells and cell debris. 200 µl of the 
supernatant was then transferred into a fresh 2 ml tube for subsequent freeze and thawing 
cycles. Intracellular virus was harvested by first washing the cells with 1 ml PBS. Cells were 
gently scraped in 1ml PBS and transferred into a 2 ml tube. Cells were pelleted at 700 g for 5 
min and resuspended in 200 µl of fresh medium. For freeze and thaw cycles equivalent 
volumes (here 200 µl) of intra and extracellular virus were transferred 3 times into liquid 
nitrogen followed by thawing at 37°C. Finally samples were spun down for 5 min at 700 g to 
remove broken cells and the supernatant was transferred into a fresh tube. Depending on the 
respective virus construct different initial dilutions were made and virus titers were 
determined by limiting dilution assay.   
 
siRNA lipofection/ electroporation followed by infection with full-length virus 
Cells were either presilenced by lipofection or electroporation as described earlier. 48 h post-
silencing cells were infected with Renilla luciferase reporter virus at an approximate MOI of 
0.2. Experiments were performed in duplicates. 
 
siRNA electroporation of stable replicon cell lines 
100 µl of 1x10^7 cells/ ml of LucUbiNeo_JFH1 and LucUbiNeo_ConET were electroporated 
with 2.5 µl of siRNA. Electroporated cells were resuspended in 6 ml fresh DMEMcplt. 350-
400 µl were seeded into a 24 well plate to be harvested 48, 72 and 96 h post electroporation 
for luciferase reporter activity assay. 100 µl were seeded into a 96 well plate for the 
determination of the cell viability and 1 ml was seeded into a 12 well for harvesting for 
Western Blot analysis. Experiments were performed in duplicates. 
 
Lentiviral transduction of target cells followed by infection with full-length virus 
Typically 2-3 x10^4 cells (Huh7.5, Huh7.5FLuc, Huh7/LunetCD81H) were seeded per 24 
well. In parallel 0.5x10^4 cells were seeded per 96 well for cell viability assay. One day later 
cells were transduced with the corresponding lentivirus at an MOI of 1, 2 or 4. 24 h later the 
inoculum was removed and 500 µl/ 24 well or 100 µl/ 96 well of fresh media was added. 48 h 
post transduction cells were infected with full-length Renilla luciferase reporter virus of HCV 
and DENV at a MOI of 0.2. 6 h later the inoculum was replaced by 500 µl/ 24 well or by 100 
µl/ 96 well of fresh media respectively. 48 h post infection and 96 h post transduction cells 
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were harvested for Luciferase reporter activity assays. In case of reinfection the supernatants 
were spun down at max speed for 10 min and transferred onto naive Huh7.5 cells for another 
incubation period of 48 h. Experiments were performed in duplicates. 
Lentiviral transduction of target cells followed by transfection of pTM expression 
constructs for immunofluorescence analysis 
For the expression of T7-promotor driven constructs as in case of pTM-based expression 
plasmids, Huh7-Lunet/T7 cells stably expressing the T7 polymerase were used [242].  
1x10^4 cells/ 24 well were seeded onto coverslips one day prior to transduction with 
lentivirus at a MOI of 4. 24 h post transduction the media was replaced by fresh DMEMcplt 
containing 1.5 µg/µl Puromycin for the selection of transduced cells. 54 h post transduction 
cells were transfected using the Mirus TransITLt1 transfection reagent (Mirus Bio, Madison, 
USA) according to the manufacturer’s protocol. 72 h post transduction and 14-16 h post 
transfection cells were fixed with 4% PFA in PBS for 15 min at RT and processed for 
immunofluorescence analysis. 
 
Lentiviral transduction of stable replicon cell lines 
0.5 x 10^4 LucUbiNeo_Con1ET and LucUbiNeo_JFH1 cells were seeded per 96 well. One 
day later cells were transduced with Lentivirus at a MOI of 1, 2 and 4. Cells were harvested 
for Luciferase reporter activity assay as well as cell viability assay 48, 72 and 96 h post 
transduction. Experiments were performed in triplicates. 
 
Luciferase reporter activity assay 
Depending on the format different amounts of Luciferase lysis buffer were added to the 
washed cells for lysis at -20°C (250 µl/ 12 well, 100µl/ 24 well, 30µl/ 96 well). Samples were 
analyzed either using the tube luminometer Lumat LB9507 or the plate Luminometer Mithras 
LB940 (Berthold Technologies, Bad Wildbad, Germany), the later one being less sensitive. 
For measuring Renilla luciferase activity by the tube luminometer, 20 µl of the lysate were 
transferred into a measurement tube and 100 µl of luciferase assay buffer containing 1.4 µM 
Coelenterazine (PJK Chemikalien, Kleinblittersdorf, Germany) were added and measured for 
10 sec. For measuring the Firefly luciferase activity 10 µl lysate were mixed with 360 µl 
assay buffer containing ATP and DTT. To each measurement 200 µl of the 0.2 M Luciferin 
containing luciferase assay buffer were automatically added by the machine and 
measurements were carried out for 20 sec. Measurements were generally performed in 
duplicates. The plate reader is able to determine Firefly and Renilla luciferase activity within 
the same sample in parallel. First Luciferin containing assay buffer is added, followed by 
Firefly luciferase activity measurement. Next, Coelenterazine containing assay buffer is 
added to the same well and Renilla Luciferase activity is measured using the respective filter. 
By the addition of SDS the reaction is stopped.  
 
HCV Core ELISA 
Core ELISA analysis was carried out by the Analysen Zentrum Universitätsklinik Heidelberg. 
Samples were prepared by lysing cells in 0.5% Triton-X-100 in PBS or adding 10% Triton-X-
100 to the respective supernatants to a final concentration of 1% Triton-X-100. An 
appropriate dilution of the sample of interest in a final volume of 0.5–1ml was transferred into 
a collection tube and stored at -20°C until measurement.  
 
Dose response assays using JcR2A or DENVR2A reporter virus 
For dose response assays using the HCV or DENV Renilla reporter virus 1x10^4 Huh7.5 
cells were seeded per 96 well. The next day, cells were either i) pretreated for 24 h prior to 
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infection ii) treated while infection or iii) drug treatment started 6 h post infection. Either way, 
infection was allowed for 6 h followed by removal of the inoculum and the addition of drug 
containing media. Cells were then incubated in presence of the drug or the corresponding 
water/ DMSO control for 48 h followed by lysis of the cells. Effect of drug treatment on entry/ 
replication of the reporter virus was next assessed by luciferase activity assay as described 
earlier. 
 
Dose response assays using stable replicon cell lines  
For dose response assays using stable replicon cell lines, 1x10^4 LucUbiNeo_JFH1 and 
LucUbiNeo_Con1ET were seeded per 96 well. One day later medium was replaced by drug 
or the corresponding water/ DMSO control-containing medium at different concentrations of 
the compound. Cells were harvested 48, 72 and 96 h post treatment and effects on 
replication were assessed by luciferase assay as described earlier.   
 
Dose response assays upon transfection of subgenomic replicon RNA 
Lunet cells were electroporated with subgenomic Firefly luciferase reporter replicon RNA and 
seeded into 24 well plates. 4 h post electroporation the media was replaced by drug or water/ 
DMSO containing medium. Additionally cells were lysed to assess the input RNA levels for 
each condition. Next cells were harvested 24, 48 and 72 h post treatment and effects of drug 
treatment on replication were analyzed by luciferase assay as described earlier.  
 
2.2.7 RNAi screens 
 
Comparative Lipid droplet RNAi screen 
The LD RNAi screen was designed and performed by Dr. G. Alvisi. 
LD RNAi library – Due to the lack of a commercially available library of genes whose gene 
products are implicated in LD homeostasis in human liver cells, a custom made RNAi library 
was assembled. Thus, based on several studies that identified potential candidates 
regulating LD morphology a homemade RNAi library of 230 genes was generated [236, 237, 
246-249]. Next, ON-TARGETplus® SMARTpool siRNAs were purchased from Dharmacon, 
that were pre-spotted onto 96 well plates. Several controls were included in case of the virus 
screen: Dharmacon ON-TARGETplus® Non-Targeting Control Pool, PI4KIIIA 
(Phosphatidylinositol-4-kinase-III alpha), Apolipoprotein E. Additionally two different RNAi 
oligonucleotides targeting the Renilla luciferase were used. In case of the virus screens, 5 µl 
of siRNAs (100 µM) were spotted into white assay plates, while black plates were used for 
the LD morphology imaging screen. In case of the imaging screen a SMARTpool siRNA 
targeting the PLK-1 was added as control of the silencing efficiency.  
Virus screen setup, performance and statistical analysis – Huh7.5FLuc cells were 
silenced by reverse transfection of SMARTpool siRNAs. To this point, the lipid free 
transfectant Interferin was diluted 1:40 in optimem and 40 µl were then added per 96 well to 
the pre-spotted plates. Plates were spun for 5 sec at 700 rpm and subsequently incubated 
for 10 min at RT under shaking. Next 8 x10^3 Huh7.5Fluc cells were added to each well in a 
volume of 155 µl DMEM. They were subsequently spun down as before and transferred into 
cell culture incubators (37°C, 5% CO2). 8 h later the supernatant was removed and replaced 
by 200 µl of fresh DMEM. Infection with HCV or DENV Renilla luciferase reporter virus was 
performed 36 or 48 h later, respectively. To this point the supernatant was removed and cells 
were infected at a MOI of 0.2 (TCID50/ cell) in a volume of either 150 µl for HCV or 50 µl for 
DENV. Cells were then incubated for 60 (HCV) or 48 h (DENV). Cell supernatant were next 
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transferred onto naïve Huh7.5 (HCV) or Vero (DENV) cells, which had been seeded 24 h 
earlier at a concentration of 5 or 10 x10^3 cells/ 96 well respectively. 12 h later 100 µl of 
fresh medium was added.  Furthermore silenced cells were lysed and plates were stored at -
20°C. The reinfection was allowed for 24 (DENV) or 48 h (HCV) which was followed by lysis 
of the cells.  The effect of gene knockdown on viral replication was assessed by measuring 
Renilla luciferase activity in whole cell lysates. In order to identify candidates important for 
early events of the viral replication cycle such as entry and replication the Renilla luciferase 
counts in the infection plates were normalized to the corresponding Firefly counts, 
representing cell number. To determine host factors involved in assembly and release of 
infectious virions the Renilla activity measured in the reinfection plates was normalized to the 
respective Renilla counts of the infection plates. Statistical and bioinformatical analysis of the 
screen data was performed Prof. Dr. Lars Kaderali and his group at the University of 
Dresden.  
LD morphology screen setup, performance and statistical analysis – The SMARTpool 
siRNA transfection was performed as described above, with the exception that 2.45 x10^3 
Huh7/LunetCD81H-TRFP cells were seeded. The plates were again spun and 8 h later the 
transfection medium was replaced by 100 µl of fresh DMEM. 80 h post siRNA transfection 3 
wells of the siRNA non-targeting control per plate were treated with either BSA-loaded oleic 
acid (100 nM) or Triacsin C (2.7 µM) to induce or inhibit LD biogenesis, respectively. 16 h 
post treatment cells were incubated for 30 min with DMEM containing 20 µg/ ml Bodipy 
493/503 and 1 µg/ ml Hoechst 33342 at 37°C and 5% CO2. Cells were then washed 3 times 
with 100 µl of 0.1 M PHEM, subsequently fixed with 4% PFA for 15 min at RT and again 
washed as before. The plates were then automatically imaged with an Olympus IX81 
automated microscope using a 20x objective. For image analysis four different 12-bit images 
were taken. These four different images comprised the visualization of the cell boundary 
(RFP), of the cellular nuclei and two images of the Bodipy 493/503 labelled LDs. These two 
images were taken with different acquisition times in order to guarantee the recording of LDs 
of low intensity, as well as to circumvent saturation in case of strong signal intensities. For 
each candidate 9 different positions within the same well were imaged. The screen was 
performed in quadruples. The following features were extracted and analyzed: cell area, 
nucleus area, LD total area, LD mean area, LD cell area coverage, LD number, LD mean 
intensity, LD total intensity, LD mean distance to nucleus, cell mean intensity, nucleus mean 
intensity. Importantly genes were classified as hits when their knockdown lead to significant 
changes in either one of the LD related features. The z-score threshold was set to >2 and <-
2. 
 
Small scale LTP RNAi screen (designated as Lipid transfer protein /LTP screen) 
The siRNA ON-TARGET plus SMART pools were reconstituted in RNAse free water to a 
final concentration of 100 µM. 2.5 µl aliquots were prepared and stored at -20°C. siRNA was 
transfected by electroporation. To this end, cell monolayers of Huh7.5FLuc cells were 
detached by trypsinization, resuspended well in fresh preheated DMEMcplt and single cell 
suspensions were counted. The respective amount of cells were spun down at 700 g for 5 
min, washed with PBS, spun again and resuspended in Cytomix. 100 µl of 1.5x10^7 cells/ ml 
cytomix were used per electroporation. Therefor the cell suspension was added to the 
siRNA, resuspended well, transferred into the electroporation cuvette (0.2 cm gap) and 
electroporated with the following settings: 166V, 0.5 µF. Electroporated cells were 
immediately resuspended in 6 ml of preheated fresh DMEMcplt. 100 µl of the cell suspension 
were seeded per 96 well plates (white bottom) in triplicates. In order to decrease edge 
effects, the outermost wells of the 96 well plates were omitted and filled with 200 µl of media. 
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36 or 48 h post electroporation cells were infected with HCV Renilla reporter virus (JcR2A, 
MOI 0.5) or DENV Renilla reporter virus (DENVR2A, MOI 0.5) respectively. 24 h post 
infection the inoculum was replaced by 100 µl of fresh DMEMcplt. In case of DENV infection 
10 mM Hepes was added to the media. Our pretests revealed that infection with JcR2A for 
60 h or with DENVR2A for 48 h followed by reinfection of naïve cells for 48 h resulted in the 
best window between the non-targeting and the positive controls. The latter ones included 
siRNA ON-TARGET plus SMART pools targeting the cellular Phosphatidylinositol-4-kinase III 
alpha (PI4KIIIA), the Apolipoprotein E, both known HCV dependency factors as well as the 
Renilla luciferase or the DENV non-structural protein NS1 [121, 250]. Infection was allowed 
for 60 h in case of JcR2A and 48 h in case of DENVR2A prior to lysis of the cells in 30 µl 
Renilla luciferase lysis Buffer. For reinfection, the supernatant of the infected cells was 
transferred onto naive Huh7.5 or Vero cells, seeded 1 day prior to infection at a 
concentration of 1x10^4 cells/ 96 well. Reinfection was allowed for 48 h before lysis of the 
cells with 30 µl Luciferase lysis buffer. Luciferase activity assays were conducted as 
described earlier. 
To allow accurate statistical analysis 6 independent repetitions were carried out, each time 
using different plate layouts and freshly thawed cells of the same passage. Prof. Dr. L. 
Kaderali carried out statistical analysis of the RNAi screen raw data. To this end, effects of 
siRNA knockdown on viral entry/ replication were determined by dividing the Renilla (Rluc) 
counts measured in the infection plates by the respective Firefly (Fluc) counts of the same 
well. This allowed the normalization of detected viral replication to the respective amount of 
cells present per well. Effects of siRNA mediated knockdown on the viral reinfection 
efficiency were determined by dividing the RLuc counts measured in the reinfection plates by 
the RLuc counts determined in the corresponding infection plate. Outliers caused by 
technical difficulties were removed from the analysis.  A z-score treshhold of >2 and <-2 was 
used for hit definition, as well as a p-value < 0.05. 
 
2.2.8 Biochemical assays 
 
Cell viability measurement by cell proliferation reagent WST-1 (Roche) 
Cell viability measurements were typically conducted in a 96 well format and performed in 
triplicates. The WST-1 reagent contains a stable tetrazolium salt which is reduced to soluble 
formazan by a complex cellular mechanism. This reduction is largely dependent on the 
presence of Nictotinamide Adenine Dinucleotide (Phosphate) NAD(P)H, an energy rich 
metabolic intermediate that is generated throughout glycolysis and citric acid cycle for the 
production of ATP. Therefore the rate of conversion of tetrazolium salt (red) to formazan 
(dark red) correlates to the amount of present NAD(P)H and the metabolic activity/viability of 
the present cells. To this end, cells were incubated with 10 µl/ 96 well of WST-1 reagent for 
approximately 30 - 45 min. Cell viability was determined by measuring the absorbance at 450 
nm in the Tecan XFluor4 reader (Wiesbaden, Germany) 
 
Cell titer glo® Luminescent Cell viability assay (Promega) 
Cell viability measurements were typically conducted in a 96 well format and performed in 
triplicates. The cell titer glo cell viability assay is based on the determination of ATP present 
in the cell lysates as an indicator for cell viability/ metabolic activity. To this end an extensive 
amount of Firefly luciferase and substrate is added to the cells. As the Firefly luciferase 
activity is largely dependent on ATP, the measured luminescence correlates to the present 
ATP levels and is therefore an indicator for cell viability/ metabolic activity. Cells were 
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typically incubated with a 1:1 mixture of the cell titer glo reaction mixture and DMEMcplt for 
10 min at RT before measurement was conducted. In case of infected cells, cells and 
supernatants were inactivated by the addition of Triton-X to a final concentration of 1% prior 
to measurement. 
 
 
NS4B-HA affinity purification 
One 80% confluent 15 cm dish of Huh7/Lunet-T7 (Blasticidin) was transfected with the pTM 
expression construct encoding the NS3-3’ of genotype 2a (JFH1) that either contained wild-
type NS4B or a Hemagglutinin affinity (HA)-tagged version. 6 h post transfection, the medium 
was replaced by media containing 1 µM Topfluor-Cholesterol (TFC). Cells were harvested 18 
h later and HA-specific affinity purification was performed by Dr. D. Paul as described 
elsewhere [114]. The presence of TFC in immunoprecipitates or the perinuclear supernatant 
of complete cell lysates was measured using the Luminometer Mithras LB940. Samples were 
further processes for detection of NS5A and NS4B by Western Blot.  
 
2.2.9 Imaging  
 
Indirect immunofluorescence 
Cells were grown on coverslips, washed once with PBS and fixed with 4% PFA in PBS for 15 
min at room temperature. Cells were typically permeabilized with digitonin (50 µg/ ml in PBS) 
for 10 min at RT and subsequently blocked with 3% fatty acid free BSA in PBS for 30 min at 
room temperature. Coverslips were then incubated with the primary antibody diluted in 1% 
BSA/PBS for 1h at room temperature. After washing three times for 5 min with PBS, 
coverslips were incubated in the dark with the corresponding secondary antibody diluted in 
1% BSA/PBS. Next cells were incubated for 1 min with DAPI (DNA stain) for staining of the 
nucleus followed by three washes with PBS. Depending on the specimen, coverslips were 
mounted with glycerol based Fluoromount G (Southern Biotech) or Vectashield (Vector 
Laboratories Inc., Burlingame, USA). Samples were stored in the dark at 4°C. 
 
Neutral lipid staining with Bodipy or LipidTOXTM 
Neutral lipids present in lipid droplets were visualized for light microscopy using the 
fluorescent dye Bodipy493/503 or HSC LipidTOXTM Neutral Lipid stain (Thermo Fisher 
Scientific, Waltham, USA). To this end after secondary antibody incubation and prior to the 
last washing steps coverslips were incubated for 10 min with 20 mg/ml Bodipy495/503 in 
PBS for 20 min at room temperature. In case of staining with more than 3 colors, HSC 
LipidTOXTM was used. LipidTOXTM was added to the secondary antibody and visualized by 
excitation at 647 nm and detection in the far red.  
 
Microscopes and Image analysis programs 
Samples were analyzed using the Leica Sp2 confocal laser scanning microscope or 
PerkinElmer ERS-6 spinning disc confocal microscope. Image analysis was performed using 
Fiji software package based on Image J (NIH) or Imaris 8 software (Bitplane, Zurich, 
Switzerland). Deconvolution was carried out using Autoquant X3 (Bitplane, Zurich, 
Switzerland). 
 
Free cholesterol staining using filipin complex or filipin III 
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Free cholesterol staining was carried out using the filipin complex that contains 8 isomeric 
components with filipin III as the major component or filipin III (Sigma Aldrich, St. Louis, 
USA). Filipin complex or filipin III is a tool widely used for the visualization of free and 
unesterified cholesterol [251, 252]. As filipin III has been shown to perforate the membrane 
[253] permeabilization of the samples through detergent was omitted. Filipin binds to free 
cholesterol forming a filipin-cholesterol complex with a detection range similar to ultraviolet 
light  (360/ 460nm). 
 
Image analysis: Determination of LDs labeled with Bodipy493/503 
For quantification of Bodipy493/503 labeling in cells the plugins „DogSpot Enhancer2D“ and 
„Double Threshold“ of the Fiji software were used. To this point background was equally 
subtracted for all pictures analyzed. By the use of the before mentioned plugins, the area, 
number and integrated density of the Bodipy493/503 signal per cell was determined.  
 
Image analysis: Determination of volumes of filipin positive structures 
Quantification of the volume of filipin III positive structure was carried out using the Imaris 
software. Therefor z-stacks were taken that captured the complete volume of a cell. Images 
were first deconvolved. Using the Imaris software, a surface was fitted filling the filipin III 
positive structures as good as possible. To this end the signal threshold was adapted as well 
as seed points were set, that allowed the program to distinguish between structures that 
were in close proximity. The settings were used to calculate and compare the volume of 
filipin III positive structures of different treatment conditions.  
 
Image analysis: Colocalization analysis 
Colocalization of two signals was determined using the „Intensity correlation Analysis“ Plugin 
of Fiji. To this end, background signal was equally subtracted for all samples analyzed. 
Pearson Correlation coefficient or Manders correlation coefficients were determined.  
 
Life cell imaging and movie analysis 
Huh7/LunetCD81H cells were electroporated with 5 µg of subgenomic viral RNA (sbNS3-3’, 
NS5A-mCherry, JFH1) and plated into 8 well Lab-Tek® imaging chamber. Media was 
replaced by U18666A or control containing media 24 h prior to the start of imaging. Topfluor-
Cholesterol (TFC) was added to the cells for 10 min before extensive but careful washing 
with fresh media. The chamber environment (in particular CO2) was allowed to equilibrate for 
30 min before the onset of imaging. Live cell imaging was performed in Phenol-Red free 
imaging media at 37°C and 5% CO2. Images were taken every 15 min for approximately 16 
h. Thereby the complete volume of each cell was imaged by taking three sequential z-stacks.  
Image analysis was performed using the Fiji software. To determine the TFC accumulation 
velocity of TFC in NS5A positive cells background was equally subtracted for all samples. 
Only a single plane was analyzed, thus the z-stack with the strongest TFC signal at the 
perinuclear region was chosen. The signal intensity of TFC at the perinuclear region was 
determined by measuring the Integrated Density. To determine the colocalization efficiency 
of TFC and NS5A stringent background subtractions was performed. Colocalization was 
determined as described before.  
 
Sample preparation for Electron microscopy (EM) 
3x10^4 Huh7/Lunet-T7 (Zeocin) cells were seeded onto coverslips per 24 well. 24 h later, 
cells were treated with the respective concentrations of the cationic amphiphile. After another 
24 h cells were transfected with the respective pTM expression construct encoding the NS3-
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3’ of genotype 2a (JFH1) or genotype 1b (Con1ET). 6 h later medium was changed into 
compound containing medium again. 24 h post transfection cells were washed three times 
with PBS and fixed with 2.5% Glutaraldehyde + 2% Sucrose for 30 min at RT. Cells were 
then washed five times with CaCo Buffer for 5 min and stored at 4°C until further processing. 
The subsequent steps were performed by Dr. I. Romero-Brey. Cells were treated with 2% 
OsO4 in CaCo buffer for 40 min on ice, and rinsed with water. Cells were then treated with 
0.5% uranyl acetate (dissolved in water) for 30 min, and rinsed again with water. Samples 
were dehydrated by treatment with an ethanol series (first 40% Ethanol followed by 50%, 
60%, 70%, 80%, for 5 min each, and then 95% and 100% for 20 min each). Embedding, 
sectioning and staining was performed as described elsewhere [254]. DMV diameters were 
measured using the iTEM application software (version 5.2 Olympus). 
 
2.2.10 Statistical analysis 
Statistical analysis was performed using the GraphPad Prism or Microsoft Excel software. 
Statistical significances were calculated by using the two-tailed, unpaired Student’s t-test or 
the one-way analysis of variance (ANOVA) and Dunnett’s Multiple Comparison test when 
several conditions where compared to a single control (***, p< 0.001, **, p< 0.01, *, p< 0.05). 
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3.1 Identification and characterization of novel factors involved in lipid droplet 
homeostasis and in the replication cycle of HCV and DENV 
 
LDs are dynamic lipid storage organelles that play a central role in the cellular lipid 
homeostasis. Mobilization or storage of neutral lipids is mainly regulated by LD-associated 
proteins [232]. While two independent RNAi screens led to the identification of novel factors 
that regulate LD morphology in drosophila cells, cellular factors involved in LD homeostasis 
in human liver cells are only poorly characterized [236, 237]. Interestingly the replication 
cycles of the liver-tropic Hepatitis C virus, and the related Dengue virus, have been reported 
to depend on LDs, although the organelle’s precise role is yet unclear [148, 255]. Thus, the 
identification and characterization of cellular factors regulating LD function might shed new 
insight into the connection between the viruses and the cellular organelle. This could lead to 
the identification of potential targets for therapeutic treatment of HCV and DENV infection. 
 
3.1.1 Setup, performance and statistical analysis of the LD-RNAi screen  
 
Setup of a bipartite comparative RNAi screen. With the aim to identify novel factors 
involved in LD homeostasis in liver cells and in the replication cycle of HCV and DENV, Dr. 
G. Alvisi from our laboratory performed a comparative RNAi screen targeting genes 
implicated in LD biology (unpublished data). Due to the lack of a commercially available 
siRNA library he assembled a home-made library based on present literature. The majority of 
the genes had earlier been identified by a RNAi screen as LD homeostasis regulators in 
drosophila cells, thus their human orthologues were added to the library, which finally 
comprised 230 genes (Figure 3.1A, Supplementary Table S 1) [236, 237, 246-249]. In a 
comparative screen, the effect of gene knockdown was assessed on i) the full replication 
cycle of HCV or DENV reporter viruses, engineered to express Renilla luciferase (Figure 
3.1C) and on ii) LD morphology in a microscopy-based study (Figure 3.1B). Details of the 
screen setup can be found in Figure 3.1 and under section 2.2.7. 
In order to identify host factors regulating LD homeostasis, Dr. Alvisi assessed the effect of 
gene knockdown on LD morphology in a microscopy-based approach (Figure 3.1B). To this 
end Huh7/LunetCD81H cells stably expressing Tag-RFP-T, enabling the visualization of the 
cell boundary [243] were silenced for 96 h. Control cells transfected with non-targeting siRNA 
were treated with BSA-loaded oleic acid or Triacsin C to promote or inhibit LD formation, 
respectively. Lipid droplets were labeled with the fluorescent neutral lipid stain 
Bodipy495/503 [256]. In an automated quantitative image analysis changes in the following 
LD features were measured: LD total area, LD mean area, LD cell area coverage, LD 
number, LD mean intensity, LD total intensity, LD mean distance to nucleus (Figure 3.1B).  
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Figure 3.1 Primary screen setup (A) Composition of the LD RNAi library. The number of genes taken from the 
respective reference is indicated. (B) LD morphology screen. Huh7/LunetCD81H stably expressing Tag-RFP-T, a 
marker of the cell border, were reverse transfected with ON-TARGETplus® SMARTpool siRNA. 80 h later a 
fraction of the cells transfected with the non-targeting siRNA control were treated with either 100 nM BSA-loaded 
oleic acid or 2.7 µM Triacsin C to induce or inhibit LD formation, repectively [256]. The remaining fraction of the 
control cells was left untreated. 96 h post silencing, cell nuclei were stained with Hoechst and LDs were visualized 
by the use of Bodipy493/503. Cells were then fixed and plates were automatically imaged.  Four different images 
were taken, including one for cell nuclei (Hoechst), one for the cell boundary (RFP) and two images with different 
acquisition times for Lipid droplets (Bodipy493/503). The latter aimed to allow the acquisition of low Bodipy signal 
intensity and to prevent saturation in case of strong signal intensities. Last, different features were extracted and 
data was bioinformatically analyzed. (C) Virus screen. Gene silencing in Huh7.5FLuc was conducted by reverse 
transfection of the above mentioned siRNA pools. 36 (HCV) or 48 h (DENV) later cells were infected with Renilla 
luciferase reporter HCV or DENV respectively.  60 (HCV) or 48 h (DENV) post infection i) supernatants were 
transferred onto naïve Huh7.5 (HCV) or Vero cells (DENV) and ii) cells were lysed. Reinfection of naïve cells was 
allowed for 24 or 48 h in case of DENV or HCV respectively, which was followed by cell lysis. In order to 
determine the viral replication efficiency, Renilla luciferase activity was measured in cell lysates. The results were 
analyzed as following: Effects on entry and replication were determined by normalizing the Renilla counts 
(replication) in the silenced cells to the respective Firefly counts, which represent the cell number (Step I). In order 
to determine potential changes in infectious particle production Renilla counts in the reinfection plates were 
normalized to those of the infection plates (Step II). The obtained data was bioinformatically analyzed. Adapted 
from Dr. G. Alvisi.   
 
To address the importance of the selected candidates in the viral replication cycle of HCV or 
DENV, a primary screen was performed using the ON-TARGETplus® SMARTpool siRNA. 
Pre-silenced Huh7.5 cells stably expressing Firefly luciferase were infected with the 
respective Renilla luciferase reporter virus (Figure 3.1C). In silenced cells, measuring and 
normalizing the Renilla luciferase counts (viral replication) to the Firefly luciferase counts (cell 
number) allowed determining the effect of gene knockdown on early phases of viral 
replication, namely virus entry and RNA replication (Figure 3.1C, Step I). In a second step 
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the cell supernatants of silenced cells were transferred onto naive Huh7.5 (HCV) or Vero 
(DENV) cells for reinfection. Thus, by measuring the Renilla luciferase counts in the 
reinfection plates and subsequent normalization to the corresponding Renilla luciferase 
counts in the infection plates, changes in virus particle assembly and release were 
determined (Figure 3.1C, Step II). Hit candidates were then further analyzed in a 
deconvolution screen, which was performed under the same conditions using four individual 
siRNA oligos that were comprised in the original ON-TARGETplus® SMARTpools 
(Supplementary Table S 1). A deconvolution screen was not performed for the image-based 
LD morphology screen.  
 
Statistical analysis and hit definition. For the analysis of the primary image-based LD 
morphology screen, genes were classified according to their knockdown phenotype. Genes 
whose knockdown altered at least one of the following features: LD total intensity, total LD 
area or LD area coverage were considered to alter cellular lipid storage. If their knockdown 
led to changes in LD count, LD mean intensity, LD distance to nucleus, or LD mean area 
they were considered to be important for regulating lipid distribution. A z-score threshold of 
>2/<-2 was used. 
In case of the virus replication screens, hit candidate genes identified in the primary screen 
as being important for entry/ replication (step 1) or assembly/ release (step 2) of HCV or 
DENV were defined using a z-score threshold of >2.5/<-2.5. For hit classification of the 
deconvolution screen a less stringent z-score threshold of >2/<-2 was used. When two out of 
the four siRNAs were giving the same phenotype as determined in the primary screen, the 
gene was considered as a high confidence hit. Candidates were defined to act as restriction 
factors (RFs) if their knockdown enhanced viral fitness, conversely genes were classified as 
dependency factors (DFs) when their knockdown impaired viral replication. Hit candidates 
with opposing effect on early (step 1) and late (step 2) phases of viral replication were 
defined as life cycle regulators. The statistical analysis of the screen data was conducted by 
Dr. Lars Kaderali and his group at the University of Dresden. 
 
3.1.2 Performance of control siRNAs and hit calling 
 
Robust performance of the RNAi screen. A general marker of the quality of the screen 
performance is the distribution of z-scores of the individual control siRNAs in comparison to 
the z-scores of the target genes [257]. In the present screen a siRNA targeting the Renilla 
gene, present in the genome of both reporter viruses was used as positive control. Moreover, 
siRNAs targeting host factors known to be involved in HCV RNA replication (PI4KIIIA, [250] ) 
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or assembly/ release of  HCV infectious particles (Apolipoprotein E, [121]) served as 
additional controls for Step I and Step II of the screen, respectively.  
	  
Figure 3.2 Performance of control siRNAs (A) Results of the primary virus screen. Individual siRNAs are listed 
according to their z-scores. The z-scores of individual genes are indicated in grey; a blue color marks the z-scores 
of the non-targeting siRNAs. The positive siRNA controls of viral entry and replication are indicated in either red 
(Renilla luciferase) or orange (PI4KIIIA, HCV specific). Z-scores of siRNAs targeting the Apolipoprotein E (ApoE), 
an important host factor for infectious particle production of HCV are indicated in green. Known host factors 
involved in HCV or DENV replication cycle are depicted. Selected host factors with a potential novel function are 
underlined. (B) Results of the LD morphology screen. The z-scores of individual siRNAs targeting the gene of 
interests are depicted in grey, while the non-targeting control is shown in blue. The z-scores upon Triacsin C or 
oleic acid treatment are illustrated in green or red respectively. Adapted from Dr. G. Alvisi. 
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As expected, silencing of the Renilla luciferase gene substantially impaired the early phase 
of HCV and DENV replication. In contrast the non-targeting controls did not cause major 
changes, indicated by a z-score that fluctuates around 0 (Figure 3.2A). Furthermore, gene 
knockdown of PI4KIIIA impaired entry/ replication of HCV but not DENV, and silencing of the 
Apolipoprotein E specifically altered HCV particle assembly/ release. (Figure 3.2A A, 
Supplementary Table S 2). Thus all controls behaved as predicted indicating the high quality 
of the screen performance.  The screen confirmed the involvement of several already 
described factors such as DDX3, COPA, COPB1 or DDX6 in the early events of HCV or 
DENV replication, respectively [76, 154, 258, 259]. In addition the results revealed host 
factors with potential novel function in the replication cycle of these viruses. (Figure 3.2A A, 
underlined factors are novel).  
As indicated earlier, in case of the high content image-based LD morphology screen two 
control conditions were included that are known to inhibit or enhance LD formation, namely 
treatment with Triacsin C or BSA-loaded oleic acid respectively [256]. Indeed, Triacsin C 
substantially reduced neutral lipid storage as well as neutral lipid distribution, while treatment 
with oleic acid had the opposite effect. Additionally, transfection of the siRNA non-targeting 
control had no effect on any of the evaluated features, indicating that the introduction of the 
siRNAs did not affect LD morphology per se (Figure 3.2A B, Supplementary Table S2).  
Interestingly knockdown of subunits of the proteasome as well as of the Coat protein 
complex I vesicle machinery appeared to enhance the mean of LD counts or the LD mean 
area in human hepatoma cells, respectively (Figure 3.2B). 
The bipartite primary screen led to the identification of 133 genes involved in the replication 
cycle of HCV and/or DENV and 59 genes that alter LD features. The results of the primary 
screen are summarized in Figure 3.3, the Supplementary Table S2, S3 and S4.  
Of the 93 HCV hits, half of the hits appeared to be important for the early phase of the viral 
replication cycle, while only 26 affected later stages. 18 genes were classified as life cycle 
regulators. In case of the 82 DENV hits, 32 and 37 candidates were found to be important for 
early or late stages of the viral replication cycle, respectively. 13 life cycle regulators were 
identified (Figure 3.3A, B). Of these 133 viral hit genes, 51 were specific for HCV, 42 were 
common for both viruses and the remaining 40 were unique for DENV (Figure 3.3B). With the 
help of the deconvolution screen 61 high confidence hits were identified to be unique for 
HCV, while 16 DENV specific high confidence hits were found. Both viruses shared 13 
common high confidence hits (Figure 3.3D, Supplementary Table S 5). Thus the 
deconvolution screen confirmed the importance of 67.6% of the primary hits for either virus. 
The best hit recovery rate was obtained for HCV, for which 78.8% of the primary hits were 
confirmed to be high confidence hits (Figure 3.3E).   
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Figure 3.3 Primary and deconvolution screen results (A) Results of the primary screen. The number of genes 
either affecting entry/ replication (black bar) or assembly/ release (grey bar) or having an opposing effect on both 
steps (white bar) is depicted. (B) Diagram showing the number of HCV or DENV specific hit genes. The number 
of hit candidates common for both viruses is indicated in the overlapping section of both circles.  (C) LD 
morphology hits. Genes shown to affect lipid storage and/ or lipid distribution are depicted. (D) High confidence 
hits identified by the deconvolution screen. The number of genes that are either specific for HCV or DENV or 
common for both viruses is shown. (E) Hit recovery rate of the deconvolution screen. The hit recovery rate is 
defined as the percentage of primary hits that were confirmed to be high confidence hits by the deconvolution 
screen. 
The image-based LD morphology screen led to the identification of 59 hits, 40 of which 
showed an impact on lipid distribution, the remaining 19 candidates were additionally 
involved in lipid storage (Figure 3.3C). These hit candidates were members for several major 
cellular pathways, such as the COPI vesicular trafficking machinery (COPA, COPB1, 
COPB2, COPZ1), the proteasome degradation pathway (PSMC3, PSMC4, PSMC6, PSMD1, 
PSMD12, PSMD2, PDMD3) as well as translation initiation factors (EIF3C, EIF3E, EIF3F, 
EIF3G). The complete list of hit candidates is depicted in Supplementary Table S 4. 
 
3.1.3 Analysis of the connection of LD-dependent viruses and the lipid storage 
organelle 
 
Central role of LDs in the replication cycle of HCV and DENV. Given that the LDs play a 
pivotal role in the replication cycle of HCV and DENV, we argued that targeting genes that 
alter LD function would most likely also affect either virus. Indeed our screen had a relatively 
high hit rate of 57.8% (Figure 3.4A). Furthermore we were able to confirm that 25.7% of the 
analyzed genes were indeed affecting LD morphology in human hepatoma cells (Figure 
3.4B). Interestingly almost 80% of those genes had an additional effect on either virus, and 
about 40% were common hits (Figure 3.4C). This suggests a strong relationship between the 
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replication cycle of HCV and DENV and LD homeostasis, and furthermore that HCV and 
DENV depend on similar LD-related pathways.  
	  
Figure 3.4 Analysis of the relationship of the viral replication cycle and LD biology based on the primary 
screen data. (A) Percentage of the 230 genes that alter HCV and/ or DENV replication cycle. (B) Percentage of 
the 230 genes with a given phenotype on LD morphology. (C) Percentage of the 59 LD hits that have an 
additional effect on the replication cycle of HCV and/or DENV. Adapted from Dr. G. Alvisi. 
 
3.1.4 Bioinformatic analysis of LD RNAi screen 
 
Enrichment of hit candidates involved in major cellular pathways. In order to gain a 
better insight into the cellular pathways that might be involved in the viral replication cycles 
as well as LD homeostasis a bioinformatic analysis was performed, in which the hits were 
grouped according to their most relevant function and to their cellular localization. This 
highlighted the importance of members of several biological processes involved in RNA 
metabolism, cell cycle control and protein degradation for both viruses.  Most interestingly 
the vesicular coat protein compIex I (COPI) transport machinery appeared to regulate LD 
biology as well as the viral replication cycles and thus might represent a central hub (Figure 
3.5).  
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Figure 3.5 Schematic representation of the subcellular localization of hit candidates identified by the 
primary screen. The most relevant function of several candidates is presented and indicates the enrichment of 
distinct cellular pathways, i.e. Coat protein complex I (COPI) vesicle trafficking, eukaryotic translation initiation 
factor 3 complex eIF3. The following colour code for hit definition was used: HCV: red (solid line), DENV: green 
(solid line), LD: blue, HCV+DENV: yellow, HCV+LD: red (punctate line), DENV+LD: green (punctate line), 
HCV+DENV+LD: black. The grey filling indicates that the candidate gene was identified to be a high confidence 
hit for HCV and/ or DENV by the deconvolution screen. Scheme was adapted from Dr. G. Alvisi. 
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3.1.5 Follow-up studies of the LD RNAi screen 
 
3.1.5.1 Selection of candidates for in depth characterization  
 
Building on the screening results that had been obtained by Dr. Alvisi, I joined in for the 
subsequent follow-up studies, with the aim to elucidate in more detail the role of several 
candidates in the viral replication cycles and LD homeostasis. We therefore chose to focus 
on candidates that were either involved in all three processes, or specific for both viruses. 
The candidates and their respective phenotypes are depicted in Figure 3.6A and B. 
 
	  
Figure 3.6 Candidates for follow-up studies. (A) Schematic representation of the hit distribution of the primary 
screen. (B) Knockdown phenotype of the respective candidate on entry/ replication or assembly/ release of HCV 
or DENV or LD morphology. The arrows pointing to the top or the bottom represent an enhancement or 
impairment of the respective step in the viral replication cycle upon gene knockdown. Arrows pointing to the left 
and right indicate that no effect was observed. Note that several subunits of the COPI coat are summarized, thus 
different outcomes are possible, depicted by several arrows. The stars indicate the association to different fields 
in (A). 
Comparative bioinformatic analysis of the RNAi screen data suggested the COPI-mediated 
membrane trafficking machinery to act as a central node connecting all three processes. Our 
screen revealed, that knockdown of several members of the COPI coat efficiently reduced 
HCV entry and replication while increasing assembly and release of infectious particles.  
Dengue virus entry and replication was also impaired, while assembly and release of virions 
was either enhanced or reduced, depending on the COPI subunit.  In agreement with earlier 
studies performed in drosophila cells, our screen identified the COPI system as a regulator of 
LD homeostasis, which was manifested by alterations in cellular lipid storage [236, 237] 
(Figure 3.2). In initial experiments transient siRNA-mediated knockdown of several COPI 
subunits did not cause a significant reduction in HCV RNA replication, while depending on 
the siRNA oligo used and on the siRNA gene target the viral reinfection efficiency was either 
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found to be enhanced or unaltered (Supplementary Figure S1). We found that only short 
periods of gene knockdown up to 48 h were well tolerated by our cellular system 
(Supplementary Figure S1D). Given that we were not able to reproduce the RNAi screen 
phenotype we set our major focus on another hit candidate, the DEAD box RNA helicase 3 
(DDX3/DDX3X), which has a potential role in HCV and DENV life cycle (Figure 3.2A).  
DDX3 is an established HCV entry/ replication dependency factor [76, 154], which was 
confirmed by our screen (Figure 3.2). Intriguingly the deconvolution screen revealed an 
additional role of the host factor in infectious particle production, which had not been 
described thus far. This is particularly interesting, as DDX3 was reported to be recruited to 
LDs by its interaction with the HCV core protein [260]. Furthermore our screen identified a 
novel function of DDX3 as an important dependency factor for DENV particle production 
(Figure 3.2 , Figure 3.6). 
 
3.1.5.2 The DEAD box RNA helicase 3, X-linked (DDX3X, DDX3) 
 
In 2007 DDX3 was reported for the first time to be required for the replication of stable 
subgenomic HCV gt1b replicons [154]. Two years later, a RNAi screen targeting 62 host 
genes that interact either with HCV proteins or viral RNA confirmed the role of DDX3 in early 
events of the viral replication cycle (gt2a) [76]. So far the only hepatitis C virus protein that 
has been found to interact with DDX3 is the structural protein core [155, 156]. Until now, the 
function of this interaction remains unresolved. One study demonstrated that the interaction 
of both proteins is dispensable for the replication cycle of HCV (JFH1, gt2a), while another 
study indicated a possible function in RNA replication of genotype 1b replicons [260, 261].  
 
3.1.5.2.1 Involvement of the DEAD box RNA helicase DDX3 in the replication cycle of 
HCV and DENV 
 
The first set of experiments aimed to confirm the results of the RNAi screen that indicated a 
role of DDX3 in entry and replication of HCV. Additionally our screen implicated a novel 
function of the protein in infectious particle production of both HCV and DENV. Given that 
DDX3 has been implicated to interact with the HCV core protein at LDs we speculated that 
the protein could directly be involved in HCV virion biogenesis [260]. 
 
DDX3 is involved in early events of HCV reporter but not of DENV reporter virus 
replication cycle. In initial experiments DDX3 expression was silenced by transient 
electroporation of either one of two different siRNA oligos into target cells. In a similar setup 
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as compared to the RNAi screen, the effect of gene knockdown on the full infectious cycle of 
HCV or DENV was assessed (Figure 3.7A).  
 
Figure 3.7 DDX3 knockdown affects HCV reporter but not DENV reporter virus replication cycle.  (A) 
Description of the experimental setup. Huh7.5FLuc cells were electroporated with the respective siRNA. 48 h post 
silencing, cells were infected with HCV or DENV Renilla luciferase reporter virus at a MOI of 0.5. 48 h later cells 
were lysed and cell supernatants were transferred onto naïve cells for 48 h of reinfection.  (B-C) Effect of gene 
knockdown of DDX3 on the entry/replication (left panel) and on the reinfection efficiency (right panel) of HCV or 
DENV Renilla luciferase reporter virus. Relative light units (RLU) are depicted as percentage of the non-targeting 
siRNA control. (D) Effect of gene knockdown on cell viability. Cell viability was assessed by measuring the 
metabolic activity of the cells using the WST-1 assay at different time points post siRNA electroporation. (E) 
Validation of knockdown efficiency. Cell lysates were harvested at the time-point of infection (48 h post siRNA 
epo) or reinfection (96 h post siRNA epo) and DDX3 protein levels were determined by Western Blot. Beta actin 
served as loading control. (A-D) The mean and standard deviation of at least 3 independent experiments are 
shown.  (***, p< 0.001, **, p< 0.01, *, p< 0.05). 
In agreement with the screen data, siRNA-mediated DDX3 gene knockdown efficiently 
impaired entry and replication of HCV Renilla luciferase reporter virus, while it caused no 
changes in the early events of DENV replication (Figure 3.6B, Figure 3.7B and C, left 
panels). Knockdown of the known HCV RNA replication dependency factor PI4KIIIA, used as 
a positive control, dramatically reduced the Renilla luciferase reporter activity. We confirmed 
that the impact on virus replication was not a consequence of cell death, as DDX3 gene 
Results I 71  
 
silencing had only mild effects on cell viability (Figure 3.7D). However we were not able to 
validate the DDX3 knockdown phenotype of the screen on assembly and release of either 
virus under the given experimental conditions (Figure 3.6B, Figure 3.7B, C right panel). This 
could possibly be due to an inefficient gene knockdown. Indeed, we observed that DDX3 
protein levels were severely reduced at the time point of infection (48 h post siRNA 
electroporation), while its expression appeared to partially recover at later stages, coincident 
with the time frame when most HCV particles are expected to be formed and released from 
the cell (Figure 3.7E). 
 
DDX3 knockdown only mildly affects HCV RNA genome replication. The observed effect 
of DDX3 silencing on HCV replication suggests that this host factor might be involved in viral 
entry or post entry steps such as RNA translation and replication.  
 
 
Figure 3.8 Effect of DDX3 gene knockdown on RNA replication of gt1b (LucUbiNeo_Con1ET) and gt2a 
(LucUbiNeo_JFH1) stable Firefly luciferase replicon cell lines. (A) Description of the experimental setup. 
Stable replicon cell lines of gt1b or 2a were electroporated with the respective siRNA and viral RNA replication 
efficiency was determined at different time points post silencing. (B-C) Left panels: The effect of DDX3 gene 
silencing on RNA replication of gt2a and gt1b stable Firefly luciferase reporter replicons was determined by 
measuring the Firefly luciferase activity in cell lysates at different time points post silencing. Relative light units 
72 I Results 
 
(RLU) are shown. Right panels: Effect of DDX3 gene knockdown on cell viability as determined by WST-1 assay. 
The mean and standard deviation of 6 independent experiments are shown (***, p< 0.001, **, p< 0.01, *, p< 0.05). 
(D-E) The DDX3 gene silencing efficiency was analyzed by Western Blot. DDX3 and beta actin protein levels at 
48, 72 and 96 h post siRNA electroporation are shown for (D) LucUbiNeo_JFH1 or (E) LucUbiNeo_Con1ET. 
In order to elucidate this in more detail we made use of gt2a (LucUbiNeo_JFH1) and gt1b 
(LucUbiNeo_Con1ET) stable Firefly luciferase reporter replicon cell lines (Figure 3.8). 
DDX3 gene knockdown did not alter the viral RNA replication efficiency of gt2a replicons, 
while it mildly reduced gt1b RNA replication (Figure 3.8B, C). Importantly, DDX3 silencing did 
not significantly affect cell viability, especially in the case of siDDX3(2), the siRNA giving the 
best phenotype on virus replication (compare Figure 3.8C, E, left and right panels). Silencing 
of PI4KIIIA however substantially impaired RNA replication of both viral genotypes (Figure 
3.8B, C, left panels.) We further assessed the silencing efficiency by measuring DDX3 
protein levels over time. We found that protein expression was reduced to different extent 
depending on the time point and siRNA used (Figure 3.8D, E). In general, we obtained an 
overall better silencing efficiency upon transfection of siDDX3(2) as compared to siDXX3(1), 
which correlated with a mildly stronger effect of siDDX3(2) transfection on early events of the 
HCV replication cycle (compare Figure 3.7B and E, Figure 3.8C and E). Taken together 
these results could indicate a specific role of DDX3 early in HCV replication.  
 
DDX3 knockdown causes a slight reduction in infectious particle production of gt2a/2a 
and gt1b/2a intra-/ intergenotypic chimeras. In a last set of experiments we aimed to 
confirm the involvement of DDX3 in HCV particle production. To this end, we made use of 
two viral full-length Renilla luciferase reporter constructs, which share the same non-
structural proteins of gt2a, but differ in the sequence of the structural proteins (and parts of 
NS2). The most efficiently replicating construct, is based on an intragenotypic chimera, 
designated Jc1, consisting of the core to NS2 sequence of the infectious isolate J6CF (gt2a) 
and the remaining sequence of JFH1 (gt2a) [100]. Similar to this virus construct, an 
intergenotypic chimera of gt1b and 2a, with two cell culture adaptive mutations that enhance 
viral particle production was used [262]. Both viral genomes had an integrated Renilla 
luciferase reporter gene that allowed a sensitive and efficient readout of viral RNA replication 
(Figure 3.9B).  
In order to circumvent the negative effect of DDX3 gene silencing on early events of HCV 
replication, siRNA was transfected 48 h after the electroporation of in vitro transcripts of the 
respective full-length Renilla luciferase reporter virus. 48 h post silencing cell supernatants 
were transferred onto naïve cells for the determination of the viral reinfection efficiency 
(Figure 3.9A). Under these conditions gene knockdown of DDX3 did not affect viral 
replication (Figure 3.9C) but caused a mild, but significant, reduction of released infectivity. 
This effect was almost comparable to the ApoE knockdown condition, which resulted in the 
expected reduction in infectious particle production (Figure 3.9D). Importantly, DDX3 protein 
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levels were reduced upon DDX3 gene silencing, while the number of silenced cells remained 
unaffected (Figure 3.9E, F). This indicates that the observed effect of DDX3 silencing on the 
late stages of the viral replication cycle was not due to cell death.  
 
	  
Figure 3.9 Effect of DDX3 gene knockdown on later stages of full-length Renilla luciferase reporter virus 
replication. (A) Description of the experimental setup. (B) Scheme of constructs used in this experiment. Two 
different intra-/ intergenotypic chimeras containing the Renilla luciferase reporter gene were used. Gt2a/2a: 
J6/JFH1, also designated JcR2A, gt1b/2a: Con1R2A/JFH1 [262]. (C) Effect of DDX3, PI4KIIIA or ApoE gene 
knockdown on viral replication. Replication was determined by measuring the Renilla luciferase activity in cell 
lysates. (D) Effect of DDX3, PI4KIIIA or ApoE gene silencing on the assembly and release of infectious particles. 
Reinfection efficiency was determined by measuring the Renilla luciferase activity in cell lysates of reinfected 
cells. (C-D) The mean relative light units (RLU) and standard deviation of at least 4 independent experiments are 
shown (***, p< 0.001, **, p< 0.01, *, p< 0.05). (E) Cell number as determined by measuring the Firefly luciferase 
counts. The effect of gene knockdown on the cell number, as an estimate for cell viability, was determined for 
cells electroporated with either viral construct in addition to siRNA and is summarized in the panel. (F) DDX3 
gene knockdown efficiency as determined by Western Blot 48 h post silencing. 
 
Taken together, DDX3 seems to be important for early events in the HCV replication cycle. 
Additionally DDX3 might further be involved in HCV particle production.  
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3.1.5.2.2 Analysis of the cellular distribution of DDX3 in HCV or DENV infected cells 
 
DDX3 has been reported to interact with the HCV core protein resulting in the protein’s 
relocalization to LDs in HCV infected cells [155, 156, 260]. This is of peculiar interest, given 
that DDX3 was found to promote late stages of the viral replication cycle (Figure 3.9), 
possibly infectious particle production, which in turn is suggested to involve LDs [136, 138].  
 
DDX3 is relocalized to LDs in HCV but not in DENV infected cells. Indeed 
immunofluorescence analysis of HCV (Jc1, gt2a) infected as compared to uninfected cells 
revealed a striking relocalization of the cytosolic DDX3 protein pool to dot-like structures at 
close proximity of LDs (Figure 3.10A, C). 
Although DDX3 and the HCV core protein were found to surround the same lipid droplets, 
they did not substantially colocalize. Instead the DEAD box RNA helicase was found at sites 
adjacent to the viral core protein (Figure 3.10A, white arrow). Similar to the HCV core protein, 
the DENV capsid protein localizes to LDs (Figure 3.10B, white arrow). Interestingly DDX3 
was not found to change its cellular distribution in DENV infected cells and remained evenly 
distributed in the cytosol, similar to the protein’s localization in mock cells (Figure 3.10B, C). 
This suggests that the recruitment of DDX3 to LDs might specifically depend on the presence 
of the HCV core protein at the lipid storage organelle.  
 
	  
Figure 3.10 Cellular distribution of DDX3 in HCV or DENV infected cells. Huh7HP cells were infected with (A) 
HCV (Jc1), (B) DENV (DENV-2 16681) at a MOI of 5 or were (C) left uninfected. 48 h post infection cells were 
processed for indirect immunofluorescence. Cells were labelled for the nuclei with DAPI (grey), the viral capsid or 
core proteins (green), endogenous DDX3 (red) and lipid droplets (LDs, blue). Representative pictures of HCV or 
DENV infected cells as well as of an uninfected cell are shown. Note that the signal intensity of DDX3 was 
enhanced in order to visualize the cytosolic distribution of DDX3 in mock cells. The areas highlighted with a white 
box are shown in larger magnification in the insets. Scale bars indicate 10 µm or 5 µm in the insets.   
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The HCV core protein is sufficient for recruitment of DDX3 to LDs. The HCV core 
protein has been shown to recruit other viral replicase components such as the viral RNA 
and several non-structural proteins to LDs [136]. Although in a yeast two hybrid screen a 
direct protein-protein interaction of the viral core with DDX3 was observed [156], it is still 
possible that under authentic infection conditions, the recruitment of DDX3 to LDs is involving 
any of the other viral components. Another interesting possibility would be that DDX3, being 
an RNA binding protein, could be trafficked together with viral RNA molecules to LDs [263].  
 
 
Figure 3.11 Localization of DDX3 to lipid droplets is dependent on the presence of the HCV core protein. 
(A) Distribution of DDX3 in Huh7/Lunet or gt2a stable replicon cells (LucUbiNeo_JFH1). DDX3 is shown in red, 
NS5A in green. Scale bars indicate 10 µm. (B) Distribution of DDX3 in Huh7/Lunet-T7 cells expressing the core 
protein of different genotypes: Jc1 (gt2a), JFH1 (gt2a), Con1 (gt1b), H77 (gt1a). The core is shown in green, 
endogenous DDX3 in red, cell nuclei in grey and lipid droplets in blue. Magnifications of the area encircled by a 
white box are shown in the insets. Scale bars represent 10 µm.  
In order to examine in more detail the viral determinants that induce this tremendous 
redistribution of DDX3 we performed a set of immunofluorescence studies (Figure 3.11). In 
order to rule out the involvement of any of the non-structural proteins NS3-5B in the 
recruitment of DDX3 to LDs we analyzed the protein’s localization in stable replicon cell lines 
of gt2a (LucUbiNeo_JFH1), which lack the viral proteins core to NS2. In this case, DDX3 was 
found evenly distributed in the cytosol, similar as compared to the protein’s distribution in 
control Huh7/Lunet cells (Figure 3.11A). In contrast, the sole expression of the core protein 
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of different genotypes induced an efficient recruitment of DDX3 to dot-like structures at LDs, 
similar to that observed in infected cells (compare Figure 3.10A and Figure 3.11B).  
 
In summary, the cytosolic DEAD box RNA helicase DDX3 is recruited to LDs in HCV infected 
cells in a core-dependent manner. The fact that DDX3 is recruited by the core protein of 
several genotypes supports the notion that this host factor has an important role in the HCV 
replication cycle.   
 
3.1.5.2.3 Studying the effect of disrupting DDX3 relocalization to LDs on the viral 
replication cycle 
 
Extensive comparative studies of two hepatitis C genomes, namely Jc1 and JFH1, led to the 
interesting finding that the J6 core moiety of Jc1 showed a fairly stable binding to LDs, while 
only few lipid droplets were covered by the viral core protein. The JFH1 core in contrast was 
shown to extensively localize around LDs where it was highly mobile and exchangeable. It 
was argued that the lower mobility of the J6 core at LDs might somehow facilitate particle 
assembly, which would contribute to the more efficient infectious virion production in case of 
Jc1 as compared to the low assembly competent JFH1 [264]. In addition the core protein of a 
Jc1 mutant, incapable of virus assembly, was found to heavily accumulate around LDs. This 
suggests that the rapid release of viral particles in case of J6 might prevent the accumulation 
of core protein around LDs [264]. These observations generally raise the question which viral 
or host determinants might contribute to differences in the efficiency of infectious particle 
production. Given the interaction of the HCV core protein with the cellular DEAD box RNA 
helicase DDX3, we hypothesized that the recruitment of this host factor to LDs might 
contribute to HCV particle production. We further wondered whether the infectious particle 
production of different viral genotypes was similarly dependent on DDX3 recruitment to LDs 
by the viral core protein.   
 
LD core coverage determines DDX3 relocalization efficiency. In a first set of experiments 
we performed immunofluorescence analysis to compare the distribution of DDX3 and of the 
viral core protein in cells replicating the highly assembly competent Jc1, its assembly 
deficient mutant Jc1ΔE1E2 or the low assembly competent JFH1. Almost all cellular LDs 
were observed to be covered by the HCV core protein of JFH1 and Jc1ΔE1E2 (core in 
doughnut shaped structures), while the Jc1 core protein showed the expected less prominent 
association to LDs (core in dot-like structure) (Figure 3.12A) [264]. Quantification of the 
DDX3 relocalization efficiency, defined as percentage of NS5A positive cells with a DDX3 
speckle-like phenotype, demonstrated a dot-like distribution of DDX3 in almost all cells 
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transfected with the low (JFH1) or assembly incompetent (Jc1ΔE1E2) viral constructs. In 
marked contrast, DDX3 remained cytosolic in 80% of cells transfected with the highly 
assembly competent Jc1 (Figure 3.12B). In line with our previous observation of the HCV 
core protein being the sole determinant for DDX3 recruitment to LDs, these results indicate a 
correlation between LD-HCV core coverage and the efficiency of DDX3 recruitment.  
 
 
 
Figure 3.12 HCV isolate specific differences in DDX3 relocalization efficiency. (A) Localization of 
endogenous DDX3, lipid droplets and the viral core protein in HCV transfected cells. Huh7/Lunet cells were 
electroporated with the genomic transcripts of Jc1, JFH1 or Jc1ΔE1E2 or a water control. 72 h post 
electroporation cells were fixed with 4% PFA and processed for indirect immunofluorescence. The HCV core 
protein (green), endogenous DDX3 (red), lipid droplets (blue) and the nuclei (DAPI, grey) are shown. 
Magnifications of the area highlighted with a white box are shown. Scale bars represent 10 µm in the overview or 
5 µm in the insets respectively. (B) Percentage of NS5A positive cells with given DDX3 distribution 72 h post viral 
RNA transfection. Results of two independent experiments are shown; at least 70 cells were analyzed per 
experiment and per condition. 
 
The Y35A core point mutation disrupts DDX3 relocalization to LDs. We next aimed at 
investigating the role of DDX3 recruitment to LDs during HCV infection. Given its interaction 
with the viral core protein, DDX3 might most likely be involved in steps of viral particle 
production. In addition we wondered whether distinct viral chimeras that differ in their 
infectious particle assembly competence [262] would depend equally on the recruitment of 
DDX3 to LDs. To this end we introduced either one of the two core point mutations, Y35A or 
F24A, into several different viral constructs (Figure 3.13). Both mutations have earlier been 
described to disrupt DDX3-core protein interaction, with Y35A having a higher efficiency as 
compared to the F24A mutation [260]. We choose to introduce these mutations into core 
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protein of several viral chimeras, that share the NS2 to 3’ moiety of gt2a and but contained 
the remaining parts of either one of two different HCV genotypes and subtypes (gt1a, 1b, 
2a). Note, the gt1b/2a (Con1/JFH1) and gt1a/2a (H77/JFH1) chimeras exhibit two to three 
cell culture adaptive point mutations that substantially enhance infectious particle production 
as compared to the corresponding wild-type constructs [262].  
 
	  
Figure 3.13 Schematic representation of viral constructs used in the subsequent experiments. Either one 
of the two point mutations Y35A or F24A that have been described to interfere with protein interaction of DDX3 
and HCV core were introduced into the viral core proteins [260]. In case of two constructs additional adaptive 
mutations were introduced which have been reported to substantially enhance infectious particle production [262]. 
 
Immunofluorescence analysis of the cellular distribution of DDX3 showed that upon the 
introduction of the Y35A point mutation into the HCV core protein of either genotype, DDX3 
was no longer found in dot-like structures at LDs, but remained evenly distributed in the 
cytosol (Figure 3.14A, B). Of note, the DDX3 protein levels were the same in cells replicating 
wild-type or mutant virus (Figure 3.14C). This suggests that the HCV core mediated 
recruitment of DDX3 to the LDs represents a relocalization of the cytosolic pool, while overall 
DDX3 proteins levels and possibly protein stability remain unaltered. In addition, these 
results reinforce the notion that the HCV core protein is the sole viral factor mediating DDX3 
recruitment to LDs.  
 
Disrupting core-mediated relocalization of DDX3 to LDs through the Y35A core point 
mutation does not affect HCV RNA replication but reduces infectious particle 
production as well as HCV core protein levels. To elucidate the impact of the Y35A core 
mutation on the viral replication cycle, intracellular as well as extracellular viral titers were 
determined by limiting dilution assay. To this end, viral titers were determined 48 or 72 h after 
transfection of in vitro-transcribed viral RNAs of the Jc1, JFH1, Con1/JFH1 and H77/JFH1 
constructs, carrying or not the point mutation in core. While differences in the extracellular 
titers would account for an impact of the mutation on the release of infectious particles, 
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differences in intra- and extracellular titers would be an indication of an impaired virus 
assembly process.  
 
	  
Figure 3.14 Effect of Y35A HCV core point mutation on DDX3 distribution. (A) Immunofluorescence analysis 
of DDX3 localization in Huh7/Lunet cells 72 h after transfection of the respective constructs depicted in Figure 
3.13. Endogenous DDX3 is shown in red, the viral core protein in green, lipid droplets in blue and cell nuclei in 
grey. Magnifications of the area highlighted with a white rectangle are shown. Scale bars represent 10 µm in the 
overview or 5 µm in the respective magnification pictures. Note that in order to illustrate the cytosolic distribution 
of DDX3, the signal of DDX3 was enhanced in case of the Y35A mutants and the mock control (B) Percentage of 
NS5A positive cells with given DDX3 distribution. The results of a single experiment are shown. At least 100 cells 
per condition were analyzed. (C) Western Blot analysis of the protein levels of DDX3 and beta actin in cell lysates 
72 h after transfection of the viral RNA. 
We found no significant difference in intra- or extracellular virus titers after 48 h of viral RNA 
transfection (Figure 3.15A). However at a later time point (72 h post viral RNA 
electroporation), both intra and extracellular viral titers were reduced ~10-fold in case of 
mutant Jc1, Con1/JFH1 as well as H77/JFH1. This result indicates a defect in infectious virus 
particle assembly when DDX3 is not properly recruited to LDs (Figure 3.15B, C). In contrast 
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the core point mutation did not alter viral titers of JFH1Y35A, which were similarly low as 
compared to the corresponding wild-type virus (Figure 3.15B).  
 
	  
Figure 3.15 Effect of Y35A HCV core point mutation on the full replication cycle of HCV. (A-C) Intra and 
extracellular viral titers as determined by limiting dilution assay. Huh7/Lunet cells were electroporated with the 
viral RNA. 48 and 72 h post electroporation intra and extracellular viral titers were determined. (A) n=2, (B) n=4, 
(C) n=1 (***, p< 0.001, **, p< 0.01, *, p< 0.05). (D) Protein levels of NS5A, NS3, beta actin and the viral core 
protein in cell lysates 72 h post viral RNA transfection. A representative picture of a Western Blot is depicted. (E) 
Quantification of the Western Blot analysis of two to three independent experiments. HCV core signal was 
normalized to protein expression of a non-structural protein (NS). wt= wild-type 
In order to exclude the possibility that the reduction in titers is simply a reflection of different 
replication capacities among the viral mutants, we measured NS5A and NS3 protein levels 
by Western Blot. All mutant viruses appeared to replicate to similar extent as no dramatic 
differences in the levels of the non-structural proteins were detected (Figure 3.15D). This 
result further suggests that the recruitment of DDX3 to LDs is dispensable for HCV RNA 
replication.  
In the course of these experiments, when we analyzed the core protein expression it became 
apparent that mutant core protein levels of all genotypes tested were reduced by almost two-
fold in comparison to the respective wild-type counterpart (Figure 3.15D, E). Although the 
levels of core protein reduction did not correlate to the corresponding reduction in viral titers, 
it cannot be ruled out that, at least in parts, the reduced core protein levels account for the 
lower viral titers. Interestingly, the introduction of the F24A point mutation into Jc1 led to a 
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substantial decrease of viral titers while the protein levels of core where not reduced but 
conversely, increased (Figure 3.15B, D, E, indicated by black arrow).  
 
The F24A core point mutation abrogates DDX3 relocalization, impairs infectious 
particle production and partially reduces HCV core protein levels. As the F24A core 
mutation caused a drop in intracellular and extracellular viral titers while not substantially 
reducing the core protein levels of Jc1, we assessed the effect of this point mutation on the 
cellular distribution of DDX3.  
	  
Figure 3.16 Effect of F24A HCV core point mutation on the cellular distribution of DDX3. Huh7/Lunet cells 
were electroporated with the wild-type or F24A mutant constructs depicted in Figure 3.13. 72 h post 
electroporation cells were fixed and processed for immunofluorescence staining of NS5A (green), DDX3 (red) and 
cell nuclei (grey). Scale bars represent 10 µm or 5 µm in the inset, respectively. Note that the DDX3 signal was 
increased in case of the F24A mutants and the mock control to visualize the protein’s cytosolic localization.  
As observed for the Y35A core mutant, DDX3 was found evenly distributed in the cytosol of 
cells transfected with the F24A core mutant virus (Figure 3.16). In the case of cells 
replicating the corresponding wild-type virus DDX3 was found in defined spots in close 
proximity to NS5A often present in doughnut shaped structures, suggesting the protein’s 
accumulation around LDs (Figure 3.16). 
To elucidate whether the F24A mutation differentially affects the replication cycle of the 
distinct virus chimeras of low or high assembly efficiency, intra- and extracellular viral titers of 
mutant and wild-type virus were assessed 72 h post viral RNA transfection. As observed 
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before in the case of the Y35A mutation, intracellular and extracellular titers of the F24A 
mutant viruses were reduced by almost 10-fold in case of Jc1, Con1/JFH1 and H77/JFH1. 
No difference was observed between wild-type JFH1 and its respective F24A core mutant 
version (Figure 3.17A). In addition we introduced the F24A mutations into full-length Renilla 
luciferase reporter genomes and assessed the replication and reinfection efficiency of wild-
type and mutant virus. In agreement with our previous results replication was unaltered in 
presence of the F24A mutation, as determined by the Renilla luciferase activity in cell lysates 
48 and 72 h post viral RNA transfection in addition to measurements of NS5A protein levels 
(Figure 3.17B, E). Interestingly the reinfection efficiency of all mutant viral constructs, 
including JFH1F24A, was significantly impaired as compared to their respective wild-type 
counterparts (Figure 3.17C).  
The decrease of intra- and extracellular viral titers to similar extent (Figure 3.17A) suggests a 
defect in HCV particle assembly. Another possibility could be that the decrease in viral titers 
is caused by a reduced infectivity of assembled particles (specific infectivity). Thus we 
determined the intracellular and extracellular core protein levels by core ELISA, which can be 
used as an indication of the total amount of particles present in the sample, independent of 
their infectious potential (Figure 3.17D). To this end, intra- and extracellular core protein 
levels were determined 72 h post viral RNA transfection. In order to normalize for the 
differences in input RNA, the amount of intracellular core protein was determined 4 h post 
transfection.  We observed that intra- and extracellular F24A mutant core protein levels were 
reduced 72 h post transfection, which would suggest that the recruitment of DDX3 to LDs 
does not alter specific infectivity of viral particles but instead affects the viral assembly 
efficiency (Figure 3.17D, numbers indicate fold reduction of mutant core protein levels as 
compared to wild-type). However we observed an additional reduction of mutant core protein 
levels early after viral RNA transfection (4 h post electroporation), which indicates that 
mutant core protein levels are generally lower as compared to the wild-type condition (Figure 
3.17D). This could possibly be due to defects in viral RNA translation or an inefficient 
recognition of the mutant core protein by the antibody used. Indeed, earlier results indicated 
that a core antibody (C750) specific against the N-terminal epitope of core that comprises the 
region of the point mutation recognizes the mutant core proteins to lower efficiency as 
compared to the wild-type protein (data not shown). In contrast the core antibody C830, 
specifically targeting the core polyprotein and frequently used in our Western Blot analysis, 
was shown to recognize wild-type and mutant protein to similar extent (Supplementary 
Figure 2). Unfortunately we were not provided with any information regarding the epitope 
recognized by the antibody used in the core ELISA. Taken together, due to the present 
technical limitations the core ELISA results cannot easily be interpreted. In order to 
corroborate further whether the F24A mutation altered mutant core protein stability, the HCV 
Results I 83  
 
core protein levels were assessed by Western Blot using the C830 core specific antibody. 
The mutant core protein levels were found to be reduced in case of two out of the four 
mutant chimeras, namely, JFH1F24A and H77/JFH1F24A (Figure 3.17E, F). There was no 
obvious correlation between the extent of reduced core protein levels and the observed 
reduction in infectious particle assembly. In fact, although the F24A mutation in the context of 
JFH1 reduced the core protein levels by almost two-fold, this mutant showed the least 
reduction in the viral reinfection efficiency (compare Figure 3.17A, C, E, F). 
 
 
	  
Figure 3.17 Effect of F24A HCV core point mutation on the full replication cycle of HCV. (A) Intra- and 
extracellular viral titers 72 h post viral RNA transfection as determined by limiting dilution assay. The mean and 
standard deviation of two independent experiments are shown; only 1 experimental result is presented in case of 
“JFH1 extra”. (B-C) Replication and reinfection efficiency of wild-type and F24A core mutant Renilla luciferase 
reporter virus. Renilla luciferase activity was measured in Lunet/Huh7 cells transfected with the respective 
construct. Cells were harvested 4, 48 and 72 h post viral RNA transfection. Supernatants collected 48 and 72 h 
post transfection were used for reinfection of naïve Huh7.5 cells. The results of three independent experiments 
are shown. Mean and standard deviation of relative light units (RLU) are depicted (***, p< 0.001, **, p< 0.01, *, p< 
0.05). (D) Core ELISA analysis of the intra- and extracellular core protein levels of cells transfected with wild-type 
or F24A core mutant virus. The mean and standard deviation of two independent experiments are shown. The 
numbers indicate the fold reduction as compared to the respective wild-type condition. (E) Western Blot of NS5A, 
core and beta actin protein levels present in whole cell lysates of (A). A representative picture is shown. The 
NS5A, beta actin and core signals were detected on the same membrane. (F) Quantification of core protein levels 
as determined by Western Blot in two independent experiments. The core protein levels were normalized to the 
expression levels of a non-structural protein (NS).  wt= wild-type 
 
In summary our data indicates that the core-mediated relocalization of DDX3 to LDs is 
dispensable for HCV RNA replication, while it might play a role in infectious particle 
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production. Given that some of the core mutants showed decreased core protein levels, it 
cannot be excluded that the point mutation alters core protein stability and thus impairs 
infectious particle formation.  
3.1.5.2.4 Studying the role of the DDX3 core interaction in the HCV replication cycle 
 
There are several indications that DDX3 might be involved in the regulation of cellular lipid 
metabolism. In an image-based miRNA screen that assessed the role of 327 human miRNAs 
in LD morphology, several miRNAs were identified to reduce the cellular lipid content by 
more than 60%. Interestingly DDX3 was predicted to be targeted by one of the hit miRNAs. 
Follow-up studies that focused on the effect of siRNA-mediated knockdown of DDX3 on LDs 
revealed a slight reduction by 20% in the cellular LD content [246]. Additionally, while our 
study was in progress, DDX3 was described to recognize the 3’ untranslated region of HCV 
RNA, which subsequently triggers a signaling cascade leading to the induction of lipogenic 
genes. This in turn enhances lipid droplet formation that could support HCV particle 
production [158]. Thus we wondered whether the core-dependent recruitment of DDX3 to 
LDs is important for the DDX3 mediated regulation of the cellular neutral lipid content.  
 
Effect of F24A core mutation on cellular neutral lipid content. To address the question 
whether the localization of DDX3 to LDs is important for the induction of lipogenesis and thus 
the formation of lipid droplets, we studied the LD content of cells transfected with either wild-
type or the F24A mutant of the high or low assembly competent Jc1 or JFH1 respectively. To 
this end cells were transfected with the respective full-length viral constructs and the cellular 
neutral lipid content of NS5A positive cells was determined by immunofluorescence using the 
neutral lipid stain Bodipy493/503 (Figure 3.18A). Several LD features were extracted. The 
overall neutral lipid content per cell was determined by measuring the overall Bodipy493/503 
signal intensity (Integrated Density) (Figure 3.18 B). The LD coverage was defined as the 
percentage of the cell cytoplasm covered by Bodipy. Furthermore the LD area (size of an 
individual LD) as well as LD number/ cell area were determined for cells transfected with Jc1 
and its corresponding F24A mutant (Figure 3.18 D, E). This analysis was not feasible for 
cells transfected with JFH1, as LDs were found to cluster and were not easily distinguishable 
(Figure 3.18 A, white arrows). The overal neutral lipid content and LD coverage was higher in 
Jc1- or JFH1- transfected cells as compared to mock cells, suggesting an induction of neutral 
lipid storage in HCV replicating cells (Figure 3.18 B, C). In general the results of the 
immunofluorescence analysis were not highly reproducible, indicating the high susceptibility 
of the read-out towards variations in the experimental procedure, such as the efficiency of 
the LD staining. Analyzing the overall neutral lipid content as well as the LD coverage, it 
appeared that the cellular neutral lipid content and distribution was slightly reduced in case of 
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cells transfected with the F24A mutant virus (Figure 3.18 B, C). This was reproducible in 
regard to JFH1 and its respective mutant, while in case of Jc1 the results were contradicting. 
Although there were statistical significant differences in LD area as well as LD number/ cell 
area between the different conditions, these differences where either subtle or not 
reproducible (Figure 3.18 D, E). 
 
	  
Figure 3.18 Effect of F24A core mutation on the cellular neutral lipid content. (A) Lipid droplet staining in 
Huh7/Lunet cells transfected with wild-type or F24A mutant virus. 72 h post viral RNA transfection cells were fixed 
and lipid droplets were stained with the neutral lipid stain Bodipy489/503 in addition to the labelling of the viral 
NS5A. Representative pictures of the lipid droplet (LD) staining are depicted. White arrows indicate LD cluster. 
(B-E) Quantitative analysis of LD features. Results of two independent experiments are shown. (B) The overall 
neutral lipid content was assessed by measuring the integrated density of the Bodipy489/503 signal intensity per 
NS5A positive cell. (Experiment N°1: n>20, experiment N°2 n>16, n= number of cells). (C) The LD coverage was 
defined as the percentage of the area of the cytoplasm covered by LDs. (experiment N°1: n>20, experiment N°2 
n>16). (D) The LD area was measured per individual LD. LD area was not determined for wild-type and mutant 
JFH1, as in these cases the LDs were clustering and thus could not be separated efficiently. (E) The LD number 
was normalized to the cell area of the respective cell (experiment N°1: n>17, experiment N°2 n>16, n= number of 
cells). (D-E) Whisker box plot. Whiskers range from 10 to 90 percentile. (***, p< 0.001, **, p< 0.01, *, p< 0.05) 
DDX3 recruitment is dispensable for its role in HCV particle production. The rather 
weak effect of DDX3 gene knockdown on the HCV reinfection efficiency (Figure 3.9B) and 
the inconsistent/ unsteady phenotype of the HCV core mutants concerning mutant core 
protein levels and HCV particle production (Figure 3.15 and Figure 3.17) raised the question 
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whether the HCV core dependent recruitment of DDX3 to LDs is of any importance to the 
virus, in particular to virion biogenesis.  
 
	  
Figure 3.19 Sensitivity of wild-type and F24A core mutant virus towards DDX3 gene knockdown (A) 
Schematic representation of experimental setup. Huh7/Lunet cells were transfected with the respective viral RNA 
constructs. 48 h later cells were transduced with siRNA. 48 h post siRNA transfection supernatants were 
transferred onto naïve cells for reinfection. Viral replication efficiency was determined by measuring the Renilla 
luciferase activity in cell lysates. (B) Viral replication efficiency of wild-type and F24A core mutant virus upon gene 
knockdown of DDX3, PI4KIIIA or ApoE. (C) Viral reinfection efficiency of wild-type and F24A core mutant upon 
gene knockdown of DDX3, PI4KIIIA or ApoE. The mean relative light units (RLU) and standard deviation of 4 
independent experiments are shown. The data is presented as percentage of the non-targeting siRNA control. 
(***, p< 0.001, **, p< 0.01, *, p< 0.05) 
To tackle this question, we compared the sensitivity of mutant and wild-type virus particle 
production towards DDX3 gene knockdown. We argued that core mutant virus particle 
production should not be altered upon DDX3 silencing as compared to transfection with the 
non-targeting control siRNA, while wild-type virus should show an impairment of infectious 
particle production upon DDX3 gene knockdown. Given that in some cases the F24A 
mutation appeared to reduce HCV core protein levels, we focused on those mutants that 
exhibited protein levels comparable to the wild-type version, namely Jc1 and Jc1F24A as 
well as Con1/JFH1 and Con1F24A/JFH1. In order to circumvent potential effects of DDX3 
knockdown on early events of virus entry, the viral constructs were electroporated into 
Huh7/Lunet cells, which were transfected with the respective siRNA 48 h later (Figure 
3.19A). We observed that under these conditions the replication efficiency was reduced only 
upon silencing of the known HCV replication dependency factors PI4KIIIA (Figure 3.19 B). 
Importantly, the infectious particle production of F24A mutant and wild-type virus was 
reduced to similar extent by DDX3 or ApoE knockdown (positive control) (Figure 3.19 C). 
This suggests that the recruitment of DDX3 to LDs by the HCV core protein is dispensable 
for its function in HCV particle production. 
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3.2 Studying the role of LTP-assisted cholesterol traffic in HCV replication 
 
3.2.1 Distribution of unesterified cholesterol in HCV infected cells 
 
Infection by positive-strand RNA viruses is characterized by massive rearrangements of the 
cellular endomembrane system, giving rise to the so-called replication organelles or 
replication factories [130]. HCV infection has been reported to induce ER-derived single, 
multi and double membrane vesicles (DMVs) [113, 265]. Appearance of the latter ones 
correlates with HCV RNA replication kinetics and purified DMVs were shown to be bona fide 
replication sites [113, 114, 266]. While the induction of DMVs is believed to be facilitated by a 
concerted action of viral and co-opted cellular proteins, the precise lipid composition of DMVs 
remains elusive. The fact that HCV RNA synthesis occurs at lipid raft-like membrane 
domains suggests an enrichment of specific lipid species [127, 128]. Indeed electron 
microscopy-based analysis of DMVs purified from HCV replicating cells indicated an 
important role of cholesterol as a structural component of the DMVs [114]. 
 
As part of this PhD project we aimed to unravel whether and how HCV might exploit cellular 
membrane homeostatic pathways in order to recruit specific lipids such as cholesterol, for the 
biogenesis and maintenance of viral replication organelles. Therefore we first sought to 
investigate whether HCV induces alterations in the distribution of cellular unesterified (free) 
cholesterol. To this end the distribution of unesterified cholesterol was monitored in HCV 
infected cells by using specific dyes and confocal microscopy analysis. 
 
3.2.1.1 Time course analysis of the distribution of endogenous free cholesterol in 
HCV infected cells  
 
Free cholesterol accumulates at the perinuclear region of HCV infected cells. The 
distribution of free cholesterol in HCV infected cells was visualized by using filipin III, 
designated as filipin, an antifungal polyene derived from streptomyces filipinensis. Filipin has 
been widely applied as a probe to study sterol partitioning in membranes as it selectively 
binds free, unesterified cholesterol, forming a fluorescent complex [251].  
First we analyzed the cellular distribution of free cholesterol in HCV infected cells at different 
time points starting from 24 h post infection (Fig 3.20). Earlier time points were omitted as the 
low NS5A levels did not allow a specific discrimination of infected from uninfected cells. 
During the proceeding course of infection an accumulation of free cholesterol in the 
perinuclear region of the cytoplasm was observed, concomitant with a decrease of the lipid’s 
plasma membrane localization. Importantly, the cholesterol distribution in uninfected cells 
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remained constant over time (Fig 3.20A). To quantify this phenomenon, we classified the 
HCV infected, NS5A positive cells according to the most prominent type of free cholesterol 
distribution either (i) being mainly at the plasma membrane (ii) being present as discrete 
cytoplasmic dots, presumably representing isolated vesicles or (iii) accumulating in a web-
like structure at the nuclear periphery of the cytoplasm. Indeed, early in infection (24 h p.inf.) 
most of the free cholesterol was found at the plasma membrane or vesicular structures. Later 
(32 h p.inf.), the majority of the cells exhibited a prominent labeling of vesicular structures, 
which appeared to redistribute to a diffuse web at later times of infection (48 h. inf.). 
However, in uninfected cells free cholesterol was mainly found at the plasma membrane or in 
vesicular structures (Figure 3.20B).  
	  
Figure 3.20 Distribution of free/ unesterified cholesterol in HCV infected and mock cells. (A) Distribution of 
unesterified cholesterol in HCV infected cells over time. Huh7/LunetCD81H cells were infected with Jc1 (MOI5) 
and fixed 24, 32 and 48 h post infection. The viral non-structural protein 5a (red) was visualized by indirect 
immunofluorescence. Unesterified cholesterol (grey) was labelled using the fluorescent free cholesterol marker 
filipin. Three representative images for each time point of infection are depicted. Two uninfected cells are shown 
depicting the most prominent cholesterol distribution in mock cells. The areas highlighted with white rectangles 
are shown as enlargement adjacent to the corresponding picture. For better visualization purposes the signal 
intensities were equally enhanced. Scale bars represent 10 µm in the overview and 5 µm in the inset pictures. (B) 
Classification of cells according to the most prominent cholesterol distribution. Cells were classified according to 
three possible cholesterol/ filipin distributions: i) cholesterol mainly present at the PM ii) cholesterol mainly found 
in distinctive vesicles iii) cholesterol accumulating at the perinuclear region of the cytosol in a web-like and diffuse 
structure. The results of a single experiment are shown. (C) Quantification of the filipin signal 24, 32 and 48 h post 
infection. The integrated fluorescent density of the filipin signal in NS5A positive or negative cells was measured. 
7-25 cells of a single experiment were analyzed. (D) Quantification of the degree of NS5A and filipin signal 
overlap 48 h post infection. The degree of colocalization of NS5A and filipin was determined by measuring the 
Manders correlation coefficient. At least 20 cells of a single experiment were analyzed. (E) Distribution of free 
cholesterol at late time points of infection. Huh7/LunetCD81H cells were infected with Jc1 (MOI5) for 72 h. Cells 
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were fixed and processed for fluorescence microscopy. The yellow border indicates a NS5A positive, whereas the 
blue border marks a NS5A negative cell. Both regions of interests are shown in the adjacent blow-up. Scale bars 
represent 10 µm in the overview and 5 µm in the inset pictures. (F) Degree of intracellular filipin accumulation. 
Integrated fluorescent density of filipin was measured in more than 20 NS5A positive or negative cells. (G) 
Correlation of integrated fluorescent density of filipin and NS5A. The NS5A signal intensity is plotted against the 
respective filipin signal intensity determined in individual cells. More than 20 cells of a single experiment were 
analyzed. The red line indicates a linear regression of all data points (R-square: 0.45). (H) Quantification of the 
degree of NS5A and filipin signal overlap 72 h post infection. The degree of signal overlap was determined by 
measuring the Manders correlation coefficient. Results of more than 20 cells of a single experiment are shown. 
(***, p< 0.001, **, p< 0.01, *, p< 0.05) 
In order to judge the HCV-induced intracellular cholesterol accumulation, we further 
quantified the signal intensity of filipin at the perinuclear region of the cytoplasm over time.  
With progressing infection (48 h and 72 h p.inf.) the measured signal intensities were 
significantly increased in infected as compared to mock cells. (Figure 3.20C, E, F). 
Interestingly, we additionally observed a (although weak) positive correlation of NS5A and 
filipin signal intensities at the single cell level (i.e. the higher the abundance of NS5A the 
stronger the intensity of filipin) (Figure 3.20G). Furthermore to estimate the subcellular 
localization of free cholesterol with respect to NS5A, used as potential marker for viral 
replication sites [113, 114], we measured the degree of both signals 48 and 72 h post 
infection. This analysis showed that NS5A and filipin partially colocalized, as determined by 
the Manders correlation coefficient (Figure 3.20 D, H). Taken together HCV infection resulted 
in the recruitment of unesterified cholesterol to the perinuclear region of the cytoplasm where 
also the viral replicase protein NS5A localized. These results suggest a biological link 
between HCV replication and the distribution of free cholesterol in infected cells.  
 
3.2.1.2 Studying the fate of plasma membrane derived free cholesterol at early and 
late stages of HCV replication by live cell imaging 
 
Our and previous studies suggest that HCV induces changes in the cellular cholesterol 
distribution potentially aiding the establishment or maintenance of the DMVs, the putative 
sites of RNA replication [79, 114]. However, neither the source of the lipid nor the molecular 
mechanisms underlying the cellular cholesterol redistribution have been fully elucidated yet.  
Cholesterol could possibly be recruited from the plasma membrane (PM), the cellular site 
where the majority of unesterified cholesterol resides [162]. Indeed our previous results 
suggest a relocalization of plasma membrane localized cholesterol to the perinuclear region 
(Fig 3.20). To further corroborate this, we next aimed at visualizing the dynamics of plasma 
membrane cholesterol in HCV replicating cells, using live cell imaging.  
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3.2.1.3 Setting up the conditions for live cell imaging of Topfluor-Cholesterol (TFC) 
dynamics 
 
Plasma membrane (PM) derived TFC is redistributed in HCV replicating cells. In order 
to study the fate of PM derived cholesterol we made use of commercially available 
fluorescently tagged cholesterol, which exhibits a Bodipy moiety attached to its alkyl side 
chain, designated Topfluor-Cholesterol (TFC) (Figure 3.21A). While the introduction of 
fluorescent tags into proteins and into the even smaller lipids can greatly change their 
properties, TFC has been described to closely mimic the distribution and traffic of 
unesterified cholesterol [267, 268]. TFC has been reported to prominently label the plasma 
membrane early after TFC addition and being subsequently distributed to vesicular 
structures, suggested to be endosomes [267].  
 
In a first set of experiments we determined the distribution pattern of TFC in fixed cells 
(Figure 3.21B). To this end Huh7.5 cells were pulsed with 4 µM TFC for 10 min, followed by 
extensive washing with fresh media and fixed at different time points after TFC addition. In 
order to address the distribution of TFC we imaged the whole cell volume taking several z-
stacks. 10 min after pulsing, TFC was readily found in dot-like structures and labeled the 
cytosol (Figure 3.21B, first panel). With proceeding time, TFC increasingly labeled distinct 
spots, presumably representing vesicular structures such as endosomes (Figure 3.21B, 
white arrows). After 1 h of incubation, TFC became apparent at the perinuclear region of the 
cytoplasm in a Golgi- or ER-like pattern and additionally detected as clear, bright round 
structures of 1- 1.2 µm diameter, possibly being lipid droplets (Figure 3.21B, orange and 
yellow arrows respectively). In order to visualize the previously described integration of TFC 
into the PM shortly after its addition [267] we analyzed the TFC distribution at earlier time 
points. Indeed, 5 min post TFC addition, TFC was found at the plasma membrane but also 
labeled the perinuclear region of the cytoplasm (Figure 3.21C). In summary, in line with an 
earlier report we observed that TFC was integrated into the plasma membrane from which it 
was rapidly distributed into vesicular structures as well as to the perinuclear region of the 
cytoplasm and thus potentially to the ER/ Golgi. TFC might further become esterified and 
incorporated into lipid droplets [267]. This suggests that TFC mimics the distribution of 
endogenous (mostly unesterified) cholesterol and hence, represents a useful tool to monitor 
the dynamics of plasma membrane derived cholesterol in live cell imaging. 
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Figure 3.21 Pretests for Topfluor-Cholesterol (TFC) live cell imaging. (A) Chemical structure of Topfluor-
Cholesterol (Avanti Polar lipids). (B) Naïve Huh7.5 cells were pulsed with 4 µM TFC for 10 min, followed by 
extensive washing with fresh media. Cells were fixed 10, 15, 30 or 60 min after TFC addition and the TFC 
localization was analyzed by confocal microscopy. Enlargements of the areas highlighted with a white rectangle 
are shown below. White arrows point to TFC in vesicular structures, the yellow arrow labels TFC in potential lipid 
droplets. Orange arrows indicate a juxtanuclear localization of TFC. Scale bars represent 10 µm. (C) Naïve 
Huh7.5 cells were pulsed for 5 min with 2.3 µM TFC and cells were fixed 5 min later. Two pictures of the same 
cell are shown. The upper panel depicts TFC at the plasma membrane, the lower panel the intracellular 
accumulation of TFC. Scale bars represent 10 µm. (D) LunetCD81H cells stably expressing core to NS2 
transfected with the subgenomic replicon were pulsed for 10 min with either 1 or 4 µM TFC respectively, followed 
by extensive washouts with fresh imaging media. TFC dynamics was imaged live; thus every 15 min the cells 
were imaged taking 3 sequential z-stacks. Only a single stack is shown in the figure. The yellow asterisk indicates 
dead cells. Note that for the two pictures labeled with a white asterisk the signal was enhanced by auto-contrast. 
Scale bars represent 10 µm. 
With the aim to visualize cholesterol dynamics throughout the full infection cycle of HCV, we 
took advantage of the trans-complementation system that is based on the ability to split the 
viral genome which allows the reconstitution of a full infectious cycle under biosafety level 2 
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conditions [98]. To this end Huh7/LunetCD81H helper cells expressing the viral proteins core 
to NS2 (core, E1, E2, p7, NS2) were transfected with the subgenomic replicon containing a 
fluorescent protein (mCherry) tagged NS5A. Providing the structural proteins in trans allows 
infectious virus-like particle production, which however, only support a single round infection 
and are incapable to spread [98]. 
We first performed long-term live cell imaging in HCV replicating Huh7/LunetCD81H_core-
NS2 cells to monitor the distribution of exogenous cholesterol using TFC. 
Huh7/LunetCD81H_core-NS2 helper cells were incubated with either 1 or 4 µM of TFC for 10 
min. The excessive TFC was removed by extensive washing with fresh imaging media. While 
using the higher concentration of 4 µM allowed an efficient detection of the weak TFC signal 
at early time points, the fluorescent signal was readily saturated after 300 min of imaging. 
Further high amounts of TFC seemed to be cytotoxic (Fig 3.21D, upper panel). In contrast 
pulsing cells for 10 min with 1 µM TFC, followed by extensive washing with fresh media, did 
not affect cell viability and allowed the detection of the fluorescently labeled lipid throughout 
the entire imaging period up to 15 h (Figure 3.21D, lower panel). 
 
3.2.1.4 Studying Topfluor-Cholesterol dynamics early and late in HCV replication  
 
With the aim to understand whether HCV infection alters the subcellular distribution of free 
cholesterol pools of the plasma membrane, we studied the time-dependent distribution of 
TFC in HCV replicating cells. LunetCD81H_core-NS2 cells, transfected with the subgenomic 
replicon, were pulsed with 1 µM of TFC for 10 min, followed by extensive washing. The 
distribution of fluorescently labeled cholesterol as well as of mCherry tagged NS5A was 
monitored over 17 h. Therefore images were acquired every 15 min with 3 sequential z-
stacks to cover the entire cell volume. To further elucidate whether HCV utilizes cholesterol 
differently at early as compared to late stages of viral replication, cells were pulsed with TFC 
at either 30 h (“early” setup) or 53 h (“late” setup) post electroporation respectively (Figure 
3.22A, B). Earlier time points were not studied since the low NS5A signal did neither allow 
adequate imaging nor the discrimination between transfected and mock cells. Upon 
measuring of the NS5A signal intensity over time we observed a time-dependent increase in 
NS5A fluorescence intensity reflecting the increase in HCV RNA replication in the “early” 
setup, while the NS5A signal remained constant at later time points suggesting a steady 
state of viral replication (Figure 3.22C).  
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Figure 3.22 Experimental setup of live cell imaging of Topfluor-Cholesterol (TFC) added early or late in 
HCV replication. (A-B) Huh7/LunetCD81H cells expressing the viral proteins core to NS2 were transfected with 
in vitro transcripts of a subgenomic replicon containing mCherry tagged NS5A (sgNS3-3’ 5Amcherry, gt2a). (A, 
early) 30 h or (B, late) 53 h later, cells were pulsed with 1 µM TFC for 10 min, followed by extensive washing. 
TFC distribution was imaged every 15 min for 17 h. (C) NS5A signal intensity over time, early or late in replication. 
The results of two independent experiments are shown. The median of the analysis of at least 8 cells per 
experiment is shown and is presented as fold of the value of the earliest time point of measurement (t=200 min). 
 
TFC accumulates in the perinuclear region of the cytoplasm of HCV replicating cells. 
First we analyzed the overall dynamics of TFC within 17 h of imaging (Figure 3.23). To this 
point the TFC distribution in NS5A positive cells, designated as HCV positive, as well as 
NS5A negative cells, designated as HCV negative/ mock cells, was analyzed at three 
different time points. Note that these “mock” cells do stably express the viral proteins core to 
NS2. In agreement with our previous results, TFC accumulated in the perinuclear region of 
the cytoplasm of HCV positive cells when either added early or late in replication (Figure 
3.23A, B). Comparing the fluorescent lipid’s distribution it appeared that upon its addition late 
in replication TFC was present in a more diffuse pattern around the nucleus, whereas early in 
replication it labeled more distinctive structures (Figure 3.23A, B, number 2 and 3). In mock 
cells TFC appeared to be more dispersed in vesicular structures throughout the cytosol 
(Figure 3.23A, B number 1).  
We next aimed at determining whether there are differences in the extent of TFC 
accumulation at the perinuclear region when comparing “mock” to HCV replicating cells, 
similar to what was observed earlier for endogenous free cholesterol (Figure 3.20). To this 
end we measured the TFC recruitment velocity, which we defined as the TFC signal intensity 
at the perinuclear region of the cytoplasm in NS5A positive or mock cells over time.  
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Figure 3.23 Topfluor-Cholesterol (TFC) dynamics at early and late stages of HCV replication. (A-B) TFC 
distribution over time in cells pulsed with TFC either (A) early or (B) late in replication. The TFC and NS5A 
distribution in Huh7/Lunet_Core-NS2 cells either transfected with (+HCV, filled stars) or without (-HCV, empty 
stars) the subgenomic replicon (containing mCherry tagged NS5A) is shown in the upper and middle panels. The 
distribution of NS5A and TFC is shown in representative pictures at three different time points post TFC addition. 
Enlargements of the cells indicated by the yellow number are presented in the lowest panel. Scale bars represent 
5 µm. (C) TFC recruitment velocity of cells pulsed early (circle) or late (rectangle) in replication. TFC signal 
intensities at the perinuclear region were measured over time in HCV replicating or mock cells (white and green 
symbols respectively). Two independent experiments are shown. The median of at least 6 cells per experiment is 
shown. The presented values were normalized to the value measured at the earliest time point (t=200 min). (D) 
Raw TFC signal intensities. The median of at least 6 cells per experiment is depicted. The results of two 
independent experiments (presented in C) are shown. (E) Correlation of TFC and NS5A signal intensity at the 
perinuclear region as determined in individual cells pulsed with TFC early or late in replication. Each dot 
represents the intensity measurements of a single cell at a specific time. One representative result of three 
independent experiments is shown. R-square: 0.7792. 
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There was no apparent difference in the rate of TFC accumulation between mock and HCV 
replicating cells. Yet, TFC was accumulating faster in HCV replicating and mock cells, when 
added 30 h post electroporation as compared to later time points (Figure 3.23C). Given the 
equal TFC accumulation velocity of HCV replicating and of mock cells, the observed 
difference in TFC incorporation at early as compared to late time points of replication might 
be due to an altered behavior of the cells throughout the course of the experiment. We 
further analyzed the correlation of NS5A and TFC signal intensities. Indeed there was a 
slight time-dependent increase of TFC intensity, which further correlated positively with an 
increase in NS5A signal intensity when TFC was added early in replication (Figure 3.23E).  
Given our previous results indicating a fast uptake and redistribution of TFC within the first 
hour after TFC addition (Figure 3.21B, C), we wondered whether changes in TFC dynamics 
are controlled by fast feed-back regulation and thus of short duration. Hence potential 
differences in the uptake velocity between HCV replicating and mock cells might have been 
missed in our present analysis. Indeed when comparing the raw TFC signal intensities in 
HCV replicating cells it became apparent that they were slightly elevated as compared to 
mock cells. In particular when TFC was added late in replication the TFC signal was 
enhanced already at the earliest time point of measurement as compared to the mock control 
as well as compared to cells in the early phase of replication (Figure 3.23D). Therefore we 
analyzed the time-dependent lipid uptake starting from the earliest time point possible. Given 
the used experimental limitations the detection of TFC was possible starting from 75 min post 
pulse. Hence the TFC accumulation velocity was determined by measuring the lipids 
intracellular fluorescence intensity over time starting from 75 min post addition (Figure 3.24). 
In agreement with our previous analysis, TFC accumulated in either vesicular structures 
(Figure 3.24A, 2+HCV) or a more diffuse pattern (Figure 3.24B, 2+HCV) around the nucleus 
in HCV replicating cells. Again, TFC was of lower intensity and appeared more evenly 
distributed in vesicular structures throughout the cytosol in mock cells (Figure 3.24A, B 1-
HCV). When we analyzed the rate of intracellular TFC accumulation no reproducible 
difference between mock and HCV replicating cells was observed (Figure 3.24C). However 
similar to our previous analysis, we observed that the TFC raw signal intensities were 
elevated (already 75 min post TFC addition) when cells were pulsed late in HCV replication, 
as compared to the respective control condition (Figure 3.25D). This could indicate that even 
earlier time points need to be analyzed.  
96 I Results 
 
 
Figure 3.24 Topfluor-Cholesterol (TFC) dynamics in the early phase upon TFC addition at early or late 
stages of HCV replication. (A-B) TFC distribution over time in cells pulsed with TFC either (A) early or (B) late in 
replication. The TFC and NS5A distribution in Huh7/Lunet_Core-NS2 cells either transfected with (+HCV, lower 
panels) or without (-HCV, upper panels) the subgenomic replicon (containing mCherry tagged NS5A) is shown. 
Scale bars represent 10 µm. (C) TFC recruitment velocity of cells pulsed early (circle) or late (rectangle) in 
replication. TFC signal intensities at the perinuclear region were measured over time in HCV replicating or mock 
cells (white and green circles respectively). Two independent experiments are shown. The median of at least 6 
cells per experiment is shown. The median is presented as fold of the value at the earliest time point of 
measurement (t= 75 min).  (D) Raw values of TFC signal intensities. The results of two independent experiments 
(presented in C) are shown. The median of at least 6 cells per experiment is shown. 
 
Taken together, exogenously added cholesterol as determined here for TFC is efficiently 
trafficked to the nuclear periphery of the cytoplasm in HCV replicating cells. While under the 
given experimental setup, the overall accumulation velocity was found to be similar in 
presence or absence of viral replication, the fluorescent lipid’s distribution pattern appeared 
different, with TFC clustering at the perinuclear region of the cytoplasm in HCV replicating 
cells as compared to a more dispersed vesicular TFC pattern in mock cells. In addition, when 
TFC was added late in HCV replication, intracellular TFC levels were higher in HCV 
replicating cells as compared to mock cells. 
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3.2.1.5 Analysis of TFC recruitment to HCV replication sites  
 
TFC is trafficked to NS5A positive sites. Given the fact that HCV replication appears to 
trigger the accumulation of plasma membrane derived cholesterol at the perinuclear region, 
we examined whether TFC could be found at sites of viral replication. For this purpose we 
analyzed the co-traffic of TFC with NS5A, a multifunctional viral protein involved in RNA 
replication and particle production [74, 77, 81]. NS5A has so far been the only non-structural 
protein that tolerates the insertion of a fluorescent tag while retaining replication competence 
of subgenomic replicons [73]. In Live-cells, NS5A has been described to form large immobile 
structures with a diameter up to several microns, preferentially found at the perinuclear 
region of the cytoplasm, which might represent the viral replication complexes. Besides, 
small vesicular structures scattered throughout the cytosol that exhibit fast saltatory 
movement were observed [73, 269]. Indeed NS5A was found in puncta but also exhibited a 
diffuse web-like distribution at the perinuclear region of the cytoplasm (Figure 3.25A, B, 
NS5A insets, white arrows). Shortly upon addition of TFC early in replication, the fluorescent 
lipid was present in small puncta with no apparent colocalization with NS5A (Figure 3.25A, 
first panel “150 min”, TFC inset, white arrows). With proceeding time, TFC accumulated in a 
diffuse structure and also distinct spots at the perinuclear region, where it partially 
colocalized with NS5A. (Figure 3.25A, yellow arrows). When cells were incubated with TFC 
at late time points of infection, the fluorescent lipid was mainly recovered in a diffuse web, 
where it partially colocalized with NS5A (Figure 3.25B, yellow arrows). Additionally TFC was 
found in clear round structures, possibly lipid droplets (Figure 3.25B, white arrows). We 
further quantified the degree of overlap of both signals over time. In line with our previous 
observations that indicate a recruitment of endogenous cholesterol to NS5A positive sites at 
the perinuclear region upon HCV infection, the colocalization of NS5A and exogenously 
added TFC was increasing over time (Figure 3.25C). The degree of signal overlap was 
generally higher at late stages of replication (Figure 3.25D).  
 
Taken together, our results point to a recruitment of plasma membrane derived cholesterol to 
the perinuclear region of the cytoplasm in HCV-infected cells, where in a time-dependent 
manner TFC recruitment to NS5A positive structures is observed.   
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Figure 3.25 Topfluor-Cholesterol (TFC) and NS5Amcherry trafficking over time. (A-B) TFC and NS5A 
distribution in HCV replicating cells after TFC addition (A) early or (B) late in replication. Huh7/LunetCD81H cells 
expressing the viral core to NS2 proteins were electroporated with the subgenomic replicon harboring mCherry 
tagged NS5A. The localization of NS5AmCherry and TFC upon TFC addition either (A) early or (B) late in 
replication was imaged over time. Representative pictures of three different time points are shown. The white 
rectangle marks the area for which insets of NS5A or TFC are depicted adjacently. White arrows point to either 
TFC or NS5A structures that do not overlap, whereas yellow arrows indicate structures that are TFC and NS5A 
positive.  Scale bars represent 10 µm. For visualization purposes the intensity of the signals was adjusted. (C) 
Degree of NS5A and TFC signal overlap. The Pearson correlation coefficient (PCC) of NS5A and filipin was 
determined as a measure of the degree of signal overlap over time. 4-5 cells of a single experiment were 
analyzed. (D) Median of the PCCs presented in C. 
 
3.2.1.6 Recovery of Topfluor-Cholesterol from HCV replication organelles 
 
TFC is recovered from NS4B-HA purified membrane fractions. Given the colocalization 
of endogenous but also exogenous Topfluor-Cholesterol with the HCV non-structural protein 
5A we wondered, whether PM derived cholesterol would be targeted to DMVs, the presumed 
sites of RNA replication. In order to investigate this further, we made use of a method which 
is based on the Hemagglutinin (HA)-specific affinity purification of NS4B containing 
membranes from cells stably replicating a (gt2a) replicon that harbours a HA-affinity tagged 
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NS4B. These purified membranes have been shown to be predominantly DMVs, to contain 
viral proteins such as NS3 and NS5A and to harbor enzymatically active viral replicase. 
Taken together this method represents a powerful tool to isolate and study the biochemical 
composition of HCV induced DMVs [114].  
	  
Figure 3.26 Topfluor-Cholesterol (TFC) recovery from NS4B-HA mediated DMV purification. (A) Schematic 
representation of the experimental setup. Huh7/Lunet-T7 cells were transfected with pTM-NS3-5B expression 
constructs containing the wild-type or HA tagged NS4B. 6 h later, the medium was replaced by fresh media 
containing 4 µM TFC, followed by 18 h of incubation. Cells were lysed and subjected to NS4B-HA 
Immunoprecipitation [114]. (B) Western Blot showing the NS5A and NS4B protein levels in the input as well as 
the HA-IP samples of the respective transfection condition (pTM-NS3-5B NS4B wt/ HA). 2.5% of the input and 
half of the IP samples were loaded for subsequent protein detection. (C) The NS4B, NS5A as well as TFC IP 
efficiencies are shown. TFC was measured in each sample using the Mithras Plate Luminometer (Berthold 
Technologies). Next, samples were subjected for Western Blot shown in (B). The NS4B pulldown efficiency was 
determined by calculating the fraction of the immunoprecipitated NS4B protein of the protein’s input levels. The 
TFC pulldown efficiency was determined accordingly. The grey or orange numbers present the enrichment of 
NS4B, NS5A or TFC in the HA-NS4B as compared to the NS4B-wt sample respectively. One single experiment is 
shown. 
In a pilot experiment Huh7/Lunet-T7 cells were transfected with the pTM-NS3-5B expression 
constructs that do or do not contain a HA tagged version of NS4B (Figure 3.26A). It is 
important to note that expression of the non-structural proteins NS3-5B has been shown to 
induce DMV formation in a similar fashion as compared to the DMVs found in HCV infected 
cells [113]. Cells were then incubated for 18 h with TFC, followed by HA-specific pulldown 
under native, membrane-preserving conditions. In cells transfected with the HA-NS4B 
containing expression construct, the HA-specific pulldown led to a 24- or 11.5- fold 
enrichment of NS5A or NS4B protein levels respectively, as compared to the technical 
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negative control (NS4B wild-type) (Figure 3.26B, C, grey numbers). Concomitantly, a 5-fold 
enrichment was observed for TFC, demonstrating the recruitment of exogenously supplied 
cholesterol to NS4B-containing membrane fractions (Figure 3.26C, orange number). 
 
Hence our data suggests that the cholesterol found in HCV-induced DMVs [114] is recruited 
both via mobilization of cholesterol from the PM and by incorporation of extracellular 
cholesterol. In either case, intracellular trafficking of cholesterol is required.  
 
3.2.2 Identification of important Lipid transfer proteins (LTPs) required for the HCV 
and DENV replication cycle 
 
Our results indicate that HCV alters the cellular distribution of cholesterol and moreover 
causes an enrichment of this lipid at the juxtanuclear region of the cytoplasm and at NS5A 
positive sites, likely representing viral replication sites. Due to the hydrophobic nature of 
cholesterol its spontaneous exchange between membranes through the aqueous cytoplasm 
is slow and inefficient [168]. Thus, in cells, transport of cholesterol is conducted by a 
combined action of vesicular and non-vesicular mechanisms. The latter ones involve the 
action of cytosolic lipid transfer proteins (LTPs) harboring structurally encoded targeting 
information, such as pleckstrin homology domains, that drive their localization to distinct 
intracellular membranes [168, 217] (see 1.6). 
We next aimed at identifying cellular proteins including LTPs that could allow the virus to 
specifically recruit cholesterol to sites of RNA replication. To investigate this further we 
focused on a selection of members of several protein families implicated in direct non-
vesicular lipid transfer between intracellular membranes. These comprise the members of 
the oxysterol-binding protein (OSBP)-like protein (ORP/OSBPL) family and of the 
steroidogenic acute regulatory protein-related lipid transfer (START) domain family, both 
implicated in non-vesicular sterol and/or phospholipid transport [185, 186]. Further, the 
Niemann-Pick Disease Type C1 and C2 protein (NPC1, NPC2) were targeted, because they 
facilitate the egress of LDL-derived free cholesterol from late endosomal compartments 
[207]. Additional candidates comprised the ATP-binding cassette subfamily A member 1 
(ABCA1), a protein involved in cellular cholesterol efflux [224], the membrane associated 
phosphatidylinositol transfer protein 1 (PITPNM1) acting at the Golgi/ ER interface [183], as 
well as the four-phosphate adapter protein 2 (FAPP2/PLEKHA8) [270]. More detailed 
information on the cellular targets is presented in Table 3.1. 	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Table 3.1 LTPs targeted in the RNAi screen 
 
EE= early endosome, LE= late endosome, ER= endoplasmic reticulum, PM= plasma membrane 
 
 
3.2.2.1 Setup of a RNAi screen for the identification of LTPs important for the HCV 
and/or DENV replication cycle.  
 
In search of LTPs important for HCV replication, a small scale siRNA screen was performed 
monitoring the effect of LTP gene knockdown comprising the full infection cycle of HCV in 
comparison to the related Dengue virus. A detailed description of the screen setup can be 
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found in 2.2.7. In short, Huh7.5FLuc cells were electroporated with siRNA ON-
TARGETplus® SMARTpools, omitting commonly used lipid-based transfection reagents that 
could, through the addition of exogenous lipids, affect the experimental outcome. Silencing 
was allowed for 36 to 48 h followed by infection with either Renilla luciferase reporter HCV or 
DENV at a MOI of 0.5. 36 (DENV) or 60 h (HCV) post infection, cells were lysed and cell 
supernatants were transferred onto naive cells. Reinfection was allowed for 48 h (Figure 
3.27A). Effect of gene knockdown on the early events of the viral replication cycle (part I) of 
both reporter viruses was assessed by measuring Renilla luciferase activity in cell lysates of 
the silenced cells, which were normalized to the cell number, as estimated by the 
measurement of the respective Firefly luciferase counts. Changes in the infectious virion 
assembly and release efficiency (part II) were determined by normalizing the Renilla counts 
of the reinfection plates to the respective Renilla counts in the infection plates. The screen 
was repeated 6 times, each time using a different plate layout. Importantly several siRNA 
controls were included, either exhibiting no known target, designated non-targeting (NT), or 
targeting the cellular PI4KIIIA or ApoE, both well-known dependency factors of HCV [77, 78, 
121, 143]. As such cellular factors were not well established in case of DENV, the only 
controls at hands were a siRNA ON-TARGETplus® SMARTpool directed against the Renilla 
luciferase itself as well as one against the DENV non-structural protein 1 (NS1). Several 
independent electroporations per biological replicate (run) were performed in case of the 
controls (Figure 3.27B). 
	  
Figure 3.27 Lipid transfer protein (LTP) RNAi screen setup. (A) Huh7.5FLuc cells were electroporated with 
siRNA ON-TARGETplus® SMARTpools and seeded in triplicates into 96 well plates. 36 or 48 h post silencing 
cells were infected with Renilla luciferase HCV or DENV (JcR2A, DENVR2A) respectively at a MOI of 0.5. 
Infection was allowed for either 48 or 60 h. Then cells were lysed and cell supernatants were transferred onto 
naive Huh7.5 or Vero cells for reinfection. Effect of gene knockdown on viral entry and replication (part I) was 
assessed by determining the Renilla luciferase activity in cell lysates of the infection plates, normalized to the cell 
number, as determined by measurements of Firefly luciferase activity. Effects of gene knockdown on the 
reinfection efficiency of the virus (part II) was determined by measuring and normalizing the Renilla counts in the 
reinfection plates to the respective Renilla counts in the infection plates. The screen was repeated 6 times, each 
time using a different plate layout.  (B) Table showing how many independent electroporations of siRNA per gene 
were performed per run. Several independent electroporations of the control siRNAs (non-targeting, ApoE, 
PI4KIIIA, Renilla luciferase, DENV NS1) were conducted, whereas siRNAs against a specific target gene were 
electroporated into the cells only once per biological replicate/ run. 
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3.2.2.2 LTP RNAi screen results 
 
Targeting LTPs alters the HCV but barely the DENV replication cycle. While definition of 
hit criteria can be ambiguous, in this study candidate genes were classified as hits when the 
Renilla luciferase signal was increased or decreased by at least 2 standard deviations from 
the mean of the non-targeting control, designated as z-score, and when the p-value was 
smaller than 0.05.  
	  
Figure 3.28 Screen results. (A-B) Representation of the screen results for either HCV or DENV. The z-score is 
shown for each gene. The z-score was defined as the number of standard deviations from the mean of the 
negative controls. Genes with a z-score bigger than 2 or smaller than -2 were considered to be hit candidates.  
The controls are indicated in grey, whereas hits with a significant z-score but also a p-value smaller than 0.05 are 
indicated in orange. (C) Subcellular distribution of all candidates analyzed in the screen. Hits are indicated in red. 
Some proteins can be found at several sites within the cell, which is highlighted by the respective color of the 
boundary of the symbols. PM= plasma membrane, MITO= mitochondria, EE= early endosome, LE= late 
endosome, LY= lysosome, LD= lipid droplet, ER= endoplasmic reticulum. [179, 180, 188, 190, 192, 193, 207, 
270-278] 
All controls gave the expected results, indicating a robust performance of the screen. In 
detail, knockdown of the known HCV dependency factors, such as PI4KIIIA or ApoE 
efficiently impaired early or late events in the HCV replication cycle, respectively (Figure 
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3.28A, B). Targeting the Renilla luciferase similarly affected the HCV and DENV replication 
cycle, whereas the non-targeting control did not exert any impact on viral replication (Figure 
3.28A-D). Gene knockdown of NS1 also efficiently reduced early events in the DENV 
replication cycle (Figure 3.28C).  
The small-scale siRNA screen led to the identification of 10 LTPs potentially involved in the 
replication cycle of HCV (Figure 3.28A, B). In particular, we were able to identify six HCV 
dependency factors and four HCV restriction factors (Figure 3.28A, B). OSBP has recently 
been described as important dependency factor of HCV genome replication [79] and indeed 
we obtained similar results. Additionally two more members of the OSBPL family, namely 
OSBPL3 and OSBPL9, as well as PLEKHA8/FAPP2, a glycolipid transfer protein were 
identified by our screen to regulate early events in the HCV replication cycle (Figure 3.28A). 
Gene knockdown of the (START) domain containing 3 protein (STARD3, MLN46), of 
OSBPL11, of PITPNM1 or of NPC1 significantly impaired late stages of the viral replication 
cycle. In contrast gene silencing of OSBPL1A/1B as well as of the Collagen, type IV, alpha 
(Goodpasture antigen) binding protein (COL4A3BP) enhanced HCV particle production 
(Figure 3.28B). Only two of the proteins studied, namely STARD3 and ABCA1 seemed to be 
of importance for the related Dengue virus (Figure 3.28C, D).  
 
The subcellular localization of all candidates is schematically depicted in Figure 3.28E. 
COL4A3BP, PITPNM1, OSBP and PLEKHA8/FAPP2 are Golgi associated proteins 
suggested to mediate lipid traffic between the ER and Golgi (Figure 3.28E) [180, 181, 183, 
270, 276]. The results of our screen indicate that all these proteins are of relevance for the 
HCV replication cycle (Figure 3.28A, B). OSBPL9 and OSBPL11 can both be found at 
contact sites of the Golgi apparatus and late endosomes. OSBPL3 is present at the ER and 
plasma membrane [179, 185, 275]. All of them were found to affect HCV replication or 
particle production (Figure 3.28A, B). NPC1, STARD3 and OSBPL1A are present at late 
endosomal and lysosomal compartments of the cell [188, 196, 279]. All three proteins were 
identified to be crucial regulators of the replication cycle of HCV (Figure 3.28A, B, E).  
 
3.2.2.3 Validation of selected candidates by shRNA-mediated knockdown  
 
The primary screen results suggest an important role of LTPs residing at the ER/Golgi 
interface in the replication cycle of HCV. Indeed, while this study was in progress, numerous 
reports demonstrated that several LTPs involved in lipid transfer between ER and Golgi, 
namely OSBP, COL4A3BP and PLEKHA8/FAPP2 were hijacked by the virus for efficient 
replication [79, 129, 280]. Therefore, we decided to focus mainly on members involved in 
lipid traffic through the late endosomal/ lysosomal pathway, involving NPC1, STARD3, 
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OSBPL1A/1B but also PITPNM1, for which our screen results suggested a so far 
undescribed role in HCV replication. In a first step we aimed to confirm the results of the 
siRNA screen. For this purpose we made use of the MISSIONTM TRC shRNA library 
commercially available from Sigma Aldrich. The gene knockdown efficiency of five different 
shRNAs per gene was validated and the ones causing the best gene knockdown were used 
for the following studies (Supplementary Figure 3).  
 
3.2.2.4 Validation of selected candidates 
 
shRNA-mediated knockdown of NPC1, STARD3, OSBPL1A and PITPNM1 indicates 
their involvement in early events of the HCV replication cycle. The LTP RNAi screen 
suggested a novel role of NPC1, STARD3, PITPNM1 and OSBPL1A/B in late stages of the 
HCV replication cycle. Nevertheless, there are many sources of errors that can affect the 
outcome of RNAi screens such as cell death or cell clumping, different infection efficiencies, 
siRNA off-target effects, different silencing efficiencies, etc. [257]. Therefore a first set of 
experiments focused on the validation of the screen phenotype. To this end the impact of 
shRNA-mediated gene knockdown on the early phase of the viral replication cycle was 
assessed by measuring HCV Renilla reporter luciferase activity in silenced cells. Additionally 
the reinfection efficiency of virus released from silenced cells was quantified (Figure 3.29B). 
Lentiviral transduction of shRNA was applied in order to achieve an efficient long lasting 
knockdown and for each biological replicate, naive cells were freshly transduced with shRNA 
encoding lentivirus. A shRNA targeting the PI4KIIIA and a shRNA targeting ApoE served as 
positive controls for HCV RNA replication and particle production, respectively. Additionally 
the results of two different non-targeting controls were combined and are designated as 
shNT (Figure 3.29).  Surprisingly, gene knockdown of NPC1, STARD3, OSBL1A/1B and 
PITPNM1 in the two highly permissive human hepatoma cell lines (Huh7.5Fluc, 
Huh7/LunetCD81H) efficiently reduced entry and replication of the hepatitis C Renilla 
luciferase reporter virus (Figure 3.29C, D, upper panels), which stands in contrast to the 
primary siRNA screen data where they were identified as being required for late stages of the 
viral replication cycle. Amongst the candidates present in the late endosomal/ lysosomal 
pathway the most prominent phenotype was observed by shRNA-mediated silencing of 
NPC1, which impaired early phase replication to a similar extent as silencing of the PI4KIIIA 
positive control (Figure 3.29C, upper panel). No additional effect on the release of infectious 
virus was observed, while gene knockdown of ApoE caused a two-fold reduction in progeny 
virus production (Fig. 3.30C, middle panel). Upon gene silencing of STARD3 or OSBL1A/1B, 
virus entry and replication was reduced by at least two-fold. Furthermore the release of 
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infectious virus from STARD3 or OSBPL1A silenced cells seemed to be either unaffected or 
slightly increased, depending on the shRNA used (Figure 3.29C).   
	  
Figure 3.29 Validation of selected candidates by shRNA-mediated knockdown. (A) Schematic 
representation of the cellular localization of selected candidates. Hits are shown in red and were either (1) 
associated with the endo-/lysosomal pathway or (2) present at the ER/ Golgi interface. (B) Scheme of 
experimental setup. Huh7.5FLuc cells or Huh7/LunetCD81H were transduced with shRNA containing lentiviruses 
(MOI 1). 48 h post transduction, cells were infected with Renilla luciferase reporter HCV.  48 h post infection, (i) 
cells were lysed and (ii) cell supernatants were transferred onto naive Huh7.5 cells. Reinfection was allowed for 
48 h followed by lysis of the cells. Effect of gene knockdown on viral replication or reinfection was assessed by 
measuring Renilla luciferase activity in the respective cell lysates. (C-D) Effect of gene knockdown of host factors 
involved in the endo-/lysosomal pathway or present at the ER/Golgi interface on the viral replication cycle. At 
least two different shRNAs were used per candidate gene. The results of two different non-targeting controls were 
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combined and are designated as shNT. Only the best working shRNAs targeting either the PI4KIIIA or ApoE were 
used as positive controls. Changes in viral replication were analyzed by measuring the Renilla luciferase activity 
and the given relative light units (RLU) are presented as percent of the non-targeting control. Simultaneously cell 
viability was determined using the cell titer glo assay. Cytotoxic effects of shRNA treatment are indicated with a 
cross. Mean of duplicates and standard deviations of two independent experiments are shown. 
Importantly, cell viability measurements revealed that shRNA-mediated gene silencing of 
most of the target genes was well tolerated, except of depletion of STARD3, which caused 
cytotoxic effects (Figure 3.29C, lower panel). Gene knockdown of the Golgi associated 
PITPNM1 by 3 different shRNAs led to a profound reduction of entry and replication of the 
hepatitis C Renilla luciferase reporter virus (Figure 3.29D, upper panel). Concomitantly, the 
release of infectious particles was reduced in a similar range with one shRNA inducing an 
increase in infectious particle production. (Figure 3.29D, middle panel). Additionally the 
shRNA (1) and (3) did not affect cell viability, while shRNA (2), causing the most prominent 
phenotype, was observed to substantially reduce cell viability (Figure 3.29D, lower panel.) 
Altogether, shRNA-mediated gene knockdown of proteins implicated in the lipid traffic 
through the endo-/lysosomal pathway and of the Golgi-localized PITPNM1 impaired the early 
phase of the viral replication cycle, including steps in virus entry and replication. When 
analyzing the effect of gene silencing on the release of infectious particle production no 
additional or no consistent phenotype was observed. Given that the most prominent and 
reproducible phenotype was obtained for NPC1 gene knockdown, we decided to focus on 
this cellular factor for further in depth characterization.   
 
3.2.3 Evaluating the role of the Niemann-Pick Disease Type C1 protein in the HCV 
replication cycle 
 
In the following we focused on the Niemann-Pick Disease Type C1 protein (NPC1), 
mutations in which have been linked to an eventually fatal lysosomal storage disorder the 
Niemann-Pick Disease Type C (NPC) [201]. This disease is characterized by an impaired 
egress of cholesterol, but likely also of other lipids, from late endosomal/ lysosomal 
compartments resulting in their intracellular accumulation in the endo-/ lysosomal vesicles 
[198]. Given our previous results of a HCV-induced perinuclear accumulation of (endogenous 
and exogenously supplied) free cholesterol (Figure 3.20, Figure 3.23, Figure 3.24) and 
assuming that cholesterol is an important structural component of the DMVs [114] we 
wondered whether an altered intracellular lipid traffic caused by the loss of NPC1 function 
would cause a defect in HCV RNA replication.  
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3.2.3.1 Dissecting the role of NPC1 in early events of the HCV replication cycle  
 
NPC1 is important for steps in HCV RNA replication. Being localized to the endosomal/ 
lysosomal compartment NPC1 has been described to be required for the escape of incoming 
Ebola virus particles from lysosomal vesicles [281]. Thus, given our previous results we 
wondered whether NPC1 was indeed involved in HCV RNA replication or rather important for 
earlier events such as virus entry. To this point we determined the relevance of NPC1 for 
RNA replication of subgenomic reporter replicons, thereby bypassing the viral entry step 
(Figure 3.30C, D). In order to produce most consistent results, we simultaneously determined 
the effect of NPC1 gene knockdown on the full replication cycle of HCV and DENV Renilla 
luciferase reporter virus as well as on subgenomic reporter replicons and in parallel 
harvested samples for cell viability assay, Western Blot and for determination of the 
knockdown efficiency by RT-qPCR. (Figure 3.30A, B). As observed before, shRNA-mediated 
gene knockdown of NPC1 efficiently impaired the early phase of the HCV replication cycle, 
while not exerting an additional effect on virus particle production. In agreement with the 
results of the screen, DENV entry and replication was only mildly altered upon gene 
knockdown, however one shRNA significantly increased the release of infectious particles. 
Importantly cell viability was not substantially impaired (Figure 3.30B, three upper rows). 
Evaluation of the knockdown efficiency by RT-qPCR revealed a correlation of the extent of 
the reduction in NPC1 transcript levels with the observed effect on HCV genome replication, 
indicating that the effect of NPC1 gene knockdown on viral replication is specific (Figure 
3.30B, 4th row). We further determined NS5A protein levels in cell lysates of silenced cells at 
the end of the experiment. While the effect of NPC1 or PI4KIIIA gene knockdown on Renilla 
luciferase activity were comparable, the protein levels of NS5A were much more reduced 
upon knockdown of PI4KIIIA as compared to NPC1 (compare Figure 3.30B HCV panel 
‘entry/ replication’ with Figure 3.30E,F). Nevertheless NPC1 gene silencing reduced NS5A 
protein levels by almost two-fold when compared to the non-targeting control (Figure 3.30E, 
F). In parallel Huh7/Lunet cells containing a persistent, selectable subgenomic Firefly 
luciferase reporter replicon of genotype 2a (LucUbiNeo_JFH1) or of genotype 1b 
(LucUbiNeo_Con1ET) were transduced with shRNA containing lentivirus (Figure 3.30C). 
Silencing of NPC1 gene expression significantly reduced replication of subgenomic RNA of 
either genotype. Of note, RNA replication of the genotype 1b replicon was impaired to a 
larger extent as compared to the genotype 2a replicon (Figure 3.30D, two upper panels). 
Indeed, in case of genotype 1b, lentivirus-mediated knockdown at the highest MOI (MOI4) 
reduced, the Firefly luciferase reporter activity to almost similar extent as compared to the 
positive control (PI4KIIIA). In contrast, genotype 2a RNA replication was on average 
decreased maximally two-fold upon NPC1 gene knockdown, whereas the silencing of the 
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PI4KIIIA gave similar results as observed for the genotype 1b replicon (Compare Figure 
3.30D, left and right panel). Importantly gene silencing of NPC1 did not impair the cell 
viability of both stable replicon cell lines (Figure 3.30D lower panels). 
	  
Figure 3.30 NPC1 gene knockdown reduces HCV RNA replication. The effect of gene knockdown of NPC1 on 
the full infection cycle of Renilla luciferase reporter HCV or DENV (A-B) as well as on replication of stable Firefly 
luciferase reporter replicons (C-D) was assessed. (A) Schematic representation of experimental setup. Huh7.5 
cells were transduced with shRNA containing lentivirus at different MOIs (1, 2, 4). 48 h post transduction cells 
were infected with Renilla luciferase reporter HCV or DENV respectively at a MOI of 0.5. 48 h post infection (i) 
cells were lysed, (ii) supernatants were transferred onto naive Huh7.5 or Vero cells for reinfection, (iii) total 
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cellular RNA was collected to determine the knockdown efficiency and (iv) the cell viability was assessed by cell 
titer glo assay. (B) Effects of gene knockdown on early and late events of the HCV and DENV replication cycle. 
Effect of gene knockdown on entry/ replication was determined by measuring Renilla luciferase activity in cell 
lysates harvested 48 h post infection. As positive control a shRNA targeting the PI4KIIIA was included. 
Determining Renilla luciferase activity in cell lysates of the reinfection plates allowed to assess alterations in 
particle production. shRNA-mediated knockdown of ApoE served as positive control. Relative light units (RLU) are 
presented. Cell viability was analyzed simultaneously by performing the cell titer glo assay. Knockdown efficiency 
was measured by determining the amount of NPC1 transcripts levels relative to the one of GADPH within the 
same sample. Results are shown either as percent or fold of the mean of two non-targeting controls (shNT). The 
mean of duplicates and standard deviation of two independent experiments are shown. (C) Schematic 
representation of experimental setup. Stable replicon cell lines of genotype 1b (LucUbiNeo_Con1ET) and 
genotype 2a (LucUbiNeo_JFH1) were transduced with shRNA containing Lentivirus at a MOI of 1 or 4. The effect 
of gene knockdown on established replication was assessed 48, 72 and 96 h post transduction. (D) Effect of gene 
knockdown on replication of gt1b and gt2a stable replicons. The replication efficiency of gt1b and 2a stable 
replicons was assessed by measuring the Firefly luciferase activity in cell lysates harvested 48, 72 and 96 h post 
transduction and relative light units (RLU) are depicted. Cell viability upon gene knockdown was measured using 
the cell titer glo assay. The mean and standard deviation of at least 3 independent experiments are shown (***, 
p< 0.001, **, p< 0.01, *, p< 0.05). (E) NS5A protein levels in NPC1 or PI4KIIIA silenced cells. NS5A protein levels 
were determined by Western Blot in cell lysates at the end of the experiment presented in (A). Beta actin served 
as loading control. (F) Quantification of Western Blot shown in (E). NS5A protein levels were normalized to the 
respective beta actin control and are presented as fold of the non-targeting controls. Data of a single experiment 
is shown. 
In order to prove that indeed NPC1 was involved in HCV replication and that the observed 
phenotype was not due to any off-target effects of the shRNAs, we sought to rescue NPC1 
knockdown by introducing a shRNA resistant NPC1 expression construct. First attempts of a 
functional rescue were unsuccessful, which could be due to an inefficient rescue of NPC1 
protein levels (Supplementary Figure 4). This remains elusive due to the lack of an efficient 
antibody that would allow the determination of NPC1 protein levels by Western Blot. 
 
Taken together NPC1 knockdown impaired early steps in HCV replication, but did not 
substantially alter the DENV replication cycle. Given the observed decline in Firefly luciferase 
activity of stable reporter replicons of genotype 1b and 2a upon gene silencing, NPC1 
appears to be involved in HCV RNA replication.  
 
3.2.3.2 Subcellular localization of NPC1 in HCV infected cells  
 
HCV does not change the subcellular localization of NPC1. NPC1 is a multi-pass 
transmembrane protein localized to the limiting membrane of late endosomes/ lysosomes 
[204]. We next analyzed the distribution of NPC1 in HCV infected and naïve cells (Figure 
3.31). In uninfected cells NPC1 labeled vesicular structures that were evenly distributed 
throughout the cytosol. A fraction of NPC1 was found in lysosomal LAMP2 positive 
compartments. Nevertheless a substantial part of the protein was present in distinct vesicular 
structures (Figure 3.31A). HCV infection did not induce any obvious alteration in the 
partitioning of the protein as NPC1 positive structures seemed similarly distributed in infected 
as compared to mock cells. Furthermore NPC1 did not colocalize with the HCV non-
structural protein 5A. Yet NS5A was found in close proximity to NPC1 positive vesicular 
structures (Figure 3.31B). 
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Figure 3.31 Subcellular localization of NPC1 in HCV infected cells. (A) Distribution of NPC1 and the 
lysosomal marker LAMP2 in naïve cells. Naïve Huh7/LunetCD81H cells were seeded and fixed 48 h later with 4% 
PFA. Staining of endogenous NPC1 (green), the lysosomal marker LAMP2 (red) and the nucleus (grey) is shown. 
An enlargement of the area highlighted with the white box is shown below. The white filled or open triangles 
indicate NPC1 structures that are either LAMP2 positive or not, respectively. (B) Distribution of NPC1 in a HCV 
infected cell. Huh7/LunetCD81H cells were infected with the full-length virus Jc1 (MOI5). 48 h post infection, cells 
were fixed and endogenous NPC1 (green) as well as the viral non-structural protein 5a (NS5A, red) were 
detected by indirect immunofluorescence. The nucleus was stained with DAPI (grey).  Enlargements of the areas 
highlighted with the white rectangles are shown below. Scale bars represent 10 µm. For better visualization signal 
intensities were equally enhanced. 
 
3.2.3.3 Studying the involvement of NPC1 in cellular free cholesterol distribution  
 
The distribution of free cholesterol is altered upon NPC1 gene knockdown. Loss of 
NPC1 function has been described to result in an impaired export of free cholesterol from 
late endosomal and lysosomal compartments, thus causing a lipid trafficking disorder [198].  
To investigate this further in the context of viral replication we analyzed the distribution of 
free cholesterol upon gene knockdown of NPC1 or of PI4KIIIA in HCV transfected cells 
(Figure 3.32A). In cells transduced with the non-targeting shRNA control, filipin was found in 
a diffuse, web-like pattern at the perinuclear region of the cytoplasm. NPC1 gene knockdown 
moderately but significantly increased the filipin signal intensity at the perinuclear region, 
while it was significantly reduced upon PI4KIIIA gene silencing. In case of the latter, filipin 
was mainly found at the plasma membrane as well as at some intracellular vesicles (Figure 
3.32A).  As NPC1 knockdown appeared to induce a clustering of filipin in large vesicles, we 
determined the vesicle volume of filipin positive structures. Indeed, silencing of NPC1 
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resulted in a slight, but significant enlargement of filipin containing vesicles as compared to 
the control condition, indicating an accumulation of unesterified cholesterol in vesicular 
structures (Figure 3.32C).  
 
	  
Figure 3.32 Effect of NPC1 gene knockdown on the cellular distribution of free cholesterol  (A) Distribution 
of free cholesterol (filipin staining) and NS5A in NPC1 or PI4KIIIA silenced or control cells. Huh7/Lunet cells were 
transfected with the HCV full-length genome Jc1. 4 h post transfection cells were transduced with shRNA 
containing Lentiviruses at a MOI of 4. 68 h later cells were fixed and free cholesterol (filipin, green) and the viral 
non-structural protein 5a (NS5A, red) were detected by indirect immunofluorescence. (B) Determination of the 
signal intensity of filipin at the perinuclear region of the cytoplasm. 20 cells of a single experiment were analyzed. 
Mean values are indicated by the red bar. (C) Quantification of the volume of filipin positive structures. The 
volumes of at least 253 structures determined in n=10-13 cells are depicted. Mean values are indicated by the red 
bar. (D) Effect of NPC1 gene knockdown on filipin distribution in Huh7Lunet/T7 cells expressing or not the non-
structural proteins (NS3-5B, gt2a). Huh7Lunet/T7 cells were transduced with shRNA containing Lentivirus at a 
MOI of 4. 48 h post transduction cells were transfected with a pTM-based expression construct encoding the non-
structural proteins of genotype 2a or with the empty vector control. 24 h post transfection cells were fixed and free 
cholesterol (green), lysosomes (LAMP1, blue) and NS5A (red) were stained by indirect immunofluorescence. The 
areas highlighted by white rectangles are shown as enlargements. Scale bars represent 10 µm. (E) Quantification 
of the volume of filipin positive structures. At least 200 structures of 10 cells of a single experiment were 
measured. Mean values are indicated by the red bar. For better visualization pictures were auto-contrasted. (***, 
p< 0.001, **, p< 0.01, *, p< 0.05) 
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In parallel, the effect of NPC1 gene knockdown on the cellular cholesterol distribution was 
tested in a HCV RNA replication independent system to circumvent a potential impact of 
reduced viral protein levels upon NPC1 gene knockdown on cellular cholesterol levels. In 
presence or absence of the non-structural proteins NS3-5B, gene knockdown of NPC1 led to 
an intracellular accumulation of filipin positive structures. These structures were found to be 
LAMP1 positive indicating their lysosomal origin (Figure 3.32D). In agreement with our 
previous observation the volume of the filipin containing structures was increased upon 
NPC1 silencing, in fact to a similar extent in either presence or absence of the non-structural 
proteins (Figure 3.32E). 
 
Hence our results indicate that NPC1 function regulates the distribution of free cholesterol. In 
addition NPC1 is involved in early events of the HCV replication cycle such as RNA 
replication. In line with our previous results that indicated a recruitment of plasma membrane 
derived cholesterol to NS5A positive sites (see 3.2.1) this points to a potential involvement of 
NPC1 mediated cholesterol traffic in HCV replication.     
 
3.2.4 Studying the effect of U18666A on HCV replication 
 
Our previous results suggested that HCV replication depends on NPC1 mediated cholesterol 
transport through the endo-/ lysosomal pathway. Nevertheless, HCV replication could also be 
regulated by any other function of NPC1, independent of the protein’s role in lipid transport. 
To further elucidate the role of endosomal lipid traffic in HCV replication, we made use of a 
drug known to mimic NPC1 loss-of-function. The compound U18666A (3bta-(2-
(diethylamino)ethoxy)androst-5-en-17-one) has been described to inhibit the egress of 
cholesterol from late endosomes and lysosomes and thus provides a useful tool in 
addressing questions on molecular trafficking through the endo-/lysosomal pathway [282]. 
 
3.2.4.1 Effect of U18666A treatment on the cellular distribution of free cholesterol  
 
Treatment with U18666A alters the distribution of free cholesterol and reduces the 
lipid’s colocalization with NS5A. We first studied the effect of U18666A treatment on the 
distribution of unesterified cholesterol and determined the lowest effective concentration 
(Figure 3.33). To this point cells transfected with full-length wild-type virus (Jc1) were treated 
for 48 h with different concentrations of U18666A. In agreement with our previous results, 
filipin was found in a diffuse web-like structure in presence of the virus in untreated cells. 
Treatment with concentrations equal to or higher as 0.625 µM U18666A induced a significant 
accumulation of filipin in dilated vesicles clustering around the nucleus, which resembled the 
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NPC1 knockdown phenotype (compare Figure 3.32A and Figure 3.33A). Interestingly the 
increase in filipin vesicle volume coincided with a decrease in the degree of NS5A and filipin 
colocalization (Figure 3.33B, C). Indeed, comparing the localization of NS5A with respect to 
filipin in untreated and treated cells, it seemed that upon addition of the drug filipin became 
excluded from NS5A positive sites (Figure 3.33A, white arrows = filipin exclusion, yellow 
arrows = colocalization).  
	  
Figure 3.33 Effect of U18666A treatment on cellular localization of free cholesterol. (A) Distribution of free 
cholesterol (filipin) and NS5A in HCV (Jc1) transfected cells treated with various concentrations of U18666A. 
Huh7/Lunet cells were transfected with full-length Jc1 followed by treatment with different concentrations of 
U18666A for 48 h. Free cholesterol (filipin, grey) and the non-structural protein 5A (NS5A, red) were labelled by 
indirect immunofluorescence. The insets show magnifications of the areas highlighted by the white rectangle. 
Scale bars represent 10 µm or 5 µm (inset) respectively. Yellow arrows indicate filipin and NS5A signal overlap, 
white arrows point to eclusion of TFC from NS5A positive sites. (B) Quantification of the volume of filipin positive 
structures in infected cells treated with U18666A. The volumes of more than 60 structures of at least 6 cells from 
a single experiment were analyzed per condition. Mean values are indicated by the red bar. (C) Quantification of 
the degree of NS5A and filipin signal overlap. The Manders’ correlation coefficient was quantified for at least 20 
cells per condition of a single experiment. The background represents the Manders’ coefficient measured in 
NS5A negative cells. (D) Quantification of the volume of filipin positive structures in HCV (Jc1, MOI 5) infected 
Huh7.5 cells treated for 48 h with 1.25 µM of U18666A. The mean values of a single experiment are shown. 250 
structures of at least 7 cells were analyzed. (***, p< 0.001, **, p< 0.01, *, p< 0.05) 
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We next asked whether something similar could be observed in infected cells treated with 
1.25 µM U18666A, the highest dose previously tested. Upon addition of U18666A, filipin was 
found in enlarged structures, irrespective of the presence or absence of the virus (Figure 
3.33D). 
 
3.2.4.2 Impact of U18666A treatment on early phases of HCV and DENV replication 
cycle 
 
U18666A impairs early events in the HCV replication cycle. As we were able to 
recapitulate the effect of NPC1 knockdown on free cholesterol distribution by U18666A 
treatment we next investigated the drug’s potential to interfere with HCV or DENV replication 
(Figure 3.34). To this point different treatment conditions were tested in the highly permissive 
Huh7.5 cell line. Cells were either pre-treated 24 h prior to infection (Figure 3.34A) or 
treatment was started at time point of infection (Figure 3.34B), or right after the removal of 
the viral inoculum (Figure 3.34C). Since the effects of U18666A have been described to be 
reversible, cells were kept in presence of the drug for 48 h [283]. Either treatment condition 
led to a maximally two-fold reduction in the entry and replication of Renilla luciferase reporter 
HCV (Figure 3.34 upper panels). The longer the treatment period the stronger the impact of 
the drug on the early phase of HCV replication. In contrast Dengue Renilla luciferase reporter 
virus replication was mainly unaffected and only altered by incubation with the highest, non-
cytotoxic, concentrations possible (Figure 3.34, middle panels). For each treatment condition 
cell viability was assessed simultaneously which demonstrated that treating cells for 48 h 
with 0.625 µM and 1.25 µM U18666A did not exhibit cytotoxic effects but significantly 
impaired viral replication by almost two-fold.  
Given the fact that the experiments were conducted in presence of the drug, the observed 
reduction in Renilla luciferase activity may have been caused by the impairment of virus 
spread or by a direct virucidal effect of the drug. In order to determine the drug’s true impact 
on viral replication, we first tested its inhibitory potential on replication of Firefly luciferase 
reporter replicon cell lines of genotype 2a and genotype 1b. Indeed treatment with 1.25 or 
0.625 µM U18666A impaired genotype 2a and genotype 1b replication, with the latter one 
being more sensitive towards drug treatment (Figure 3.34D). To corroborate this further, we 
determined the drugs effect on viral replication in Huh7/Lunet cells transfected with full-length 
wild-type virus (Jc1), therefor omitting the virus entry step. Moreover as these cells exhibit 
low cell surface expression of the HCV entry factor CD81, virus spread is largely restricted 
[240]. Interestingly NS5A protein levels, here used as a marker for viral RNA replication, 
were markedly reduced when U18666A was added 4 h post viral RNA transfection, while 
they were only little altered when the drug was added at later time points. 
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Figure 3.34 Effect of U18666A treatment on the early phase of HCV replication (A) Schematic representation 
of the experimental setup. (A) Pre+co+post treatment. Huh7.5 cells were pre-treated with U18666A, followed by 
infection with Renilla luciferase HCV or DENV (JcR2A, DENVR2A, MOI 0.5) in presence of the drug. 6 h post 
infection the inoculum was removed and fresh drug containing media was added. (B) Co+ post treatment. Huh7.5 
cells were infected with JcR2A or DENVR2A in presence of the drug. 6 h post infection the inoculum was 
replaced by fresh drug containing media. (C) Post treatment. Huh7.5 cells were infected with viral Renilla 
luciferase reporter HCV or DENV. 6 h post infection the viral inoculum was replaced with fresh media 
supplemented with U18666A. (A-C) Effect of different drug treatment conditions on the early phase of Renilla 
luciferase reporter HCV or DENV replication. The effect of drug treatment on viral replication was assessed by 
measuring Renilla luciferase activity in the cell lysates; relative light units (RLU) are shown. Additionally cell 
viability was measured by cell titer glo assay. Of all drug concentrations tested, only those that were not cytotoxic 
are shown. (D) Effect of 48 h treatment with U18666A on stable Firefly luciferase reporter replicon cell lines of 
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gt2a (LucUbiNeo_JFH1) and gt1b (LucUbiNeo_Con1ET).  Effect of drug treatment was determined by measuring 
the Firefly luciferase activity in cell lysates. Cell viability was determined by cell titer glo assay. Relative light units 
(RLU) are depicted. (A-D) Results are shown as percentage of the untreated control. The mean and standard 
deviation of at least three independent experiments, measured in triplicates, are shown (***, p< 0.001, **, p< 0.01, 
*, p< 0.05). (E) Effect of U18666A treatment on replication of full-length HCV (Jc1) as determined by 
measurement of NS5A protein levels. Huh7/Lunet cells were transfected with full-length Jc1. (i) 4  or (ii) 48 h post 
electroporation cells were treated with different concentrations of U18666A for either 48 or 72 h. The protein 
levels of NS5A were determined by Western Blot. Beta actin served as loading control. The numbers indicate 
changes in NS5A protein levels or in the ratio of the hyperphosphorylated (p58, upper band) to the basal 
phosphorylated (p56, lower band) form of NS5A. Data is represented as fold of the untreated control.  
Moreover, drug treatment caused a reduction in the hyperphosphorylated form of NS5A 
(p58) as compared to its basal phosphorylated version (p56) (Figure 3.34E). Altogether, this 
suggests that U18666A affects early stages in viral replication, such as RNA replication.  
The molecular mechanisms of how U18666A induces alterations in the cellular cholesterol 
distribution have not been elucidated yet. Given its structure being similar to unesterified 
cholesterol, which is targeted by NPC1 [284], it is possible that the drug mediates its 
inhibitory function by directly binding to NPC1 (Supplementary Figure 5A). While our 
preliminary results suggested that NPC1 function is not targeted by U18666A, others have 
reported a loss in sensitivity towards U18666A treatment upon NPC1 overexpression 
(Supplementary Figure 5C, D) [285]. 
 
Taken together, U18666A treatment mimicked NPC1 knockdown causing a reduction in viral 
RNA replication and an altered intracellular free cholesterol distribution. 
 
3.2.5 Studying the impact of sterol synthesis inhibitors on sterol homeostasis and 
HCV replication  
 
Our previous results suggest that alterations in the free cholesterol distribution following 
NPC1 knockdown or U18666A treatment might hamper the early phase of viral replication of 
HCV. These results encouraged us to study in more detail the potential role of endosomal 
cholesterol traffic in HCV RNA replication. In order to corroborate this hypothesis we made 
use of several cationic amphiphiles (Ro 48-8071, clomiphene citrate), which are, similar to 
U18666A, suggested to interfere with endo-/lysosomal lipid traffic. In addition they are known 
inhibitors of the sterol synthesis pathway [285]. To control for any sterol synthesis-related 
effects, we included a specific inhibitor of the sterol synthesis pathway, namely Mevastatin. 
This compound is known to target the rate-limiting enzyme of the sterol synthesis pathway, 
the HMGCoAReductase [286], but an additional impact of Mevastatin on lipid traffic has not 
been described so far.  
 
In a first set of experiments we addressed the drugs’ potential to alter the subcellular 
distribution of lipids within the cell as well as their impact on viral RNA replication.  
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3.2.5.1 Studying the effect of sterol traffic and synthesis inhibitors on cellular lipid 
distribution 
 
Cationic amphiphiles cause an accumulation of free cholesterol and the ganglioside 
GM1 in lysosomal structures. So far, this study had only focused on visualizing 
unesterified free cholesterol by the use of filipin. Given the likelihood, that not only 
cholesterol but also other lipids are affected by targeting the endo-/lysosomal lipid trafficking 
machinery, we aimed to visualize further lipid species. As HCV replication occurs at 
detergent resistant membranes, we focused on components of detergent resistant lipid rafts, 
which are cholesterol and sphingolipid rich microdomains [127, 287]. To this end, we 
attempted to visualize two raft lipids: the ganglioside GM1 and the sphingolipid 
sphingomyelin. The choleratoxin subunit b, produced by vibrio cholerae binds GM1 with high 
affinity and has therefore been frequently used as a probe for this ganglioside [288]. The 
presence of sphingomyelin in membranes can been visualized by the use of two toxins, 
lysenin and equinatoxin II [289]. In contrast to the effective visualization of GM1 with 
fluorescently tagged choleratoxin subunit B, our efforts to label sphingomyelin with lysenin 
were unsuccessful (data not shown). Thus we tested the impact of the cationic amphiphiles 
as well as of Mevastatin on the cellular distribution of GM1 and of unesterified cholesterol 
(Figure 3.35, Figure 3.36). Treatment with the amphiphiles U18666A, Ro 48-8071 and 
Clomiphene citrate caused an accumulation of free cholesterol but also of the ganglioside 
GM1 in dilated lysosomal structures (Figure 3.35A, Figure 3.36A, white arrows in inset 
pictures). Quantification of their volume revealed a slight but significant enlargement as 
compared to the untreated control (Figure 3.35B, Figure 3.36B). Furthermore these 
structures were found in clusters at the perinuclear region (Figure 3.35A, Figure 3.33A, upper 
panel). Treatment with Mevastatin barely altered the lipids’ cellular distribution. In fact GM1 
or free cholesterol positive structures were of similar size or even smaller as compared to the 
untreated control and were evenly spread throughout the cytoplasm (Figure 3.35A, Figure 
3.36A, upper panel). This was further reflected by the presence of less dilated lysosomal 
membranes (Figure 3.35A, Figure 3.36A, grey arrows in inset pictures). We further compared 
the NS5A pattern of control cells with NS5A localization in cells treated with either Mevastatin 
or the cationic amphiphiles (U18666A, Ro 48-8071, Clomiphene citrate). In case of 
Mevastatin treated or control cells, NS5A was evenly distributed in an ER-like pattern at the 
perinuclear region. However in presence of the cationic amphiphiles, NS5A was more 
frequently observed in a patchy distribution and partially accumulating in large clusters 
(Figure 3.35A, Figure 3.36A, yellow arrows).   
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Figure 3.35 Effect of inhibitors of the sterol synthesis and trafficking pathway on the subcellular 
distribution of unesterified cholesterol. (A) Distribution of NS5A, free cholesterol (filipin staining) and the 
lysosomal marker LAMP1 in infected cells treated with Mevastatin, Ro 48-8071, Clomiphene citrate, U18666A or 
the respective control. Cells were infected with full-length virus Jc1 (MOI 3). 48 h post infection cells were treated 
with the indicated drugs. 48 h post treatment cells were fixed and the distribution of unesterified cholesterol 
(grey), of the lysosomal marker LAMP1 (green) and of the non-structural protein 5A (red, NS5A) was assessed by 
indirect immunofluorescence. Representative images are shown. The insets show magnifications of the area 
highlighted with a white rectangle. White or grey arrows label dilated or smaller LAMP1 positive structures, 
respectively. NS5A clusters are indicated with a yellow arrow. Scale bars represent 10 µm. (B) Quantification of 
the volume of filipin positive structures as determined for each treatment condition. A minimum of 10 cells of a 
single experiment was analyzed, within which at least 98 individual structures were measured. The red bar 
indicates the mean of all measurements. (C) Degree of filipin and NS5A signal overlap as determined for each 
treatment condition. The Manders correlation coefficient of NS5A and filipin was determined for at least 15 cells of 
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a single experiment. The background represents the Manders’ coefficient measured in NS5A negative cells.   (***, 
p< 0.001, **, p< 0.01, *, p< 0.05) 
 
Figure 3.36 Effect of inhibitors of the sterol synthesis and trafficking pathway on the subcellular 
distribution of the ganglioside GM1. (A) Distribution of NS5A, ganglioside GM1 (as determined by the use of 
choleratoxin subunit B) and the lysosomal marker LAMP1 in infected cells treated with Mevastatin, Ro 48-8071, 
Clomiphene citrate, U18666A or the respective control. Cells were infected with full-length virus Jc1 (MOI 3). 48 h 
post infection cells were treated with the indicated drugs. 48 h post treatment cells were fixed and the distribution 
of the ganglioside GM1 (green), of the lysosomal marker LAMP1 (blue) and of the non-structural protein 5A (red, 
NS5A) was assessed by indirect immunofluorescence. Representative images are shown. The insets show 
magnifications of the area marked with a white rectangle. White or grey arrows label dilated or smaller LAMP1 
positive structures, respectively. NS5A clusters are indicated with a yellow arrow. Scale bars represent 10 µm. (B) 
Quantification of the volume of filipin positive structures for each respective treatment condition. A minimum of 10 
cells of a single experiment was analyzed, within which at least 155 individual structures were measured. The red 
bar indicates the mean of all measurements. (C) Degree of overlap of the NS5A and filipin signal. The Manders 
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correlation coefficient was determined for at least 13 cells of a single experiment. The background represents the 
Manders’ coefficient measured in NS5A negative cells.  (***, p< 0.001, **, p< 0.01, *, p< 0.05) 
 
We further analyzed the degree of overlap of either lipid with the HCV non-structural protein 
5a. In agreement with our previous results NS5A was found to partially colocalize with 
unesterified cholesterol in control cells. Mevastatin did not significantly affect the 
colocalization efficiency of the viral protein and the cholesterol marker filipin. However this 
colocalization was markedly reduced in presence of the cationic amphiphiles, suggesting a 
defect in cholesterol trafficking (Figure 3.35C). In contrast no overlap of GM1 and NS5A was 
detected in HCV infected cells and this was furthermore not altered by any of the drugs 
(Figure 3.36C). 
 
Taken together our results indicate that treatment with cationic amphiphiles, but not with 
Mevastatin leads to the accumulation of free cholesterol and GM1 in lysosomal structures. 
This is furthermore concomitant with the decrease of NS5A and cholesterol signal overlap, 
which indicates an impaired traffic of cholesterol to NS5A positive sites. 
 
3.2.5.2 Effect of sterol synthesis and trafficking inhibitors on HCV RNA replication  
 
Sterol synthesis and trafficking inhibitors impair HCV RNA replication. Assuming that 
lipid traffic through the endo-/lysosomal pathway could serve to deliver plasma membrane 
derived lipids to the endoplasmic reticulum for the generation or maintenance of the HCV 
replication sites, we studied the drugs’ antiviral potencies on viral RNA replication.  
To this point genotype 2a and 1b stable Firefly luciferase reporter replicon cell lines were 
treated with different concentrations of the respective drug for 48 h. Effects of the 48 h drug 
treatment on viral RNA replication were assessed by measuring Firefly luciferase activity in 
cell lysates. Indeed RNA replication of the genotype 1b replicon was significantly inhibited by 
two-fold by all compounds tested (Figure 3.37A, B, C upper panel). In contrast, genotype 2a 
RNA replication was only decreased upon Ro 48-8071 treatment (Figure 3.37A, B, C lower 
panel). The observed changes in Firefly luciferase reporter activity were reflected by the 
NS5A protein levels determined by Western Blot (Figure 3.37D, E).  
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Figure 3.37 Effect of sterol synthesis and trafficking inhibitors on established viral genome replication. 
(A-C) Effect of treatment with clomiphene citrate, Ro 48-8071, and Mevastatin on the RNA replication of gt1b and 
2a stable replicon cell lines. LucUbiNeo_Con1ET (gt1b) or LucUbiNeo_JFH1 (gt2a) stable Firefly luciferase 
reporter replicon cells were treated for 48 h with different concentrations of the corresponding drug or the 
respective control. Effect of drug treatment on replication was determined by measuring the Firefly luciferase in 
cell lysates, the respective relative light units (RLU) are depicted.  Additionally cell viability was determined by cell 
titer glo assay and only concentrations that did not cause cell cytotoxicity are shown. The mean and standard 
deviation of 4 independent experiments, measured in triplicates are shown. Experiments were performed in 
triplicates (***, p< 0.001, **, p< 0.01, *, p< 0.05). (D-E) Effect of drug treatment on NS5A protein levels of gt2a or 
1b stable replicon cell lines. Cell lysates were subjected to NS5A and beta-actin protein detection by Western 
Blot. Results of a single experiment are shown. 
Our previous results showed that HCV RNA replication of genotype 1b was more sensitive 
towards knockdown of NPC1 or treatment with sterol synthesis inhibitors as compared to 
genotype 2a (Figure 3.30D and Figure 3.34D). Thus, we decided to test the sensitivity of 
subgenomic Firefly luciferase reporter replicons of different genotypes (1a, 1b, 2a, 3a, 4a, 
5a, Figure 3.38) towards treatment with cationic amphiphiles or with Mevastatin. The results 
of these experiments revealed variances in the sensitivity of each replicon towards treatment 
with the given compounds. Generally gt1b replication (except of in case of Mevastatin 
treatment) was most strongly reduced, while gt4a and 5a replicons were almost unaffected 
by either drug. RNA replication of gt1a, 2a and 3a was partially diminished depending on the 
drug used (Figure 3.38B-E). Surprisingly clomiphene citrate appeared to enhance viral RNA 
replication of gt1a.  
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Figure 3.38 Effect of sterol synthesis and trafficking inhibitors on RNA replication of subgenomic 
replicons of different genotypes. (A) Schematic representation of the experimental setup. Huh7/Lunet cells 
were electroporated with in vitro transcripts of subgenomic Firefly luciferase reporter replicons of different 
genotypes: subgH77 (gt1a) subgCon1ET (gt1b), subgJFH1 (gt2a), subg3a, subg4a, subg5a. For background 
determination replication deficient replicons were included. 4 h later cells were treated with the respective drug or 
control. 48 h post electroporation, RNA replication was measured by determining the Firefly luciferase activity in 
cell lysates. (B-E) Cell viability (cell titer glo) as well as Firefly luciferase activity was measured in cell lysates and 
is presented as percentage of control. The mean and standard deviation of at least four independent experiments 
are shown. Background replication was determined by measuring Firefly luciferase activity in cell lysates 
transfected with the replication deficient replicons. Background is presented as percentage of the replication of 
genotype 4a and 5a replicons, which harbored the lowest replication efficiency and indicated by the black line. 
Experiments were performed in triplicates.  	  
3.2.5.3 Effect of sterol synthesis and trafficking inhibitors on the transcript levels of 
major regulators of sterol homeostasis  
 
No effect of sterol synthesis and trafficking inhibitors on the transcript levels of LDLR, 
HMGCoAR and ABCA1. With U18666A, Ro 48-8071, Clomiphene citrate and Mevastatin 
being inhibitors of the sterol synthesis pathway [285, 286], treatment with these compounds 
potentially induces long term changes in the regulation of the cellular cholesterol metabolism 
and thus in the absolute levels of cellular free cholesterol. Their main enzymatic targets 
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within the sterol synthesis pathway are depicted in Figure 3.39A. In general the cellular 
cholesterol content is controlled by i) LDL receptor mediated lipid uptake ii) by de novo 
synthesis catalyzed by the rate-limiting enzyme the HMGCoA reductase and iii) by 
cholesterol efflux mediated through cholesterol efflux pumps, the ATP binding cassette 
transporters ABCA1 and ABGC1. For long-term control the abundance of these proteins is 
regulated on a transcriptional level, whereas acute modulations occur via protein degradation 
[215].  
We next asked whether the aberrant distribution of free cholesterol and the reduction of viral 
RNA replication induced by CA drug treatment was linked to the compounds potential to 
inhibit the sterol synthesis pathway and thus to alter cellular cholesterol homeostasis. Due to 
experimental limitations that did not allow us to measure the overall free or esterified 
cholesterol content in drug treated cells, we argued that any drug-induced imbalance in 
cholesterol homeostasis would potentially be counterbalanced by the above mentioned 
cellular pathways. Therefore we determined the transcript levels of the three major 
regulators: the HMGCoA reductase, the LDL receptor and ABCA1 upon drug treatment. To 
this point cells were treated with the respective concentration of the compounds that had 
already successfully been used in earlier experiments. We examined the transcript levels of 
the respective target gene in HCV infected cells, treated with the drug or the control, in 
comparison to the respective levels in non-infected cells (Figure 3.39B). Virus infection 
appeared to mildly increase the transcript levels of the HMGCoA reductase or the LDL 
receptor, while not affecting ABCA1 expression (Figure 3.39B, black bars “control”). Long-
term treatment (48 h) at the given concentrations with none of the compounds led to a 
significant change in the amount of either transcript (Figure 3.39B).  
 
In summary, our results showed that treatment with amphiphilic drugs modified cellular 
cholesterol and GM1 distribution and concomitantly impaired HCV RNA replication. The latter 
was also compromised by Mevastatin, which in turn did not induce major changes in the 
cellular lipid landscape. Although all compounds are (also) inhibitors of the sterol synthesis 
pathway, no change in the transcript levels of the key regulators was observed upon long-
term drug treatment. This indicates that under the given experimental setup, treatment with 
the cationic amphiphiles might mainly alter cholesterol distribution and does not induce major 
changes in the intracellular cholesterol concentration.  
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Figure 3.39 Effect of sterol synthesis and trafficking inhibitors on transcript levels of HMGCoA reductase 
(HMGCoAR), LDLR Receptor (LDLR) and the ATP binding cassette sub-family A member 1 (ABCA1) (A) 
Schematic representation of enzymes involved in the cholesterol synthesis pathway. The enzymatic targets (blue 
lettering) of the respective drugs (red lettering) are indicated. In case of U18666A 3 enzymes within the 
cholesterol synthesis pathway are targeted, but only the one most upstream in the pathway is shown [282, 285].  
(B) Effect of drug treatment on the transcript levels of HMGCoA reductase, LDL receptor and ABCA1. Huh7.5 
cells were infected with full-length virus Jc1 (MOI5). 6 h post infection the viral inoculum was removed and media 
either containing U18666A, Ro 48-8071, Clomiphene, Mevastatin or the control was added. Total cellular RNA 
was harvested 48 h post infection. The transcript levels of the HMGCoA reductase, LDLR and ABCA1 were 
determined by RT-qPCR. They were normalized to mRNA levels of GAPDH and are presented as fold of the 
uninfected control. The mean and standard deviation of two independent experiments performed in duplicates are 
shown. 
 
3.2.6 Elucidating the biological relevance of endosomal lipid traffic in HCV 
replication 
 
Given our previous results that indicate the importance of a functional lipid transport through 
the endosomal pathway in HCV replication, we aimed at elucidating in more detail its’ 
biological relevance for the virus. Our immunofluorescence studies on the distribution of 
cholesterol upon treatment with CAs indicated a reduced degree of colocalization of NS5A 
and the lipid marker in presence of the drug (Figure 3.33, Figure 3.35). This suggests an 
impaired transport of cholesterol to sites of RNA replication. Thus we wondered whether 
altering the lipids’ distribution in cells by treatment with CAs would limit the access of HCV 
replication sites to plasma membrane derived cholesterol. For this reason we investigated 
the dynamics of TFC in cells treated with U18666A, the most potent candidate amongst the 
compounds tested before. 
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3.2.6.1 Effect of U18666A treatment on Topfluor-Cholesterol dynamics 
 
U18666A treatment alters the distribution of TFC but has no impact on the fluorescent 
lipid’s recruitment velocity. In a first set of experiments we assessed whether U18666A 
treatment alters the distribution of TFC similarly to what we had observed for endogenous 
cholesterol. To this end, cells were treated with 1.25 µM U18666A for approximately 48 h. 
Importantly, U18666A was added to the cells 24 h before the onset of imaging and kept in 
the supernatant throughout the entire experiment. Given our previous results indicating that 
U18666A was most effective when added early in replication, we assessed the drug’s effect 
on TFC distribution when added at early as compared to late stages in viral replication. 
(Figure 3.34E, Figure 3.40).  
 
 
Figure 3.40 Experimental setup of live cell imaging of Topfluor-Cholesterol (TFC) in U18666A treated cells 
early or late in HCV replication. (A-B) Schematic representation of the live cell imaging setup. 
Huh7/LunetCD81H cells expressing the viral proteins Core to NS2 were transfected with in vitro transcripts of 
subgenomic replicon containing mCherry tagged NS5A (sgNS3-3’ 5A mCherry, gt2a). (A) “Early replication” 
setup. 6 h later cells were treated with 1.25 µM U18666A. 30 h post epo cells were pulsed with 1 µM of TFC for 
10 min, followed by extensive washing. TFC dynamics were imaged every 15 min for 17 h. (B) “Late replication“ 
setup. Cells were handled as described in (A), however drug treatment was started 29 h post epo and cells were 
pulsed with TFC 24 h later. 
In untreated HCV transfected cells, TFC was observed to accumulate in the perinuclear 
region (Figure 3.41A, first and third row). Upon treatment with 1.25 µM U18666A TFC was 
almost exclusively present in large vesicular structures which was similar to the CA induced 
clustering of endogenous cholesterol (compare Figure 3.41A, second and forth row and 
Figure 3.35, Figure 3.33). Although the pattern of TFC localization was altered upon drug 
treatment, there was no reproducible difference in the intracellular TFC accumulation rate 
between treated and control cells in early or late phases of replication (Figure 3.41B, C). This 
indicates that U18666A treatment has no impact on early events in TFC trafficking, but 
possibly impairs the lipid’s egress from late endocytic compartment.  
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Figure 3.41 Live cell imaging of Topfluor-Cholesterol (TFC) in U18666A treated cells early or late in HCV 
replication. (A) TFC distribution over time in HCV replicating cells treated with 1.25 µM U18666A as described in 
Figure 3.40. Representative images of NS5A positive cells are shown indicating the TFC distribution within a 
single cell from 75 till 400 min post TFC addition. The insets show magnifications of the areas highlighted by the 
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white rectangle. The scale bars represent 10 µm. (B-C) TFC recruitment velocity of cells treated with different 
concentrations of U18666A pulsed either early or late in replication. TFC signal intensities at the perinuclear 
region were measured over time. The medians of at least 5 cells per condition are shown.  The median is 
presented as fold of the value of the earliest time point of measurement. (D-E) Raw values of the integrated 
density of intracellular TFC either added (D) early or (E) late in replication. Results of the two independent 
experiments depicted in (B, C) are shown.    
In agreement with this we observed that the raw signal intensities, early upon TFC addition, 
were elevated in cells treated with U18666A early in replication as compared to the control 
cells, indicating an intracellular accumulation of TFC (Figure 3.42D). However, this was not 
the case when TFC was added late in replication (Figure 3.42E). 
 
Our previous studies in fixed cells revealed an exclusion of cholesterol from NS5A positive 
sites upon drug treatment. Thus we wondered whether U18666A treatment might interfere 
with the traffic of PM-derived TFC to NS5A positive sites. To this point we analyzed the 
degree of NS5A and TFC signal overlap over time (Figure 3.42).  The assessment of NS5A 
protein levels indicated a slight decrease of NS5A signal intensity upon treatment early in 
replication, while they remained unaltered late in replication (Figure 3.42B). In untreated cells 
NS5A and TFC partially co-localized and the degree of signal overlap increased over time 
(Figure 3.42A, C, D). U18666A treatment did not cause an apparent alteration in the degree 
of signal overlap throughout the first 500 min of imaging (Figure 3.42C, D).  
 
Taken together U18666A alters the partitioning of TFC inducing its accumulation in dilated 
vesicles. Nevertheless the exogenously added fluorescent cholesterol was found to be 
efficiently trafficked to NS5A positive sites irrespectively of the presence or absence of the 
drug.  
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Figure 3.42 Live cell imaging of Topfluor-Cholesterol (TFC) and NS5AmCherry in U18666A treated cells 
early or late in HCV replication. (A) TFC and NS5A distribution over time in HCV replicating cells treated with 
0.625 µM U18666A as described in Figure 3.40. Representative images are shown indicating the TFC and NS5A 
distribution within a single cell from 75 till 400 min TFC post addition. The scale bars represent 10 µm. (B) NS5A 
signal intensities of cells treated with different concentrations of U18666A and pulsed with TFC either early or late 
in replication. The medians of at least 5 cells per condition are shown. Two independent experiments are 
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depicted. The median is presented as fold of the value of the earliest time point of measurement. (C-D) Degree of 
NS5A and TFC signal overlap over time. The Pearson correlation coefficient (PCC) was determined over time 
starting from 75 min post TFC addition.  The left of both panels represents the PCC determined in single cells 
over time, while the results are summarized in the right panel and the median of each condition is presented. 
Quantification of a single experiment is shown.   
 
3.2.6.2 Effect of U18666A treatment on the ultrastructure of the HCV induced 
membranous web 
 
U18666A treatment has no significant effect on DMV morphology. Functional studies on 
the role of cholesterol in HCV replication showed that its depletion causes a reduction in viral 
RNA replication and reduces the size of DMVs [79, 114]. Accordingly, our study suggests the 
importance of cholesterol traffic through the endo-/lysosomal pathway in viral replication with 
the lipid being transported from the plasma membrane to NS5A positive sites, thus 
potentially to DMVs. In order to address the question whether DMVs acquire cholesterol 
through the endo-/lysosomal pathway we analyzed the HCV induced membranous web by 
transmission electron microscopy upon U18666A treatment.  Our previous results indicated a 
higher sensitivity of genotype 1b replication towards CA treatment as compared to genotype 
2a (Figure 3.34 Figure 3.37 and Figure 3.38). For this reason we compared the drugs impact 
on the membranous web induced by the expression of the NS proteins of either genotype. To 
circumvent protein loss upon U18666A treatment when using a replication-based system, we 
made use of the T7-RNA polymerase-based expression system. This allowed us to study 
potential effects of U18666A on membranous web formation independently from its impact 
on viral replication and thus viral protein levels.  To this end, Huh7/Lunet-T7 cells were 
pretreated for 24 h with U18666A. Next, they were transfected with the given expression 
constructs encoding the non-structural protein expression cassette (NS3-5B) derived from 
gt1b or 2a and cultured for another 24 h in presence of the drug (Figure 3.43A). To control 
for drug efficiency under the given experimental treatment conditions, the subcellular 
distribution of free cholesterol was analyzed by indirect immunofluorescence, which 
corroborated our previous findings of U18666A-induced vesicular accumulation of 
endogenous cholesterol (Supplementary figure 6, Figure 3.33, Figure 3.35) Furthermore 
NS5A protein levels were determined to ensure similar protein expression in the different 
samples (Figure 3.43B B). Indeed incubating the cells with the highest concentration (1.25 
µM U18666A) appeared to reduce NS5A protein levels as compared to the control, probably 
due to a diminished cell growth. In collaboration with Dr. I. Romero-Brey alterations of the 
membranous web morphology, namely in DMV size/diameter, were analyzed by using 
transmission electron microscopy.  Our analysis indicated that treatment with the highest 
dose of 0.625 µM U18666A that did not affect NS5A protein levels, did not have a significant 
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effect on DMV size, while the higher dose mildly increased vesicle diameter (Figure 3.43C-
F).  
	  
Figure 3.43 Effect of U18666A on HCV induced membranous web. (A) Scheme of experimental setup. 
Huh7/Lunet cells (Zeocin) were treated for 24 h with U18666A or the control prior to transfection of the pTM 
expression constructs encoding the NS3-5B expression cassette of genotype 2a (JFH1) or 1b (Con1ET). 6 h post 
transfection, the medium was replaced by drug containing medium. 24 h post transfection, cells were processed 
for immunofluorescence, Western Blot and transmission electron microscopy analysis. (B) NS5A protein levels as 
determined by Western Blot. Beta actin served as loading control. Protein levels were determined in cell lysates 
harvested at the end of the experiment. (C-D) Transmission electron microscopy analysis of the membranous 
web. Representative transmission electron microscopy pictures of cells expressing the nonstructural proteins 
NS3-5B of (C) Con1ET or (D) JFH1 in presence or absence of the drug. The yellow box indicates the area 
depicted in the adjacent picture. LD= lipid droplet, DMVs= double membrane vesicles, MMWs= multi membrane 
vesicles, m= mitochondria, ER= endoplasmic reticulum. (E-F): Quantification of DMV size. The results of a single 
experiment are shown. 
 
Taken together, we observed that U18666A treatment caused an aberrant accumulation of 
(exogenously added) TFC in vesicular structures that clustered at the perinuclear region of 
the cytoplasm but it did not alter the colocalization of TFC with the viral protein NS5A.  
Additionally, CA treatment did not lead to a reduction in DMV size as determined by 
measuring DMV diameter.  
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4 Discussion
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4.1 A comparative RNAi screen targeting potential LD-factors to study their 
implications in the replication cycle of HCV and DENV 
 
4.1.1 RNAi screen analysis 
 
Here we report for the first time of the performance of a bipartite RNAi screen that aimed at 
identifying host factors of human hepatoma cells involved in LD homeostasis and at 
unraveling their potential implication in the full replication cycle of the hepatotropic HCV and 
the related DENV. In our comparative RNAi screen the effect of gene knockdown on LD 
morphology was analyzed in a microscopy based approach, while the effect of gene 
silencing on the complete replication cycle of HCV and DENV was investigated using Renilla 
luciferase reporter viruses (Figure 3.1). Using this approach we were able to identify host 
factors potentially involved in the replication cycle of HCV and/or DENV as well as in the 
regulation of LD homeostasis in human hepatoma cells (Figure 3.5).  
 
Analysis of the performance of the controls throughout the primary screening process 
revealed a robust performance of the screen (Figure 3.2). In line with this we were able to 
confirm the involvement of already established host factors such as members of the DEAD 
box RNA helicase family including DDX3 and DDX6, in early events of the replication cycle of 
HCV and DENV respectively, which highlights the reliability of the screen setup [154, 259]. In 
addition, our screen implicated a novel role of DDX3 in later stages of both viruses, which 
was the main focus of the herein presented follow-up studies.  
 
A general major concern when analyzing RNAi data is inherent to the nature of RNAi itself 
that might cause the identification of false positives due to off-target effects [290]. These 
effects are caused by imperfect pairing of siRNA strands with sequence motifs within mRNAs 
that are not the intentional targets.  Other off-target effects can be caused by innate immune 
responses to either the oligonucleotide or the delivery vehicle [290]. The use of oligo pools in 
addition to chemical modifications of the RNAi target sequence has been implemented to 
reduce the off-target effects caused by either way. In this study the primary LD and the LTP 
screen were performed with ON-TARGETplus® SMARTpools. According to the manufacturer 
these siRNA species are chemically modified in such a way that off-target effects are 
decreased, however cannot be ruled out completely [291]. Thus a common strategy to 
strengthen the reliability of RNAi screen data is the performance of a deconvolution screen, 
using four different oligos that are comprised in the siRNA pool of the primary screen [257]. 
Our deconvolution screen confirmed the importance of 67.6% of all primary hits in the 
replication cycle of either HCV or DENV. The hit recovery was largest for candidates 
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identified to be specific for HCV, highlighting the central role of LD-associated pathways in 
the HCV replication cycle (Figure 3.3). Interestingly, in case of HCV more candidates 
appeared to be involved in early as compared to late events of the HCV replication cycle 
(Figure 3.3A, Supplementary Table S 3). LDs are largely accepted to play a role in HCV 
assembly [116, 255], but their potential implication in earlier steps might so far have been 
underestimated. In fact, being storages of neutral lipids, such as cholesteryl esters and 
triacylglycerides [232], LDs could serve as sources of lipids to support the formation of the 
HCV induced membranous web. In addition HCV might usurp LDs in order to generate 
energy through beta-oxidation of fatty acids to support energy-demanding steps in viral 
replication. Interestingly, something similar has been reported for DENV [147]. The number 
of hit candidates affecting early or late steps of the DENV life cycle was similar  (Figure 3.3A, 
Supplementary Table S 3).  
 
Regarding the LD morphology RNAi screen, changes induced by Triacsin C (inhibitor of LD 
formation) or oleic acid treatment (stimulator of LD formation) were very well detected using 
our screen setup. However, in spite of this apparent good performance, candidates identified 
through this screen should be taken with caution. While our screen confirmed the 
involvement of 25.7% of all candidates tested in LD homeostasis in human hepatoma cells, 
the general impact of gene knockdown of these candidates on LD morphology was mild. 
Although a wide panel of LD morphology features was analyzed (Figure 3.1B, table) gene 
knockdown of hit candidates most often caused only mild alterations of a single feature 
(Supplementary Table S 2). Taken together this indicates, that while the controls were 
resulting in a profound „black and white phenotype“, smaller alterations in LD morphology 
upon gene knockdown were hardly detectable. Therefore siRNAs targeting host factors 
known to alter neutral lipid synthesis could represent a more appropriate measure for the 
sensitivity of our image-based readout. In fact our screen included siRNAs targeting ACAT 
(Acyl-coenzyme A: cholesterol acetyltransferase 2, catalyzing the esterification of cholesterol 
to cholesteryl esters [292]), DGAT1 (diacylglycerol O-acyltransferase 1, catalyzes the last 
step in triacylglycerol synthesis, [293])  both involved in the synthesis of neutral lipids, as well 
as the transcription factor SREBP and its co-factor SCAP, both known to regulate the 
expression of lipogenic genes [220]. One might expect that knockdown of these genes 
should affect the cellular neutral lipid content. However knockdown of either of these 
candidates did not alter LD morphology significantly in our RNAi screen (Supplementary 
Table S 2). Thus the herein presented image-based high content screen might not have 
been sensitive enough to detect small alterations in the cellular neutral lipid content. There 
are plenty of factors, such as a heterogeneous behavior of the cell population, differences in 
cell growth, RNAi transfection or infection efficiency and many more that influence the 
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outcome of RNAi screens and that render hit calling difficult. Especially in case of image-
based readouts subtle differences in the handling of the samples might lead to substantial 
differences in the staining efficiency that cannot be easily controlled. 
  
4.1.2 Potential role of COPI in HCV and DENV particle production as well as LD 
homeostasis 
 
Bioinformatic analysis of our screen data revealed the involvement of the Coat protein 
complex I, of the nuclear ubiquitin-proteasome system, of the cell cycle control machinery, 
of the EIF3 translation initiation complex as well as of members of the spliceosome in the 
replication cycle of HCV and DENV and LD homeostasis (Figure 3.5). While the involvement 
of the coat protein complex I in HCV RNA replication has been reported earlier [258, 294] our 
screen results suggests a novel role of COPI function in particle production of both viruses 
(Figure 3.2A). Due to the ‘housekeeping’ nature of this macromolecular complex studying its 
involvement in the replication cycle of these viruses or LD homeostasis might be difficult. 
Indeed our attempts to gain a better insight into the role of the Coat protein complex I 
mediated trafficking in virus infection or LD morphology were substantially hampered by the 
essential role governed by this complex in cell survival and by a low reproducibility of the 
results using RNAi-mediated interference (Supplementary Figure 1). So far the function of 
COPI in the viral replication cycle of either virus has not been elucidated, but several 
hypotheses have been put forward.  
 
Two independent studies reported that gene knockdown of specific COPI subunits or 
pharmacological inhibition of COPI function impairs HCV genome replication [258, 294]. 
Based on the observation that knockdown of factors involved in COPI recruitment caused a 
shift of NS5A from ER-like localization to LDs, which was concomitant to a reduction in viral 
RNA replication, Matto et al. hypothesized that COPI function might regulate the localization 
of NS proteins at the ER and LDs respectively [294]. According to another report COPI 
function might serve to remove the phosphatase Sac1 from PtdIns4P rich replication sites in 
order to maintain high local PtdIns4P levels and thus potentially the integrity of the 
membranous web [295].  The involvement of proteins of the secretory pathway in RNA 
replication and potentially in replication site formation has also been studied for the 
enterovirus Cocksackivirus B3 (CVB3) (Picornaviridae family). Some members of the 
Picornaviridae are known to cause substantial endomembrane remodeling, possibly 
membranes derived from the Golgi and the ER, to generate the viral replication organelles 
[130]. While one report suggested the involvement of components of the COPI trafficking 
machinery in the recruitment of the PI4KIIIbeta and the formation of the viral replication 
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organelles, this was refuted by a more recent study [296, 297]. Whether COPI could function 
in the generation or maintenance of the HCV induced membranous web remains to be 
elucidated. In line with this, our screen indicated that knockdown of several COPI 
components impaired early steps in the replication of HCV (Fig 3.2).  
 
Intriguingly our screen data suggests a so far novel role of COPI in restricting assembly 
and release of HCV and DENV particle production (Figure 3.2A, Figure 3.6B).  An 
interesting observation was made in Drosophila and HeLa cells, which showed that 
knockdown of COPI subunits caused a decreased localization of ATGL (adipose triglyceride 
lipase, catalyzes the first step in TAG hydrolysis) to the LD surface [237, 298]. Thus COPI 
function appears to regulate the association of proteins to LDs. This might further explain the 
observed over-storage of neutral lipids upon loss of COPI function [236, 237]. Hence one 
possibility could be that COPI alters the accessibility of cytosolic LDs through the HCV or 
DENV core/ capsid proteins. In case of HCV it was suggested that targeting of the viral core 
protein to LDs is of importance for the protein’s stability and thus for infectious particle 
production [138, 299]. Similar could account for DENV. As mentioned earlier, gene 
knockdown or pharmacological inhibition of COPI function in drosophila cells has been 
reported to enhance neutral lipid storage, characterized by enlarged LDs [237]. In agreement 
with this, our screen identified COPI components as important regulators of neutral lipid 
storage in human hepatoma cells (Figure 3.2B, Figure 3.6B). One can only speculate about 
the importance of lipid storage induction in infectious particle production of either virus. It has 
been shown that ablation of LDs through Triacsin C treatment only mildly impaired HCV RNA 
replication but had a more profound negative effect on infectious particle production, 
potentially due to the concomitant decrease in core protein levels [299]. Thus enhancing 
neutral lipid storage might increase the LD-core interaction platform, thereby promoting the 
protein’s stability and potentially its engagement in nucleocapsid formation. This is further 
supported by the observation that NS5A-mediated transfer of HCV genomic RNA from 
replication sites to core at LDs is essential for infectious particle production [71, 81]. In case 
of DENV, it is far less understood whether capsid at LDs is indeed involved in particle 
production [148]. Interestingly it has been reported that LDs could act as storage depots for 
excess proteins [300]. Accordingly COPI function could regulate the association of the viral 
core or capsid proteins with LDs and thereby their availability during the course of viral 
infection. Future studies could commence with the analysis of the dependence of the viral 
core/capsid protein’s association with LDs on COPI function.  
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4.1.3 High hit rate of LD RNAi screen indicates central role of the lipid storage 
organelle in the replication cycles of LD-dependent viruses 	  
Statistical analysis of the hypothesis driven RNAi screen data revealed that by targeting 
LD-associated pathways there was a high probability of affecting the replication of either one 
of the LD-dependent viruses. Indeed 57.8% of all candidates analyzed in the primary screen 
were important for either virus or both (Figure 3.4A). This hit rate is substantially higher when 
compared to the approximately 1% hit rate of other published high content screens [301] 
(Acosta and Fischl, unpublished) or to the 15 to 25% hit rate of two kinase screens 
performed for DENV or HCV respectively  (Kumar and Cortese, unpublished) [77]. Of the 
genes identified to affect LD homeostasis in human hepatoma cells (Figure 3.4B), even 
76.3% of the candidates were shown to be involved in the viral replication cycles. 
Interestingly more LD hits were specifically affecting HCV (23.7%) as compared to DENV 
(10.2%) (Figure 3.4C). This indicates that LD related pathways are of central importance 
especially for the highly liver-tropic HCV and are potentially less relevant for DENV. Indeed, 
almost every step in the HCV replication cycle is tightly linked to the lipid metabolism of 
hepatocytes, the latter process possibly being influenced by cellular LDs [302]. In line with 
this it is suggested that cytosolic LDs might serve as platforms that support the assembly of 
infectious virions. This hypothesis is supported by the findings that the recruitment of the viral 
core protein and replicase components to cytosolic LDs is essential for particle assembly, as 
well as by the observation of LDs being present at close proximity of the membranous web 
and of particle-like structures [81, 113, 136]. HCV was shown to hijack the VLDL synthesis 
pathway for infectious particle production, whose lipids might ultimately derive from ER-
luminal LDs. It could be at sites of luminal LDs, where viral particle production merges with 
VLDL synthesis [116]. Additionally HCV infection has been linked to steatosis, characterized 
by an increased fat (neutral lipid) content of the liver, possibly attributed to the presence of 
the viral core protein [303]. Taken together it is not surprising that targeting LD-related 
pathways strongly alters the replication cycle of the liver-tropic hepatitis C virus. In case of 
DENV, the role of LDs is far less understood and discussed controversially. While some 
reports suggest a virus induced autophagy-dependent degradation of LDs for energy supply, 
others reported enhanced neutral lipid storage upon DENV infection [146, 147]. The function 
of DENV capsid recruitment to LDs remains enigmatic, but could promote the coordination of 
viral RNA replication and particle production by sequestering the capsid protein to prevent 
unscheduled RNA encapsidation [146, 148]. As mentioned before, our screen data suggests, 
that DENV is far less dependent on the cellular lipid metabolism of human hepatocytes as 
compared to HCV. This is in line with the fact that while HCV is mainly liver-tropic, DENV 
targets mainly inflammatory cells such as dendritic cells (DCs), monocytes and macrophages 
as well as other various tissues including spleen, kidney, liver and lung [144].  
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Interestingly, numerous other pathogens usurp LDs during their replication cycle. 
Rotaviruses (family Reoviridae, genus Rotavirus ) were shown to depend on LD components 
for the formation of viroplasms, the sites of early viral morphogenesis and viral RNA 
replication [304]. Orthoreovirus (family Reoviridae, genus Orthoreovirus) outer capsid protein 
µ1 was reported to bind to LDs, mitochondria and the ER through amphipathic helices at the 
protein’s C-terminus which appears to be linked to the induction of apoptosis [230, 305]. 
Besides their role in cellular lipid metabolism, LDs have been implicated in innate immune 
signaling. For instance the cellular protein viperin (virus inhibitory protein ER associated 
interferon inducible) potentially exerts its antiviral activity against HCV through its interaction 
with NS5A at LDs and at the viral replication sites [306]. In contrast, the localization of viperin 
to LDs is dispensable for its antiviral activity against DENV [307].  
 
Taken together, the so far neglected lipid storage organelle appears to be of central 
importance for multiple human pathogens. Given the importance of LDs not only in cellular 
lipid homeostasis, but also in the regulation of inflammatory responses, a better 
understanding of the intimate link between pathogens and LDs is essential in order to exploit 
this knowledge for the generation of antiviral therapeutics. Unravelling the mechanisms that 
control LD function, such as the potential involvement of COPI-mediated regulation of the LD 
protein coat, could pave the path for novel strategies to fight pathogen mediated infections. 
Several pharmaceutical companies developed and tested DGAT1 inhibitors in mice that 
showed that administration of these inhibitors led besides others to weight loss and to a 
reduction in serum and liver triacylglycerides. Thus these inhibitors could represent useful 
candidates for the treatment of metabolic disorders [308]. Intriguingly DGAT1 catalyzes the 
last step in triacylglycerol synthesis and has been shown to be an important dependency 
factor for HCV infectious particle production [139]. Therefore, targeting LD function through 
DGAT1 might represent a valuable tool to fight HCV infection. Unfortunately, the above-
mentioned DGAT1 inhibitors had severe adverse effects in humans, which was suggested to 
be caused by the build-up of diacylglycerols and fatty acids upon DGAT1 inhibition [308]. In 
conclusion, while identifying host factors involved in the regulation of LD function could open 
new routes for the development of therapeutics, targeting an organelle of key importance in 
cellular lipid metabolism might remain challenging. 
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4.1.4 Studying the role of the DEAD box RNA helicase 3 in the replication cycle of 
HCV and DENV 
 
Additional to the already described involvement of DDX3 in early events of the HCV 
replication cycle [76, 154] our screen implicated a novel function in particle morphogenesis of 
HCV and DENV.  
 
4.1.4.1 Evaluation of the involvement of DDX3 in the full replication cycle of HCV or 
DENV 
 
A set of siRNA-mediated knockdown experiments aimed to re-evaluate the screen results 
(Figure 3.7, Figure 3.8, Figure 3.9). We were able to confirm the proviral role of DDX3 in 
early events of the HCV replication cycle. Indeed, gene knockdown of DDX3 caused a 
significant reduction of entry and replication of genotype 2a HCV reporter virus (Figure 3.7B). 
This is in line with a previous siRNA screen that identified the role of DDX3 in early events of 
full-length reporter virus replication of the same genotype [76]. Ariumi et al. were the first to 
describe a potential involvement of this RNA helicase in HCV genome replication by the use 
of stable genotype 1b replicon cell lines [154]. Interestingly our results revealed that the 
replication of a genotype 2a replicon was not altered upon DDX3 gene knockdown while 
genotype 1b replication was mildly reduced. The fact that, under the experimental conditions 
tested, DDX3 gene knockdown strongly impaired early events of the replication cycle of 
genotype 2a reporter virus, but had no impact on replication of a stable genotype 2a replicon, 
could imply that this DEAD box RNA helicase is mainly involved in virus entry prior to 
RNA translation and replication or in the early post-entry events leading to the 
establishment of replication. In a recent RNAi screen follow-up study, multiple in vitro HCV 
model systems were applied (i.e. HCVpp, HCVcc, subgenomic replicons) in order elaborate 
the precise step in the viral replication cycle affected by selected host factors. This revealed 
the importance of DDX3 in entry of HCVpp (clathrin-dependent entry) but also of the unrelated 
VSVpp (Vesicular stomatitis, clathrin-dependent entry) and MLVpp (Murine leukemia virus, 
clathrin-independent entry) [157] possibly indicating a more general role of DDX3 in 
endocytic events. The same study further reported the importance of DDX3 in replication of a 
genotype 2a subgenomic replicon. Thus an involvement of DDX3 in viral RNA replication is 
likely, although we were not able to recapitulate this, which could possibly be due to an 
inefficient sustained gene knockdown by transient siRNA transfection. Nevertheless it seems 
that the viral subgenomic replicons used in this study (Con1_ET (gt1b) and JFH1 (gt2a)) 
differ in their sensitivity towards DDX3 gene knockdown. In this respect it is interesting to 
note, that throughout our studies on host factors and their implications in the viral replication 
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cycle we repeatedly observed a higher sensitivity of the cell culture adapted Con1_ET 
replicon (three replication enhancing mutations in NS3 (T1280I an E1202G) and NS4B 
(K1846T) [86]) towards manipulation of the cellular environment when compared to the 
genotype 2a counterpart (Figure 3.20, Figure 3.34, Figure 3.37, Figure 3.38). Early after the 
establishment of genotype 1b and 2a replicon systems, with the latter one being capable of 
high RNA replication without the need of replication enhancing mutations, it was observed 
that genotype 2a replication was more robust towards IFNα treatment when compared to 
genotype 1b [309]. The molecular mechanism that could account for this discrepancy and 
whether this is due to the diverging genomic sequences remains elusive. A very recent report 
documented that the over-expression of a specific host factor (Sec14L2) allowed the 
replication of wild-type replicons of various genotypes (gt1a, 1b, 2a (J6), 3a, 4a, 5a) in 
human hepatoma cells, which usually requires the presence of adaptive mutations.  In 
contrast the respective cell culture adaptive mutant replicons and the JFH1 replicon were 
only moderately influenced by Sec14L2 expression [310]. This could be a mechanism by 
which cell culture adapted mutants acquire the ability to cope with the lack of a proviral factor 
or to circumvent the negative effects of a restriction factor present in human hepatoma cells. 
This could further point to a differential dependency of distinct genotypes (including their 
wild-type or cell culture adapted mutant variants) on host factors and therefore could account 
for the different sensitivities of subgenomic Con1ET or JFH1 RNA replication towards DDX3 
gene silencing.  
 
In conclusion DDX3 is likely to be involved in virus entry and genomic RNA replication 
of HCV. So far the precise role in either step has not been elucidated. Initial data on Human 
Cytomegalovirus indicated a proviral involvement of DDX3 in virus spread and its 
incorporation into the virion [311]. Similarly, DDX3 was found to interact with HBV 
polymerase (Pol) and to become incorporated into HBV nucleocapsids. In this context, DDX3 
was suggested to act as host restriction factor of HBV possibly inhibiting viral reverse 
transcription. [312, 313]. Whether DDX3 is also incorporated into the infectious HCV particle 
remains to be determined. Indeed, DDX3 was shown to bind the 3’ NTR of the viral (+) RNA 
and could thus become part of the assembled particles [314].  
DDX3 is a multifunctional protein implicated in several processes involving RNA (RNA 
splicing, mRNA export, transcriptional and translational regulation, ribosome biogenesis), cell 
cycle control and apoptosis [151]. Its pleiotropic functions in RNA metabolism might be 
usurped by HCV. Some reports claim that DDX3 suppresses cap-dependent translation but 
in turn enhances translation of highly structured 5’ NTRs. Details on the underlying 
mechanisms are ambiguous and it remains unclear whether DDX3 can indeed regulate the 
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translation of specific transcripts and whether this would also apply to HCV IRES mediated 
RNA translation [315]. 
 
Our screen further indicated a novel proviral role of DDX3 in particle production of DENV, 
which we were not able to recapitulate in our transient siRNA knockdown experiments 
(Figure  3.2, Figure  3.7C). Not much is known about the role of DDX3 in the DENV 
replication cycle. It was reported that DDX3 interacts with the viral RdRp NS5 and that 
interference with DDX3 protein expression impairs steps in viral RNA replication in Huh7.5 
cells [153]. However, a more recent report showed that DDX3 gene silencing promotes viral 
replication in interferon competent HEK293T cells, which contain in contrast to Huh7.5 cells a 
functional RIG-I mediated interferon pathway. These results indicated an antiviral role of the 
cellular RNA helicase, possibly by modulating the antiviral innate signaling and the induction 
of type I IFN production in response to DENV infection [316]. Given that our silencing 
experiments were performed using the interferon defective cell line Huh7.5FLuc we may 
have missed the antiviral effect of DDX3. This issue will be discussed in more detail later in 
context of the role of DDX3 in HCV infections. Taken together present data on the role of 
DDX3 in the DENV replication cycle is ambiguous. 
 
4.1.4.2 Studying the implication of DDX3 recruitment by the HCV core protein in the 
viral replication cycle  
 
In addition to the already described role of DDX3 in early events of HCV replication, our 
screen described a novel proviral function of this host factor in HCV particle production 
(Figure 3.2). Indeed transient DDX3 gene knockdown by siRNA transfection revealed a slight 
but significant reduction in infectious particle production (Figure 3.9). 
 
Studying the cellular localization of DDX3 in HCV or DENV infected cells we observed a 
relocalization of the cytosolic protein pool to core covered lipid droplets in HCV but not in 
DENV infected cells (Figure 3.10). Thus, one might argue that HCV- or DENV-induced 
changes of the LD protein coat, i.e. through the association of the viral core/ capsid proteins 
to LDs, do not contribute to the recruitment of the cellular helicase. Instead, DDX3 
relocalization may result from a specific recruitment of the RNA helicase through 
determinants inherent to HCV proteins present at LDs. In line with earlier publications we 
identified the HCV core protein as sole determinant for DDX3 relocalization (Figure 3.11). 
[154]. However, we cannot exclude the involvement of other cellular proteins or of cellular or 
viral RNA acting as linker between both RNA binding proteins. When comparing the 
localization of DDX3 in cells transfected with the low assembly competent JFH1 or the 
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assembly deficient Jc1ΔE1E2 or with the highly assembly competent Jc1 we observed a 
correlation of LD core coverage with the DDX3 relocalization efficiency (Figure  3.12). In line 
with an earlier report we could observe a prominent localization of the JFH1 core as well of 
the Jc1 core of the assembly mutant (Jc1ΔE1E2) at LDs, while the Jc1 core labeled only few 
LDs (Figure 3.12) [264]. Concomitantly, DDX3 was relocalized in almost all cells replicating 
JFH1 or Jc1ΔE1E2, while in case of Jc1 transfected cells, only few cells showed a profound 
relocalization of the cellular RNA helicase (Figure 3.12). This is not surprising, given that the 
viral core protein was found to be the prime determinant causing the relocalization of DDX3 
(Figure 3.11).  
 
Earlier studies showed that disrupting the DDX3-core interaction by the Y35A point mutation 
in HCV core had no significant effect on the viral replication cycle of JFH1 (genotype 2a) 
[260]. In contrast, others reported that the expression of core peptides capable of binding 
DDX3 were interfering with genotype 1b RNA replication, which could be rescued by the 
overexpression of DDX3. The same study further reported that the introduction of such core 
peptides did not alter the full replication cycle of genotype 2a virus [261]. This points to a 
varying importance of DDX3 in the replication cycle of distinct HCV genotypes. Therefore we 
wondered whether there are genotype-specific sensitivities towards disrupting the 
relocalization of DDX3 to LDs. In fact, we were curious to elucidate whether there might be 
differences in the virus’s sensitivities towards the loss of DDX3 recruitment that could be 
correlated with the apparent differences in the virion production efficiencies. 
 
To this end, two single point mutations (Y35A or F24A) were introduced into the HCV core 
protein of different inter/intra-genotypic chimeras. These point mutations have earlier been 
described to interfere with the interaction of the viral core protein with the cellular DEAD box 
RNA helicase 3 [260]. By the use of inter/intra-genotypic chimeras we aimed to compare 
their sensitivity towards loss of DDX3 recruitment. These chimeras share similar sequence of 
the replicase module (NS3-5B) of JFH1 (genotype 2a) and replicate to similar extent (Figure 
3.17C). However, the assembly module, the core-NS2 sequence, derives from isolates of 
different genotypes and subtypes (2a, 1a, 1b). The J6/JFH1 chimera results in the production 
of the highest titers, Con1/JFH1 and H77/JFH1 show intermediate particle production 
efficiencies, while JFH1 (wild-type) produces only low levels of infectious particles (Figure 
3.13) [262]. Using this approach, we were able to confirm that both mutations caused a loss 
in DDX3 relocalization, which in turn remained evenly distributed in the cytosol of cells 
transfected with the mutant virus (Figure 3.14, Figure 3.16). 
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We next aimed to elucidate whether infectious particle production of these chimeras was 
differentially sensitive towards loss of DDX3 recruitment by analyzing the impact of the 
selected point mutations on the viral replication cycle. We found that disrupting the 
localization of DDX3 to HCV core at LDs had no significant impact on steps of viral RNA 
replication of the different inter/intra-genotypic chimeras (Figure 3.15, Figure 3.17). This 
stands in agreement with an earlier report that showed that the core-DDX3 interaction was 
dispensable for RNA replication of JFH1 (genotype 2a) [260]. Note, that the viral chimeras 
used in this study share the replicase cassette of genotype 2a.  As mentioned before, others 
reported that the expression of a core peptide capable of binding DDX3 impaired 
subgenomic RNA replication of a genotype 1b replicon [261]. Given this discrepancy one 
might speculate that the importance of DDX3 recruitment to LDs by the HCV core protein 
in viral RNA replication might depend on the viral genotype studied.   
 
A considerable drawback in our study on the effect of disrupting DDX3 localization to 
HCV core at LDs on HCV particle production was the partially reduced level of mutant 
core proteins. In fact, all Y35A core mutants, but only some of the F24A mutants showed 
reduced core protein levels when compared to their respective wild-type counterparts. This 
could account for the impaired production in infectious particles. Nevertheless there was no 
good correlation between the reduced amounts of core protein levels with the extent of 
impairment of infectious particle production, what makes it difficult to unambiguously 
conclude that the lower titers are a direct consequence of the lower expression of core 
(Figure 3.15, Figure 3.17).  
 
Finally we observed that DDX3 gene knockdown impaired infectious particle production 
of F24A mutant chimeras to similar extent as compared to the corresponding wild-type 
virus (Figure 3.19). Thus we conclude that inhibiting DDX3 recruitment to LDs does not affect 
its ability to support HCV particle production. In turn, changing the intrinsic properties of the 
core protein through the insertion of either one of the two studied point mutations might be 
the reason for the impairment in infectious particle production (Figure 3.17C). This has 
several implications for the understanding of the role of DDX3 per se and of its recruitment to 
LDs by the viral core protein in the HCV replication cycle. 
 
First, it appears that the recruitment of DDX3 to lipid droplets by the HCV core protein is 
dispensable for its function in the full replication cycle of HCV in the human hepatoma 
cell line Huh7/Lunet used in this study. Nevertheless this function might be important in a 
more authentic cell system. As mentioned before, human hepatoma Huh7 cells were shown 
to have a low type I interferon (IFN) production in response to viral infection and also to 
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respond only poorly to IFNs [317]. The herein used Huh7/Lunet cells are derived from Huh7 
cells, that were cured from the replication of a subgenomic replicon, and represent a highly 
permissive cell line for HCV RNA replication [239]. There are several reports describing the 
involvement of DDX3 in type I IFN induction but the protein’s exact functions are unknown. 
Being a DEAD box RNA helicase DDX3 could potentially act as viral RNA sensor. However 
the protein lacks of a signaling domain similar to the one found in the innate immune 
receptors RIG-I (retinoic acid inducible gene) or MDA-5 (melanoma differentiation antigen 5) 
[150, 318]. DDX3 was found to contribute to type I IFN induction and act at different levels of 
the signaling cascade. It was reported that DDX3 binds to MAVS and thereby upregulates 
the RIG-I mediated IFNβ promotor induction [319]. DDX3 was further suggested to act more 
downstream in the signaling cascade as signaling intermediate [152] or even as 
transcriptional activator of the IFNβ promotor [319]. All in all, while the precise mechanism 
remains elusive, DDX3 supports type I IFN production upon viral infection. Given that the cell 
line used in this study induces type I IFN only to very low levels upon viral infection, it could 
be that a possible benefit of recruiting DDX3 to LDs is only relevant in an immunocompetent 
environment. Thus one could hypothesize that HCV core-mediated sequestration of DDX3 at 
LDs aids to remove it from sites of innate induction and thus serves to counteract the cellular 
antiviral response. Whether this hypothesis holds true or not remains to be determined in a 
more authentic immunocompetent cell system. Intriguingly, studies based on overexpression 
of DDX3, MAVS and the JFH1 core protein indicated that the viral protein interferes with the 
DDX3 mediated promotion of MAVS-induced IFNβ promotor activity [320]. 
Deregulation of DDX3 has also been ascribed to tumorigenesis. In breast cancer, DDX3 is 
suggested to act as oncogene, while in case of hepatocellular carcinoma (HCC) (in particular 
of HBV positive patients) DDX3 has been found to be downregulated. The underlying 
mechanisms appear to be different but possibly include the transcriptional control of genes 
promoting or suppressing tumorigenesis by DDX3 [151]. Sequestration of DDX3 through the 
binding to the viral core protein might thus represent a strategy of the virus to interfere with 
the protein’s tumorsupressive activity and could promote HCC. 
 
Given the results obtained so far, the purpose of the core-dependent DDX3 recruitment to 
LDs remains obscure. Additionally it is still unclear whether DDX3 (or its recruitment to LDs) 
might be (if at all) of different importance for the replication cycle of distinct genotypes. Our 
initial question whether DDX3 recruitment to LDs could contribute to the different efficiencies 
in HCV particle production observed for distinct genotypes or isolates still remains 
unanswered.   
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Second, our DDX3 knockdown experiments suggest an involvement of the DEAD box RNA 
helicase in early and late events of the HCV replication cycle. Thus either the remaining 
cytosolic (non-relocalized) fraction of DDX3 is supporting steps in the viral replication cycle or 
these functions are independent of the protein’s localization. A very recent report suggested 
that DDX3 might serve as a sensor of HCV RNA, which concomitantly leads to the induction 
of the expression of lipogenic genes. This in turn could enhance the intracellular levels of 
neutral lipids, thus of LDs, and thereby resulting in a positive effect on HCV particle 
production [158]. As the HCV core protein is capable of binding viral RNA [31], we wondered 
whether the recognition of HCV RNA and subsequent induction of lipogenic genes by DDX3 
was dependent on the proteins recruitment to the LDs by the viral core protein. We showed 
that the relocalization of DDX3 by the core protein does most likely not contribute to the 
protein’s potential ability to induce lipogenesis. Although cells replicating core mutant virus of 
genotype 2a (JFH1) showed a reduced neutral lipid stain compared to cells replicating the 
wild-type virus (Figure 3.18), this could be attributed to the reduced core protein levels 
(Figure 3. 17E). Considering that the expression of core protein has been linked to the 
occurrence of steatosis in transgenic mice as well as the fact that HCV core protein was 
shown to induce SREBP cleavage [37, 321], it could be that the observed difference in the 
cellular neutral lipid content is caused by the different expression levels of mutant and wild-
type core protein.   
 
Third, DDX3 recruitment by the HCV core protein might be unspecific. Recently the 
cellular Y-box binding protein YB-1 was described to regulate the balance between viral 
replication and particle production possibly by interacting with HCV NS3 [322]. Interestingly, 
an interactome of YB-1 in human hepatoma cells indicated the protein’s interaction with 
several host factors including DDX3. Similar to the DEAD box RNA helicase 3, YB-1 was 
found to associate to LDs in a core dependent manner. Intriguingly YB-1 appeared to 
regulate the localization of its interaction partners including DDX3 to LDs, arguing that these 
factors might act in a functional complex [322]. Nevertheless, it could be that DDX3 is 
accidentally co-shuttled with YB-1 to LDs, while not being of any relevance for the virus. This 
is supported by the fact that knockdown of YB-1 and its interaction partners significantly 
reduced viral RNA replication, while stimulating infectious particle egress, highlighting their 
functional link. In marked contrast, DDX3 knockdown did not influence particle release. 
Although DDX3 was found to be a part of this protein complex (including YB-1 and its 
interaction partners), it did not act in a similar fashion [322]. Thus the role of its recruitment 
by the HCV core protein to LDs, possibly as part of a larger protein complex, in the viral 
replication cycle remains unresolved.   
 
Discussion I 147  
 
In conclusion our results indicate that DDX3 is important for early and late events of the HCV 
replication cycle in human hepatoma cells (Huh7.5, Huh7/Lunet), which is most likely 
independent of its relocalization through the HCV core protein. This interaction might 
however play a role in a more authentic cell system. Being a protein involved in a multitude 
of cellular pathways HCV might depend but possibly also restrict several cellular functions of 
DDX3. It is not surprising that this DEAD box RNA helicase plays an important role, either as 
restriction or dependency factor in the replication cycle of several other viruses, namely 
vaccinia virus, DENV or HIV [151, 153]. One might argue that this host factor could be a 
good target for the development of broad-spectrum antivirals. However a far better 
understanding of its multiple actions in the viral replication cycles is required in order to 
specifically target DDX3 function while not affecting cell homeostasis [151].  
 
4.1.4.3 Effect of the single point mutation Y35A or F24A in the HCV core protein on 
core protein stability and infectious particle production  
 
In the course of this study, we observed that the two core point mutations Y35A or F24A 
reduced core protein levels of distinct HCV genotypes to different extent (Figure 3.15, Figure 
3.17). 
 
Core protein stability has been reported to depend on its recruitment to LDs which is 
mediated by two amphipathic helices in domain 2 at the protein’s C-terminus [35]. Our 
immunofluorescence analysis revealed that the Y35A or F24A mutation did not interfere with 
the protein’s localization to LDs (Figure 3.14). However whether the amount of mutant core 
protein at LDs reflects the exact wild-type condition needs to be determined. Nevertheless, 
considering that both point mutations are present at the protein’s N-terminus (domain I) it is 
unlikely that they substantially alter the membrane targeting of the viral core protein.  
 
The N-terminus of the HCV RNA core coding region however, has been predicted to fold into 
four highly conserved RNA structures, of which the two most N-terminal stem-loop 
structures (SL47 and SL87) were suggested to contribute to RNA translation [323]. 
Indeed, the herein used core point mutations are present within SL47. However, whether a 
single point mutation would disrupt the stem-loop structure and could cause a defect in viral 
RNA translation is not known. Given our observation that only the HCV core protein levels 
but neither the amounts of NS5A or NS3 nor the RNA replication efficiency were reduced in 
the context of either point mutation argues for a core specific defect unrelated to viral RNA 
translation (Figure 3.5, Figure 3.17).   
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We were able to identify two core mutations that in the context of the full-length virus 
(Jc1F24A, Con1F24A/JFH1) did not cause reduced core protein levels but a significant 
reduction in infectious particle production (Figure 3.17). The N-terminal domain (domain I) of 
the HCV core protein is suggested to be involved in RNA binding as well as core 
oligomerization. Both are possibly dependent on the presence of positively charged amino 
acids, and thus on the net charge of domain I [31, 32, 34]. Whether the mutation of the 
uncharged amino acid Tyrosine (Y) or Phenylalanine (F) could have any impact on these 
steps and thus could account for the observed defect in infectious particle production 
remains open. It could be that these amino acid residues mediate the interaction with other 
cellular proteins important for infectious particle production.  
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4.2 Studying the role of lipid transfer protein mediated cholesterol transport in the 
HCV replication cycle 
 
Similar to other plus-strand RNA viruses, HCV induces a massive rearrangement of cellular 
endomembranes, generating the so-called membranous web that predominately consists of 
DMVs. There is increasing evidence that these DMVs represent the sites of viral RNA 
replication and are most likely generated by a concerted action of viral and host factors [113, 
130, 265]. However the precise lipid composition as well as the source of the respective 
lipids remains elusive. It has been shown that HCV alters the expression of lipogenic genes 
[37, 131], which could provide lipids for the generation of DMVs through de novo lipogenesis 
or enhanced lipid uptake from the extracellular space. In addition HCV might cause changes 
in the distribution of endogenous lipids and induce their specific recruitment to sites of viral 
RNA replication. In this study we focused on HCV induced alterations of the free cholesterol 
landscape. The fact that viral replicase components were found to be associated with 
detergent resistant membranes, suggests a specific lipid environment of the replication 
organelles [127, 128]. Indeed several studies point to unesterified cholesterol as well as 
sphingomyelin as important components of the viral replication factories and as being 
important for viral RNA replication [79, 114, 324].  
 
4.2.1 Studying the distribution of free cholesterol in HCV infected cells 
 
In a set of microscopy-based experiments we studied the fate of free cholesterol in HCV 
replicating cells and could show that endogenous and exogenously added free cholesterol 
was recruited to NS5A positive sites at the perinuclear region of HCV replicating cells (Figure 
3.20A, E, Figure 3.23A, B). In addition, we observed an increased intracellular accumulation 
of endogenous unesterified cholesterol in infected as compared to mock cells, which 
suggests that HCV alters cholesterol homeostatic pathways such as the lipid’s trafficking to 
specifically recruit it to sites of viral replication (Figure 3.20C, Figure 3.20F). The fact that in 
mock cells a substantial amount of cellular unesterified cholesterol was present at the 
plasma membrane, which was largely decreased in HCV infected cells, prompted us to 
analyze the fate of PM-derived (exogenously added) free cholesterol (Figure 3.20 A, B).  
 
Using fluorescently labeled free cholesterol (TFC) we aimed at unraveling whether HCV was 
able to recruit plasma membrane derived cholesterol to sites of viral RNA replication. In 
addition, given that cholesterol might represent an important structural component of the 
DMVs [79, 114], we wondered whether we could observe differences in the recruitment 
efficiency of TFC to the potential viral replication factories, when TFC was added at early as 
compared to late time points in replication (replication establishment vs steady state 
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replication). To this point we analyzed the dynamics and distribution of exogenously 
added TFC in HCV replicating cells, which was further supported by biochemical analysis 
of NS4B membrane fractions, the DMVs, purified from TFC pulsed cells. 
 
Of note, we and others showed that TFC incorporates into the plasma membrane from which 
it may become endocytosed and distributed throughout the cell (Figure 3.22B, C) [267]. 
Nevertheless we cannot exclude that TFC possibly interacts with lipoproteins present in the 
cell culture media and is taken up by receptor-mediated endocytosis, i.e. through the LDL 
receptor. Importantly, in either case free cholesterol will be trafficked through the endosomal 
pathway to its intracellular targets such as the PM or the ER [214]. 
 
Analysis on the dynamics of exogenously added TFC in HCV replicating cells showed no 
significant differences in the recruitment velocity between HCV replicating and “mock” cells 
(Figure 3.23C). However, it needs to be mentioned that these “mock” cells expressed the 
viral core to NS2 proteins and thus do not represent authentic uninfected cells. In fact the 
viral core protein has been described to induce SREBP activity [37], thus enhancing the 
expression of lipogenic genes, which might in turn alter lipid trafficking. Moreover, while HCV 
replication might or might not affect the uptake velocity of excess plasma membrane derived 
cholesterol the virus could exploit additional mechanisms, such as the inhibition of 
cholesterol esterification, in order to trap the lipid at viral replication sites. 
 
Assuming that free cholesterol might be of need for the generation or maintenance of the 
membranous web, we argued that cholesterol could be of particular importance at early time-
points when the viral replication organelles are about to be established. To this end, we 
studied the TFC recruitment velocity when added early or late in replication. Our results 
did not indicate a significant difference in the rate of TFC accumulation when added during 
the establishment of replication or at times of steady state replication (Figure 3.22, Figure 
3.23C, Figure 3.24C). There are several reasons that could account for this. Studies on the 
course of DMV accumulation throughout HCV infection showed a rapid increase in the 
occurrence of DMVs from 16 to 24 h post infection which remained steady in number until 48 
h post infection (Jc1, gt2a) [113]. Given the experimental limitations we pulsed the cells with 
TFC at 30 h post electroporation, the earliest time point possible. So far we cannot exclude 
that at this time the majority of viral replication sites is already established. Another possibility 
is that the cell might cope, irrespectively of the presence of the virus, with excess plasma 
membrane cholesterol by triggering the lipid’s endocytosis, its traffic to the ER and possibly 
its esterification and storage in LDs. Indeed, free cholesterol alters membrane structure and 
function [325] and thus the membrane’s cholesterol content needs to be tightly regulated. In 
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the end, there might also be no differential recruitment of cholesterol throughout the course 
of a HCV infection. For instance, it could be that during steady state replication a high DMV 
turnover rate causes a continuous biogenesis of DMVs, which might resemble the de novo 
biogenesis early in infection.  
 
While we were not able to observe differences in the recruitment velocity of TFC to the 
perinuclear region between HCV replicating and mock cells, we observed that TFC 
accumulated in a diffuse web (Figure 3.23B, Figure 3.24B) or in dot-like structures (Figure 
3.23A, Figure3.24A) at the perinuclear region in HCV replicating cells. In comparison to mock 
cells, TFC appeared to accumulate to larger extent at the perinuclear region, at least when 
added late in replication. This is in line with our previous results on the distribution of 
endogenous cholesterol upon HCV infection that showed an enrichment of free cholesterol at 
the perinuclear region in HCV replicating as compared to mock cells (Figure 3.20D, F, Figure 
3.24D). Importantly we observed a significant colocalization of endogenous and exogenous 
cholesterol with the HCV NS5A, which we used as a potential marker for the viral replication 
sites. These results suggest that HCV might actively induce the recruitment of plasma 
membrane cholesterol to sites of viral RNA replication. To corroborate this further, the 
localization of unesterified cholesterol in respect to other viral non-structural proteins, or best 
to newly synthesized RNA, as a marker for active RNA replication, should be analyzed. 
Performing elaborate NS4B-HA pulldown experiments we were able to show that TFC is 
recovered in NS4B-associated membrane fractions, which have previously been reported to 
be DMVs and the putative sites of RNA replication (Figure 3.26) [114]. Using this biochemical 
approach it will be interesting to elucidate, whether inhibition of endosomal transport of PM 
derived/ extracellular cholesterol (i.e. through NCP1 knockdown or CA treatment) influences 
the incorporation of TFC or of endogenous cholesterol into DMVs. 
Taken together we show first evidence that plasma membrane derived cholesterol is likely 
incorporated into the viral replication organelles, the DMVs. This is in line with a recent study 
that reported the recruitment of TFC to NS5A positive sites in HCV replicating cells as well as 
the enhanced association of TFC with DRMs in HCV replicating cells [79]. In this context, it 
will be interesting to investigate whether the addition of exogenous cholesterol, such as TFC, 
stimulates HCV RNA replication by for instance promoting DMV formation.  
 
As indicated earlier, HCV may not only induce the active recruitment of cholesterol to sites of 
viral replication, but could also exploit other mechanisms in order to efficiently retain the lipid 
at sites of need. This could be achieved by preventing cholesterol esterification and its 
storage in LDs. This may be addressed by measuring the degree of TFC recruitment to LDs, 
which could serve as an indicator for the TFC esterification rate.  
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In conclusion, we showed that the distribution of endogenous and exogenous free 
cholesterol is altered in HCV infected cells, suggesting that the virus hijacks pathways in 
order to reorganize the cellular cholesterol landscape. In times of immediate need the 
plasma membrane cholesterol pool can serve as readily available pool [326]. We suggest 
that HCV usurps the plasma membrane cholesterol pool and recruits the lipid to sites of viral 
RNA replication, where it could contribute to the formation of the double membrane vesicle or 
support viral RNA replication by other means. Details on the underlying mechanisms that 
allow the virus to specifically enrich cholesterol at sites of need are still scarce and most 
likely involve a concerted action of vesicular and non-vesicular lipid traffic.  
 
4.2.2 Evaluating the role of LTPs implicated in direct lipid transfer in the replication 
cycle of HCV and DENV 
 
Being an obligate intracellular pathogen, HCV hijacks cellular pathways to promote genome 
replication and infectious virus production. We observed that HCV induces alterations in the 
cellular distribution of free cholesterol, with the lipid being recruited to the potential sites of 
RNA replication (Figure 3.20, Figure 3.26). This is in line with increasing evidence suggesting 
that the positive-strand RNA virus does not simply reshape ER membranes for the 
generation of the membranous web, but instead creates a membrane microenvironment of 
specific lipid composition [79, 129, 280]. Despite the ER being the site where cellular 
cholesterol levels are controlled through anabolic and catabolic processes, the ER exhibits 
only low cholesterol levels as compared to the PM. In fact, about 65% of total free cholesterol 
are suggested to be present at the PM, while only 1-2% are found in the ER [162]. Thus the 
question arises of how cholesterol becomes specifically enriched at the viral replication 
factories that most likely derive from ER membranes [113]. The virus could exploit several 
mechanisms in order to accumulate cholesterol at its replication sites. In addition to on-site 
de novo synthesis, or to a reduced esterification of free cholesterol or enhanced liberation of 
cholesterol from LD storages, HCV might hijack the vesicular and non-vesicular lipid 
transport machinery in order to recruit and to enrich cholesterol at specific sites. In this study 
we aimed to evaluate the contribution of LTP-mediated cholesterol traffic to HCV 
replication, in particular to the generation of the membranous web. We argued that the virus 
might hijack the function of these LTPs in order to generate local membrane enrichment in 
cholesterol and potentially other lipid species such as sphingolipids. Indeed some LTPs that 
exhibit a pleckstrin-homology domain mediating PtdIns4P binding and a VAP binding 
domain, the FFAT motif, seem to be attractive targets for viral manipulation.  
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Figure 4.1 Possible model of lipid transfer through the concerted action of lipid transfer proteins at ER/ 
Golgi contact sites. Upper panel: uninfected cell. The lipid transfer proteins PITPNM1, OSBP and CERT are 
recruited to the ER through their interaction with present VAP proteins. (1) PITPNM1 shuttles the exchange of 
PtdIns and PC between ER and Golgi membranes. (2) PtdIns can serve as substrate of the PI4KIIIbeta for 
PtdIns4P production. (3) (5) This generates a PtdIns4P gradient that drives the counter-transport of PtdIns4P with 
the respective lipids targeted by OSBP (free cholesterol) or CERT (ceramide). This in turn leads to an 
accumulation of cholesterol and ceramide at Golgi membranes. (4) The phosphatase Sac1 at the ER 
dephosphorylates PtdIns4P in order to maintain the PtdIns4P gradient. Lower panel: HCV infected cell. The LTPs 
(except of FAPP2) are recruited to the viral replication sites via interaction with present VAP proteins. (1) (2) 
PITPNM1 function might be hijacked in order to provide PtdInsP for the subsequent generation of PtdIns4P by the 
PI4KIIIA at the viral replication organelles. The local high PtdIns4P levels then promote the delivery of (3) 
cholesterol by OSBP and (5) ceramide by CERT. (4) FAPP2 is potentially recruited to the viral replication sites via 
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its binding to PtdIns4P and delivers GlcCer. These actions could allow an accumulation of specific lipid species at 
the viral replication organelles. PITPNM1: membrane associated phosphatidylinositol transfer protein 1, OSBP: 
oxysterol-binding protein, CERT: ceramide transfer protein, FAPP2: four phosphate adaptor protein 2, VAP-A/B: 
vesicle associated membrane protein A/B, PtdIns: Phosphatidylinositol, PtdIns4P: Phosphatidylinositol-4-
Phosphate, PC: Phosphatidylcholine. 
There is increasing evidence that HCV might co-opt these LTPs by recruiting them to the 
viral replication sites, possibly through their binding with VAP proteins, the latter shown to be 
present in DMVs [114]. HCV was shown to recruit the PI4KIIIA to sites of viral replication and 
to stimulate the protein’s kinase activity, which leads to the generation of high local PtdIns4P 
levels [77]. This allows the establishment of a PtdIns4P concentration gradient which then 
might drive the counter-transport of PtdIns4P and cholesterol or glycosphingolipid 
precursors, and finally leads to the enrichment of the raft lipids at the replication organelles 
(Figure 4.1, HCV infected cell) [79, 129]. A similar mechanism was proposed for the 
replication of other plus-strand RNA viruses such as several members of the Picornaviridae, 
known to depend on the PI4KIIIbeta dependent PtdIns4P induction [187, 327]. The positive 
single-stranded RNA Tombus virus has been suggested to co-opt sterol transfer proteins 
through direct interaction with one of the replicase proteins thereby recruiting sterols to the 
viral replication site [328]. In the context of HCV, present studies mainly focused on OSBP, 
while OSBP- related/like proteins (ORP/OSBPLs) have been vastly neglected [79]. 
Nevertheless given that they share a similar domain structure (C-terminal sterol binding 
domain and in most cases a N-terminal FFAT motif and subsequent PH domain) it is likely 
that OSBPLs might act in a concerted fashion or even redundantly. Therefor we evaluated 
the role of several members of the OSBPL family but also of other protein families implicated 
in non-vesicular sterol transfer, such as of the START domain protein family or the NPC 
proteins in the replication cycle of HCV and DENV (Figure 3.27 table, references therein). In 
addition to the already known HCV life cycle regulators OSBP [79, 280, 329], COL4A3BP 
[280, 329] and PLEKHA8 [129], we here report for the first time of the involvement of the 
membrane associated phosphatidylinositol transfer protein 1 (PITPNM1) in the replication 
cycle of HCV (Figure 3.29C). The beforehand mentioned proteins act at ER/Golgi membrane 
contact sites, which highlights the importance of their concerted action mediating the lipid 
exchange between these two cellular compartments in the viral replication cycle. A model 
describing their potential mode of action in HCV infected cells is presented in Figure 4.1 
(infected cell). PITPNM1 is a phosphatidylinositol (PtdIns) / phosphatidylcholine (PC) transfer 
protein. In uninfected cells PITPNM1 exchanges PtdIns from the ER with PC of the Golgi. 
The Golgi localized PI4KIIIbeta subsequently phosphorylates PtdIns to PtdIns4P. The 
thereby generated PtdIns4P concentration gradient (PtdIns4P concentrations are low at ER 
but high at the Golgi) drives the counter-transport of PtdIns4P and cholesterol or ceramide by 
OSBP or CERT respectively [181] (Figure 4.1). Upon HCV infection high PtdIns4P levels at 
the replication organelles might drive the LTP-dependent delivery of free cholesterol and 
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ceramide to the replication sites. In this context, PITPNM1 could promote the local induction 
of high PtdIns4P levels by the cellular PI4KIIIA through its transfer of PtdInsP to the viral 
replication sites. In line with this, we observed that knockdown of PITPNM1 impaired early 
events of viral infection (Figure 3.29C). The involvement of PITPNM1 in HCV RNA replication 
such as its contribution to the virus induced elevated PtdIns4P levels should be addressed in 
future studies. 
 
In addition our screen results indicated an important role of OSBPL3, OSBPL9/11, described 
to function at ER/PM or Golgi/endosome membrane contact sites, in the HCV replication 
cycle. Furthermore LTPs (NPC1, STARD3, OSBPL1A/1B) involved in lipid traffic through the 
late endosomal/ lysosomal pathway appeared to be of relevance for the virus (Figure 3.28A, 
B, E) [179, 196, 274, 275, 279]. This highlights the importance of LTPs present at 
several membrane contact sites and at the LE/LY organelles in the viral replication cycle. 
This further suggests that HCV might usurp several lipid sources to acquire lipids, in 
particular cholesterol or sphingolipids.   
 
It is intriguing to note, that only two of all LTPs tested were of relevance for the replication 
cycle of the related Dengue virus (Figure 3.28C, D). This implies that the latter is possibly far 
less dependent on cellular cholesterol for viral replication or uses different cellular pathways 
as compared to HCV. HCV replication supposedly occurs at DMVs, which are protrusions of 
the ER, while DENV genome replication is suggested to involve virus induced ER 
invaginations [113, 114, 149]. Given their distinct morphology it is likely that the viruses co-
opt different cellular host factors and pathways for their generation and maintenance. In fact, 
DENV replication is independent of PI4KIIIalpha/beta mediated PtdIns4P induction, which 
stands in contrast to HCV and several members of the Picornaviridae, known to induce high 
local PtdIns4P levels, that are suggested to drive the LTP-mediated lipid traffic at the 
ER/Golgi interface (see Figure 4.1). Accordingly, the dependency of HCV and DENV on 
PtdIns4P binding proteins, such as most of the ORP family members, correlates well with 
their dependence on PtdIns4P induction through PI4Kinases [77, 79, 129, 187, 327].   
 
4.2.3 The role of LTP-assisted cholesterol traffic through the endosomal vesicular 
pathway in HCV replication 
 
Although there is increasing evidence that supports the notion of HCV co-opting LTPs in 
order to generate a specific lipid microenvironment at its replication sites, the lipid’s source 
membrane remains unknown. In case of OSBP, PITPNM1, CERT and FAPP2 this could be 
the Golgi compartment [79, 129, 181]. With the PM being highly enriched in cholesterol, 
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endocytosis of PM cholesterol or direct cholesterol transfer at PM/ER contact sites possibly 
mediated through OSBPL3 [274] could promote viral replication (Figure 3.28A, E). An 
additional major source of cellular cholesterol is the receptor-mediated uptake of LDL and 
subsequent hydrolysis of cholesterol esters in endosomal compartments, from which 
unesterified cholesterol is then transported from LE/LY to the PM or ER [162]. Several 
proteins have been implicated to mediate the sterol’s export from late endosomes and 
lysosomes, namely NPC1 and 2 and STARD3 [194, 207]. In addition OSBPL1A was shown 
to regulate the positioning of late endosomes depending on their cholesterol content [188]. 
Intriguingly, we were able to show that NPC1, STARD3 and OSBPL1A function is important 
for early events in HCV infection (Figure 3.29C). 
 
4.2.3.1 Studying the involvement of NPC1 in cholesterol traffic and HCV replication  
 
Here we report of a yet undescribed role of NPC1 in early events of the HCV but not the 
DENV replication cycle. We showed that gene knockdown of NPC1 impaired steps in viral 
RNA replication of genotype 2a and 1b stable replicons, but could possibly have an 
additional role in HCV entry (Figure 3.30). NPC1 is a transmembrane protein present in the 
limiting membrane of late endosomes and lysosomes [204]. According to this we found 
NPC1 in lysosomal, but also yet undefined vesicular structures (Fig 3.32A). Defects in NPC1 
function have been reported to cause tremendous accumulation of unesterified cholesterol in 
lipid lamellae, which bear late endosomal and lysosomal markers [201, 330]. In agreement 
with this, gene knockdown of NPC1 in human hepatoma cells led to an accumulation of 
unesterified cholesterol in large vesicles of lysosomal origin, irrespective of the presence or 
absence of the virus (Figure 3.32). So far, the precise role of NPC1 in cholesterol export from 
late endosomes remains elusive, but most likely involves several other LE proteins like NPC2 
and additional cholesterol efflux exporter [207].  
 
We showed that NPC1 knockdown indeed caused an intracellular accumulation of free 
cholesterol in lysosomal structures, which was concomitant to a reduction in viral RNA 
replication. So far we cannot rule out that NPC1 function might additionally be important for 
entry of HCV (Figure 3.31B, D). There are two possible scenarios of how NPC1 could affect 
the viral replication cycle. First, the virus eventually depends on a function of NPC1 
independent of the protein’s involvement in lipid trafficking. Second, one might argue that 
NPC1-mediated cholesterol egress from LE/LY compartments is substantial for HCV. In case 
of HCV entry, the viral fusogenicity with endosomal membranes was reported to be 
influenced by the target membrane’s lipid composition [111]. Thus accumulation of high 
cholesterol amounts upon loss of NPC1 function could impair viral fusion events. On the 
Discussion I 157  
 
other hand, similar to Ebola virus entry, NPC1 might directly control viral escape from 
endosomal membranes by interacting with one of the viral glycoproteins [281, 331]. In 
addition, given that HCV RNA replication depends on the presence of unesterified 
cholesterol [79], the NPC1-mediated export of cholesterol from LE/LY compartments might 
be essential to promote HCV RNA replication.  
 
4.2.3.2 Chemical inhibition of cholesterol traffic through the endosomal pathway and 
its impact on viral replication  
 
Considering that the uptake of LDL and its subsequent processing in endosomal 
compartments represents one of the major sources of cellular free cholesterol, it is likely that 
HCV usurps this pathway in order to recruit specific lipid species. Indeed, in HCV infected 
hepatoma cells, the cell surface expression of the LDLR receptor is enhanced [332]. In line 
with this we observed a slight increase in LDLR transcript levels in HCV infected cells (Figure 
3.39B). Thus HCV could promote the uptake of LDL in order to recruit LDL derived 
cholesterol to its replication organelles. In addition to this, HCV could usurp the PM-
cholesterol pool and induce the endocytosis of cholesterol-rich microdomains of the plasma 
membrane.  
 
Several cationic amphiphiles (CA) (U18666A, Ro 48-8071, clomiphene citrate) have been 
described to block endosomal cholesterol transport, while their mode of action is unknown 
[285]. The most prominent and frequently used CA is U18666A, reported to phenocopy 
NPC1 loss of function [282]. Accordingly we observed that U18666A treatment of HCV 
infected human hepatocytes resulted in an aggregation of free cholesterol in large vesicular 
structures in close proximity to the nucleus. Likewise, Ro 48-8071 or clomiphene citrate 
treated cells showed a profound accumulation of free cholesterol in bloated lysosomal 
organelles, which were significantly enlarged as compared to the control condition (Figure 
3.33A, B, D, Figure 3.35A, B). Intriguingly, the aberrant aggregation of endogenous free 
cholesterol was concomitant to a decrease in the lipid’s colocalization with NS5A 
(Figure 3.33C, Figure 3.35B). This suggests that free cholesterol present in LE/LY is 
transferred to NS5A positive sites, and thus potentially to the viral replication sites, which is 
inhibited upon CA treatment. In line with this we observed that, HCV RNA replication of 
several genotypes was impaired by treatment with the cationic amphiphiles (Figure 3.37, 
Figure 3.38).  
 
Several hypotheses have been put forward to explain the underlying mechanism of CA 
induced lipidosis. In case of U18666A is has been reported that overexpression of NPC1 
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reduced the impact of the drug, indicating that NPC1 function might be targeted by U18666A 
[285]. We were not able to corroborate this (Supplementary Figure 5). However given the 
compound’s structural similarity to cholesterol (Supplementary Figure 5A) it might directly 
interfere with NPC1 function, which is known to bind cholesterol [333]. Furthermore, CA were 
observed to accumulate in lysosomes where they can bind a specific lipid species forming a 
non-digestible lipid complex that subsequently aggregates in lysosomal lamellar bodies. On 
the other hand, CA might directly change the lysosomal membrane properties and thereby 
alter the function of membrane-associated proteins. In addition, CA-mediated inhibition of 
lysosomal enzymes could cause the accumulation of non-degraded lipid species [334]. The 
latter also accounts for the Niemann-Pick Disease Type A and B which are characterized by 
the accumulation of sphingomyelin, caused by a defective acid sphingomyelinase [199].  
The herein used CA were reported to cause a vesicular accumulation of free cholesterol 
similar to NPC1 loss off function [285], which was confirmed by our studies (Figure 3.35). 
Given that cholesterol preferentially associates with raft lipids [335], it is likely that defects in 
cholesterol egress convert into trafficking defects of other lipids such as of sphingolipids. In 
line with this we showed that CA treatment did not only result in the entrapment of free 
cholesterol in dilated lysosomal bodies, but also caused an accumulation of GM1 therein, 
indicating that egress of several lipids is hampered (Figure 3.35 and Figure 3.36). However 
in contrast to endogenous free cholesterol, GM1 did not colocalize with NS5A in untreated 
cells (Figure 3.36). It remains to be elucidated which lipids are transferred in addition to 
unesterified cholesterol from LE/LY storage to the viral replication factories. In this regard 
characterizing the lipid content of lamellar bodies of CA treated cells could give a further hint 
to the lipid species promoting viral replication.  
 
Taken together we hypothesize that the transport of specific lipids such as cholesterol 
from LE/LY to the replication organelles is important for viral RNA replication. 
Nevertheless, it should not be neglected that a general defect in LE/LY function that could 
alter traffic of cargo internalized by endocytosis [167] might contribute to the impairment of 
viral replication. Indeed lysosomal function is necessary for the degradation of 
macromolecules and for providing nutrients to the cell [336]. To corroborate whether the CA-
induced defect in cholesterol traffic causes the observed reduction in viral RNA replication, 
one could try to rescue viral RNA replication by the addition of exogenous cholesterol.  
Indeed our live-cell imaging analysis on the impact of CA treatment on TFC trafficking 
showed that exogenously added TFC was able to somehow overcome CA induced lipid 
trafficking defects and was efficiently transported to NS5A positive sites (Figure 3.42). Yet it 
is unclear whether TFC can rescue the CA induced impairment in viral RNA replication.  
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The inhibition of free cholesterol egress from LE/LY upon CA treatment or NPC1 knockdown 
might manifest, besides its apparent impact on the lipid’s distribution, in less obvious 
changes in cellular cholesterol homeostasis.  While LDL derived free cholesterol at the ER 
can initiate cholesterol homeostatic regulatory mechanisms, such as the reduction of 
HMGCoAR expression, this regulatory function is blocked upon treatment with the 
amphiphile U18666A [282]. Furthermore CA are inhibitors of several enzymes catalyzing the 
biosynthesis of cholesterol which potentially alters intracellular cholesterol levels (Figure 
3.39A) [282, 285]. Therefor the CA induced inhibitory effect on viral RNA replication might be 
due to either (i) a defect in the lipid’s trafficking or (ii) caused by alterations in total un-
/esterified cholesterol levels as a consequence of changes in regulatory mechanisms, such 
as cholesterol synthesis through HMGCoAR or (iii) a result of both. We argued that CA 
induced changes in cholesterol homeostasis most likely manifest in alterations of the 
transcript levels of the major regulators such as LDLR, HMGCoAR and ABCA1. Our analysis 
revealed that neither CA nor Mevastatin treatment altered the transcript levels of LDLR, 
ABCA1 or HMGCoAR  (Figure 3.39) [286]. Although this is unexpected at first, it could be 
that under the drug concentration tested, the local cholesterol levels at the ER are still 
sufficient to retain the SREBP-SCAP-Insig complex and inhibit SREBP mediated lipogenic 
gene expression (i.e. HMGCoAR). On the other hand one might speculate that in presence 
of HCV, suggested to induce SREBP activity [37], the SREBP-SCAP-Insig complex loses its 
sensitivity towards the regulation through ER localized free cholesterol.  Given the rather 
indirect read-out the true effect of CA treatment on cellular levels of free and esterified 
cholesterol remains to be determined using biochemical assays. 
 
In conclusion one might argue that under the herein tested conditions CA mainly provoked 
an intracellular accumulation of cholesterol in late endosomes/ lysosomes, while most 
likely the overall cellular cholesterol levels remained unaffected. Interestingly, Mevastatin 
treatment did not alter the localization of cholesterol or GM1 (Figure 3.35, Figure 3.38). This 
suggests that the CA induced changes in filipin and GM1 distribution are independent of the 
drugs’ potential inhibitory effects on sterol synthesis. In agreement with reports of others 
[133] we showed that Mevastatin reduced viral RNA replication (Figure 3.37C,D, Figure 
3.38). Being an inhibitor of the HMGCoAR which promotes sterol but also isoprenoid 
synthesis, it has been suggested that the impairment of HCV RNA replication is most likely 
due to defects in isoprenoid synthesis rather than to defects in the generation of cholesterol 
[135].  
 
Taken together we suggest that HCV RNA replication depends on the shuttling of 
unesterified cholesterol through the endosomal pathway. This is based on our 
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observation that (i) HCV induces the reorganization of PM derived cholesterol and most likely 
causes the recruitment of this lipid to the viral replication organelles (Figure 3.20A, B, Figure 
3.25, Figure 3.26) (ii) HCV RNA replication is significantly hampered when endosomal 
cholesterol traffic is inhibited either by targeting important LTPs or by CA treatment (Figure 
3.29C, Figure 3.30, Figure 3.32, Figure 3.33, Figure 3.34, Figure 3.35, Figure 3.36, Figure 
3.37) (iii) which is concomitant to a decreased localization of endogenous unesterified 
cholesterol to NS5A positive sites (Figure 3.33, Figure 3.35). Using a similar approach a 
recent study showed that several members of the Picornaviridae depend on endosomal 
cholesterol homeostasis to maintain viral replication with the lipid most likely acting as a 
structural component of the replication organelles [337].  
 
4.2.3.3 Relevance of endosomal lipid traffic for HCV replication 
 
The precise role of cholesterol delivered through the endosomal pathway in viral RNA 
replication remains unknown. A recent study showed that the OSBP-dependent recruitment 
of cholesterol to PtdIns4P rich replication compartments contributes to the establishment of 
the membranous web (Figure 4.1 infected cell) [79]. This is further supported by the 
observation of cholesterol being an important structural component of the DMVs [114, 127]. 
Thus HCV most likely usurps plasma membrane derived cholesterol for the generation of its 
replication organelles. Cholesterol could, by forming membrane rafts, serve as platform of 
the replicase machinery within the vesicular structures or serve to provide membrane rigidity.  
While we were able to show that exogenously added plasma membrane derived cholesterol 
(TFC) colocalized with NS5A and was readily incorporated into NS4B membrane fractions, 
presumably the DMVs (Figure 3.25, Figure 3.26), we were not able to observe an inhibition 
of this colocalization upon CA treatment (Figure 3.42A, C, D, E). This stands in contrast with 
our data obtained on the distribution of endogenous free cholesterol. In case of the latter, we 
showed that CA treatment induced cholesterol entrapment in lysosomal compartments which 
was concomitant to its decrease at NS5A positive sites, thus potentially at viral replication 
factories (Figure 3.35C). It appears that the addition of excess cholesterol can overcome the 
inhibitory effect of CA treatment. It is likely that upon the addition of excessive cholesterol 
and upon the lipid’s transport to LE/LY compartments the cell may use alternative pathways 
to remove excessive intracellular LE/LY cholesterol. For instance the activity of other LE/LY 
resident cholesterol transporters such as STARD3 could be induced.  
In agreement with our previous observations we were able to observe a strong intracellular 
accumulation of large TFC positive vesicles, which clustered around the nucleus upon CA 
treatment (Figure 3.33, Figure 3.41A). In line with the report of others these vesicles 
appeared static and immobile [210]. The loss of mobility of late endocytic compartments and 
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their aggregation at the perinuclear region has also been reported for cells lacking functional 
NPC1 [201]. It is suggested that either the accumulation of high cholesterol levels impair LE 
dynamics or the latter might be directly regulated by NPC1 function [188, 211, 338].  
 
Although we were able to show that plasma membrane cholesterol is recruited to the 
potential site of viral replication, which most probably involves its transport through the 
endosomal pathway and export by LTPs such as NPC1, the role of PM-derived cholesterol in 
viral replication remains enigmatic. Given that CA treatment was most effective when added 
early in replication (Figure 3.34 E) it is likely that cholesterol is needed for early events 
such as the establishment of the MW. Therefore lack of cholesterol might manifest in 
changes in MW morphology. Indeed earlier reports showed that changes in the lipid 
composition of the replication organelles, such as reduced PtdIns4P or cholesterol levels, 
caused a reduction in DMV size which was concomitant to a defect in viral RNA replication 
[77, 79, 114]. To our surprise we were not able to observe such changes in the DMV 
morphology upon CA treatment at concentrations that had earlier been proven to impair the 
recruitment of this lipid to NS5A positive sites as well as to impair viral RNA replication 
(Figure 3.43). It could be that U18666A treatment causes only subtle changes in the 
cholesterol content of the viral replication factories that do not become apparent in the size of 
DMVs. This could possibly be addressed by analyzing the cholesterol content of purified 
DMVs from HCV replicon cells in presence or absence of CA [114]. Additionally, 
heterogeneity in the phenotype might impede the analysis. In order to rule out that endo-
lysosomal cholesterol traffic is indeed dispensable for DMV morphology, one could use 
correlative light electron microscopy to ease the search for cells showing a strong vesicular 
cholesterol accumulation upon drug treatment and to correlate this phenotype with potential 
changes in DMV morphology. 
  
Besides of being a structural component cholesterol could regulate the proviral action of 
cellular factors or of the enzymatic activity of the viral replicase, e.g. in a similar fashion 
as compared to the allosteric control of enzymes. Several viral proteins have been reported 
to associate with distinct lipid species. The viral RdRp NS5B is able to bind sphingomyelin 
and inhibition of sphingolipid synthesis impairs viral RNA replication. The role of 
sphingomyelin association to NS5B needs to be clarified, but could mediate the membrane 
raft association of the protein [339]. The interaction of FASN with NS5B was reported to 
enhance the viral RdRp activity, however most likely independent of FASN enzymatic activity 
[340]. The recruitment of FASN to the viral replication sites in turn might support the local 
synthesis of phospholipids and could potentially contribute to palmitoylation of viral proteins 
[341]. Although NS4B was believed to be palmitoylated, very recent studies reported no 
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evidence for palmitoylation of the viral protein [342]. The most prominent cholesterol 
interaction motifs found in the transmembrane domains of membrane proteins are the CRAC 
(Cholesterol Recognition/ interaction Amino acid Consensus sequence) or the CARC motif, 
the latter exhibiting the opposite orientation of the CRAC motif [343]. Whether such motifs 
are present in the viral non-structural proteins and could mediate the association with 
cholesterol is unknown. Finally it would be intriguing to elucidate, whether cholesterol or 
other lipids have a direct stimulatory effect on the enzymatic function of the viral replicase. 
This could be addressed by studying the in vitro RNA replicase activity of crude replication 
complexes (CRCs) purified from replicon cells [344] in dependency of the addition of lipids 
such as free cholesterol.  
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The herein presented data allows us to put forward several hypotheses on the interplay of 
HCV and (A) LD-associated pathways and (B) the cellular cholesterol landscape. 
 
(A) HCV and LD-associated pathways  
The high hit rate of our hypothesis driven LD RNAI screen highlights the central role of LDs 
in the replication cycle of the two LD-dependent viruses, HCV and DENV. We found that 
several major cellular pathways are acting as central nodes and are involved in all three 
processed analyzed, such as the COPI trafficking machinery and the proteasomal 
degradation pathway. It would be intriguing to study whether these pathways link the viral 
replication cycles to LD homeostasis. Moreover gaining a better understanding of the link 
between HCV, DENV and the lipid storage organelle might reveal novel promising targets for 
antiviral therapy. Studying the function of the DEAD box RNA helicase 3 in HCV replication 
we were able to confirm its involvement in several steps of the viral replication cycle. Our 
data further suggests that the recruitment of the protein to LDs by the HCV core protein is 
dispensable for its proviral function in human hepatoma cells. As discussed earlier this 
should be re-evaluated in a more authentic immune competent cellular system.  
 
(B) HCV and the cellular cholesterol landscape 
We were able to show that HCV reshapes the cellular cholesterol landscape, which 
became apparent in our imaging analysis of endogenous and exogenous plasma membrane 
derived cholesterol. This reshaping might involve vesicular but also non-vesicular 
mechanisms and thus the action of lipid transfer proteins. In line with this we identified 
several LTPs that are implicated in direct lipid transfer at membrane contact sites of the ER/ 
PM, ER/ Golgi and possibly the ER and late endosomal/ lysosomal compartments.  
 
Our data suggests that cholesterol from late endocytic compartments, possibly derived 
from the PM or from LDL uptake, is trafficked to NS5A positive sites. This most likely 
involves the function of host factors, such as NPC1 that could act as cholesterol efflux pump 
at late endosomes. Pharmacological inhibition of lipid transport through the endosomal/ 
lysosomal pathway was shown to impair HCV RNA replication and the delivery of cholesterol 
to NS5A positive sites, thus possibly to the sites of RNA replication. Nevertheless we cannot 
exclude, that a general defect in LE/LY function caused by either NPC1 knockdown or CA 
treatment might provoke the impairment of HCV RNA replication. 
 
HCV might take advantage of several cholesterol storage compartments, possibly 
depending on their availability. While the plasma membrane cholesterol pool represents a 
‘ready to use’ pool for immediate supply, HCV could in addition induce the uptake of LDL or 
Conclusion and perspectives I 167  
 
the mobilization of cholesterol from LDs. Some Rhinoviruses were recently reported to 
mobilize cholesterol from LD pools and by recruiting it to the viral replication factories 
promoting replication on Golgi derived membranes [327]. Whether HCV usurps other 
cholesterol sources should be addressed in future studies.  
 
We showed that HCV takes advantage of NPC1-mediated cholesterol traffic through the 
endosomal pathway, however knowledge on the details of the underlying mechanism is 
scarce. It is still enigmatic how cholesterol is shuttled from lysosomal compartments to its 
intracellular target membranes such as the PM or the ER. This post-lysosomal transport 
most likely involves cytosolic receptors and/ or vesicular traffic of LE/LY. In fact knockdown 
of the ER-resident OSBPL5 was shown to cause an accumulation of cholesterol in the 
limiting membrane of LE/LY, while NPC1 loss of function manifests in the accumulation of 
free cholesterol within these vesicular structures [190, 345]. For this reason one might argue 
that OSBPL5 acts as cytosolic receptor of cholesterol exported from LE/LY through the 
function of NPC1. Although OSBPL5 was also included in our LTP RNAi screen we were not 
able to establish an importance of this protein in the viral replication cycle so far (Figure 
3.27). Nevertheless it would be worthwhile to include OSBPL5 into future studies. Another 
member of the OSBPL family, namely OSBPL1A has been reported to regulate the 
positioning of LE according to their cholesterol content, and to regulate the establishment of 
LE/ ER contact sites through its interaction with ER-resident VAP proteins [188]. We 
observed that knockdown of OSBPL1A/1B impaired early events in viral replication (Figure 
3.29C). In line with this it would be intriguing to elucidate, whether HCV hijacks the function 
of OSBPL1A or OSBPL5 in order to recruit cholesterol loaded LE/LY to the viral replication 
sites. Future studies should further implement the function of other LTPs, such as STARD3, 
and ABCA1 that act as cholesterol export shuttles at the LE/LY [193, 271]. Intriguingly 
STARD3 was recently described to contribute to the formation of ER/LE membrane contact 
sites possibly by acting with the ER resident VAP proteins [346], which might support the 
delivery of LE cargo to the ER. In conclusion, HCV might take advantage of the function of 
OSBPL1A and STARD3 in order to establish membrane contact sites between cholesterol 
loaded LE/LY and the viral replication factories. Furthermore HCV could possibly recruit 
OSBPL5 (or other OSBPLs such as OSBP) to sites of viral replication in order to enrich for 
cholesterol that is delivered from LE/LY through the action of NPC1 and additional LTPs 
such as NPC2, ABCA1 and STARD3 (Figure 5.1). In line with this it would be intriguing to 
study the dynamics of NPC1 positive vesicles in HCV infected cells as well as the localization 
of OSBPL1A, STARD3 and OSBPL5 in respect to the viral replication sites.  
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Figure 5.1 Hypothetical model of LTP-assisted cholesterol transport through the endocytic pathway to the 
viral replication sites. (A) Upon LDL receptor-mediated uptake of low-density lipoproteins, LDL is targeted to 
LE/LY for degradation, while the receptor is recycled back to the PM.  Cholesterol esters are hydrolyzed by acid 
lipases present in lysosomes but also in earlier endocytic compartments. In addition cholesterol rich plasma 
membrane microdomains are endocytosed and deliver free cholesterol to late endocytic compartments [217]. 
How free cholesterol is then leaving the LE/LY compartments is not understood, but might involve vesicular 
mechanisms as well as the action of LTPs such as of NPC1/2, STARD3, OSBPL5, OSBPL1A and ABCA1. 
OSBPL1A tethers LE/LY compartments depending on their cholesterol content to the vesicle transport machinery. 
LE of low cholesterol content are scattered throughout the cell periphery, while LE of high cholesterol content are 
transported to the microtubule minus ends. OSBPL1A further mediates the formation of LE/ER contact sites 
through its interaction with ER-resident VAP proteins [188]. OSBPL5 is an ER-resident protein that might act as 
cytosolic acceptor of cholesterol delivered through the action of NPC1/2 or other cholesterol efflux pumps [190]. 
(a) HCV might recruit OSBPL1A to the viral replication sites (the DMVS) through OSBPL1A interaction with VAP 
proteins. The interaction of OSBPL1A with Rab7 and its effectors at LE through the protein’s N-terminal ankryn 
repeats could then allow the establishment of LE/ DMV contact sites. This could support the export of free 
cholesterol from LE/LY compartments through the action of several LTPs. NPC1, possibly in a concerted action 
with NPC2 and/or ABCA1, catalyzes the egress of cholesterol from the endocytic compartment [207] and could 
transfer it onto a cytosolic acceptor such as OSBPL5. The ER resident OSBPL5 might then catalyze the counter 
transport of cholesterol and phosphatidylinositol-4phopshpate (PtdIns4P). The directionality of the transport is 
given by the high PtdIns4P levels at the DMVs. In addition STARD3 could act as LE/LY cholesterol exporter but 
might also help to establish LE/DMV contact sites by its interaction with VAP proteins [346]. In conclusion, HCV 
might hijack the function of several LTPs in order to recruit cholesterol or other lipids to its sites of replication.  
While we were able to recover PM derived cholesterol from NS4B associated DMVs, the 
function of cholesterol at these sites remains enigmatic. The lipid possibly acts as 
structural component [114] contributing to the formation of lipid rafts that might serve as 
platform of the viral replicase. In addition cholesterol could have a direct stimulatory effect on 
the HCV RNA replicase activity. This open question should be tackled in future studies and 
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might shed novel insight into the intimate connection between HCV and the host cellular lipid 
metabolism.  
 
In this study we mainly focused on the contribution of cholesterol transport to early events of 
the HCV replication cycle such as viral RNA replication and the establishment or 
maintenance of the viral replication factories, the DMVs. Given that multiple steps of the viral 
replication cycle, such as infectious particle production are linked to cellular lipid metabolism 
[302, 347], it would be intriguing to study the implication of LTP-mediated endosomal 
cholesterol transport in infectious particle production. Indeed, we observed the recruitment of 
free cholesterol to NS5A positive sites, which might not only mark the sites of viral RNA 
replication, but given the protein’s role in particle production could indicate sites of progeny 
virus assembly [81]. The fact that viral particle resembles very-low- and low-density –
lipoproteins highly enriched in cholesteryl esters [120] further supports the notion that 
directed cholesterol transport could be of importance for the assembly of infectious particles.  
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Supplementary Figure  1 Effect of gene knockdown of several COPI subunits on the HCV replication cycle  
(A) Description of the experimental setup. Huh7.5FLuc cells were electroporated with the respective siRNA and 
vRNA (JcR2A). Cells and cell supernatants were harvested 24 and 48 h post electroporation. Cell supernatants 
were used for reinfection of naïve cells. (B) and (C) show the results of two independent experiments. n.d. = not 
determined. Effect of gene knockdown of either COPI subunit alpha, gamma1 or gamma2 on viral replication was 
determined by measuring the Renilla luciferase activity in cell lysates. Relative light units (RLU) are shown. 
Concomitant, cell viability (by WST-1 assay) as well as knockdown efficiency (by RTqPCR) was determined. Two 
different siRNA oligos were used per target gene. (D) Effect of COPI subunit gene knockdown of cell viability. The 
effect of gene knockdown of the COPI alpha, gamma1 and gamma2 subunit on cell viability was determined 24, 
48, 72 and 96 h post siRNA electroporation by WST-1 assay. 
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Supplementary Figure  2 Detection of Flag tagged wild-type and F24A mutant core of different genotypes 
by the core specific C830 antibody as well as Flag tag specific antibody. (A) Huh7/Lunet-T7 cells were 
transfected with the respective pTM overexpression constructs encoding the wild-type or F24A mutant core with a 
N-terminal Flag tag. 24 h later the protein levels of Flag tagged HCV core were analyzed in parallel with 
antibodies against the Flag tag as well as against the HCV core protein. Beta actin is depicted as loading control. 
A representative image is shown. (B) Quantification of the Flag signal intensities of the respective conditions. The 
Flag signal was normalized to the beta actin loading control. Mean and standard deviation of two independent 
experiments are shown. 
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Supplementary Figure  3 Validation of shRNA-mediated knockdown efficiency. (A) Huh7.5Fluc cells were 
transduced with Lentivirus at an approximate MOI of 2. Cells were kept under puromycin selection (1 µg/ ml) for 
96 h. Cells were then harvested for the determination of the knockdown efficiency. (B) In case of no working 
antibody available, knockdown was measured by determining the transcript levels of the gene of interest by RT-
qPCR. They were normalized to mRNA levels of the housekeeping gene GAPDH. The means of triplicates are 
presented as fold of the non-targeting shRNA control. (C-F) When possible, protein levels were determined by 
Western Blot. For quantification of the knockdown efficiency target protein levels were normalized to beta actin 
and are presented as fold of the non-targeting shRNA control. In case of OSBPL1A/1B the protein levels are 
presented as fold of shOSBPL1A/1B (1). Data of a single experiment is shown. 
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Supplementary Figure  4 Attempt of rescuing NPC1 silencing by overexpression of shRNA resistant NPC1 
constructs. (A) Scheme indicating the localization of the target sequence of shNPC1 (1) and shNPC1 (2) within 
NPC1 mRNA. shNPC1 (1) targets the 3’ UTR, while shNPC1 (2) targets a sequence within the coding region. (B) 
shNPC1 (2) target sequence and the encoded amino acids. For the generation of a shNPC1 (2) resistant 
expression construct 5 silent point mutations were introduced into the target sequence. (C) Setup of NPC1 rescue 
experiments. Cells were transduced with lentivirus for either i) gene silencing followed by NPC1 overexpression or 
ii) overexpression and subsequent gene silencing. Next, cells were infected with Renilla luciferase reporter HCV 
(JcR2A) for 48 h. (D i, ii) Effect of combined silencing and overexpression on the early phase of JcR2A replication 
(measurement of Renilla luciferase activity in cell lysates) as well as on cell viability (cell titer glo assay) is shown. 
Data is presented as percentage of the non-targeting shRNA. The mean relative life units (RLU) of triplicates of a 
single experiment are shown. 
 
Supplementary Figure  5 Combination of NPC1 knockdown and U18666A treatment. (A) Chemical structure 
of U18666A. (B) Experimental setup. Huh7.5 cells were transduced with shRNA containing Lentivirus at a MOI of 
1. 48 h later cells were infected with Renilla luciferase reporter virus (MOI 0.5). After removal of the viral inoculum 
cells were treated with different concentrations of U18666A. 48 h post infection cells were lysed and viral 
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replication was determined by measuring the Renilla luciferase activity in cell lysates. (C) Effect of shRNA 
mediated knockdown of NPC1 or PI4KIIIIA combined with U18666A treatment. The same results are shown in 
both panels. Upper panel: Effect of U18666A treatment in knockdown cells. Lower panel: Effect of knockdown in 
drug treated cells. The mean relative light units (RLU) and standard deviation of two independent experiments are 
shown. Experiments were performed in triplicates. 
 
Supplementary Figure  6 Free cholesterol distribution upon U18666A treatment of cells expressing the 
non-structural proteins NS3-5B of JFH1 (gt2a) or Con1Et (gt1b). Huh7/Lunet-T7 cells were treated with 
different concentrations of U18666A for 24 h followed by transfection of the respective pTM expression constructs 
in presence of the drug. 6 h later medium was replaced by fresh drug containing medium. 24 h post transfection 
cells were fixed and free cholesterol was visualized using filipin. The white boxes highlight the areas shown in the 
enlargements below. Scale bars represent 10 µm or 5 µm respectively. 
6.2 Supplementary Tables 
 
Supplementary Tables are provided on CD. 
 
Supplementary Table S 1: Dharmacon RNAi library 
Supplementary Table S 2: Primary screen results (z-scores) 
Supplementary Table S 3: Primary screen hits (HCV and DENV) 
Supplementary Table S 4: Primary LD morphology screen hit list 
Supplementary Table S 5: Deconvolution screen hit list 
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6.3 Supplementary Movies 
 
Supplementary Movies are provided on CD. 
 
Supplementary Movie 1: Live cell imaging of Huh7/LunetCD81H cells transfected with 
the subgenomic replicon containing mCherry tagged NS5A and pulsed with 4 µM 
Topfluor-Cholesterol. Representative pictures are shown in Figure 3.21.B, upper panel. 
 
Supplementary Movie 2: Live cell imaging of Huh7/LunetCD81H cells transfected with 
the subgenomic replicon containing mCherry tagged NS5A and pulsed with 1 µM 
Topfluor-Cholesterol. Representative pictures are shown in Figure 3.21.B, lower panel. 
 
Supplementary Movie 3: Live cell imaging of Huh7/LunetCD81H cells transfected with 
the subgenomic replicon containing mCherry tagged NS5A and pulsed with 1 µM 
Topfluor-Cholesterol (TFC) early in replication. Dynamics of TFC and NS5A-mcherry are 
shown. Representative pictures are shown in Figure 3.23A. 
 
Supplementary Movie 4: Live cell imaging of Huh7/LunetCD81H cells transfected with 
the subgenomic replicon containing mCherry tagged NS5A and pulsed with 1 µM 
Topfluor-Cholesterol (TFC) late in replication. Dynamics of TFC and NS5A-mcherry are 
shown. Representative pictures are shown in Figure 3.23B. 
 
Supplementary Movie 5: Live cell imaging of Huh7/LunetCD81H cells transfected with 
the subgenomic replicon containing mCherry tagged NS5A and pulsed with 1 µM 
Topfluor-Cholesterol (TFC) early in replication. Dynamics of TFC and NS5A-mcherry are 
shown. Representative pictures early upon TFC addition are shown in Figure 3.24A. 
 
Supplementary Movie 6: Live cell imaging of Huh7/LunetCD81H cells transfected with 
the subgenomic replicon containing mCherry tagged NS5A and pulsed with 1 µM 
Topfluor-Cholesterol (TFC) late in replication. Dynamics of TFC and NS5A-mcherry are 
shown. Representative pictures early upon TFC addition are shown in Figure 3.24B. 
 
Supplementary Movie 7 - Live tracking of Topfluor-Cholesterol (TFC, green) and NS5A-
mCherry (red) in Huh7/LunetCD81H cells transfected with the subgenomic replicon 
containing mCherry tagged NS5A and pulsed with 1 µM Topfluor-Cholesterol early in 
replication. Dynamics of TFC and NS5A-mcherry are shown. A movie depicting the overlap 
of NS5A (red) and TFC (green) is presented. Representative pictures are shown in Figure 
3.25.A.  
 
Supplementary Movie 8 - Live tracking of Topfluor-Cholesterol (TFC, green) and NS5A-
mCherry (red) in Huh7/LunetCD81H cells transfected with the subgenomic replicon 
containing mCherry tagged NS5A and pulsed with 1 µM Topfluor-Cholesterol late in 
replication. Dynamics of TFC and NS5A-mcherry are shown. A movie depicting the overlap 
of NS5A (red) and TFC (green) is presented. Representative pictures are shown in Figure 
3.25.B. 
 
Supplementary Movie 9 - Live tracking of Topfluor-Cholesterol (TFC) in 
Huh7/LunetCD81H cells transfected with the subgenomic replicon containing mCherry 
tagged NS5A, pulsed with 1 µM Topfluor-Cholesterol early in replication and treated or 
not with 1.25 µM U18666A. Dynamics of TFC and NS5A-mcherry in control or U18666A 
treated cells are shown. In addition a movie showing the pictures depicted in Figure 3.41A is 
presented. 
 
Supplementary Movie 10 - Live tracking of Topfluor-Cholesterol (TFC) in 
Huh7/LunetCD81H cells transfected with the subgenomic replicon containing mCherry 
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tagged NS5A, pulsed with 1 µM Topfluor-Cholesterol late in replication and treated or 
not with 1.25 µM U18666A. Dynamics of TFC and NS5A-mcherry in control or U18666A 
treated cells are shown. In addition a movie showing the pictures depicted in Figure 3.41A is 
presented. 
 
Supplementary Movie 11 - Live tracking of Topfluor-Cholesterol (TFC) and NS5A-
mCherry in Huh7/LunetCD81H cells transfected with the subgenomic replicon 
containing mCherry tagged NS5A, pulsed with 1 µM Topfluor-Cholesterol early in 
replication and treated or not with 1.25 µM U18666A. . Dynamics of TFC and NS5A-
mcherry in control or U18666A treated cells are shown. A movie showing the overlap of the 
TFC and NS5A signal is presented. Pictures of the first 400 min post TFC pulse are depicted 
in 3.42A. 
 
Supplementary Movie 12 - Live tracking of Topfluor-Cholesterol (TFC) and NS5A-
mCherry in Huh7/LunetCD81H cells transfected with the subgenomic replicon 
containing mCherry tagged NS5A, pulsed with 1 µM Topfluor-Cholesterol late in 
replication and treated or not with 1.25 µM U18666A. Dynamics of TFC and NS5A-
mcherry in control or U18666A treated cells are shown. A movie showing the overlap of the 
TFC and NS5A signal is presented. Pictures of the first 400 min post TFC pulse are depicted 
in 3.42A. 
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